# Converus — Full Knowledge Base Text > Converus is the intelligence layer for reimbursement operations. It keeps the payer policies, contracts, fee schedules, mandates, LCDs/NCDs, and rules that drive reimbursement up to date for diagnostics, genetic testing, and specialty labs, then makes that logic usable across teams, systems, and AI workflows via app, API, and MCP. Full text of the Converus knowledge base. Source: https://converus.ai. Educational content; cite with attribution to Converus. --- # What's Actually Covered as "Preventive" Under the ACA URL: https://converus.ai/knowledge-base/aca-preventive-services-explained/ Updated: 2026-05-19 > ### At a glance > > The Affordable Care Act requires most health plans to cover specific preventive services at $0 to the patient. No copay, no coinsurance, no deductible. The list is real and large. The conditions for that $0 cost are also real, and most patient surprise bills happen when one of those conditions quietly fails. > ### Disclaimer > > This article is general educational content and is not medical, legal, tax, or financial advice. Plan rules, federal regulations, and state laws change, and coverage outcomes depend on your specific plan, provider, diagnosis, and circumstances. CPT codes, dollar amounts, and percentages referenced here are illustrative examples drawn from public sources, not quotes for any particular plan or patient. Before making decisions about your care, coverage, or any appeal, consult a qualified professional (your insurer's member services, your benefits administrator, a healthcare attorney, or your physician, as appropriate). Use this information at your own risk. ## The basic rule (Section 2713) [Section 2713 of the ACA](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/preventive-care-background) requires non-grandfathered group and individual health plans to cover a defined list of preventive services without cost-sharing. No copay. No coinsurance. No deductible. The bill at the visit is supposed to be zero. The defined list comes from three federal sources, covered below. It includes the annual wellness visit, screenings for cancers (colon, cervical, breast, lung in specific populations), childhood immunizations, the standard adult vaccine schedule, contraception, depression and anxiety screening, and dozens of other services. The list is updated each year as the underlying recommendation bodies issue new guidance. The promise is straightforward in concept. The execution involves four conditions, each of which can break. ## The four conditions for zero-cost coverage For a preventive service to actually cost you $0, all four of these must be true: 1. **The service is on the official list.** If your provider performed something that is not on the USPSTF, ACIP, or HRSA list (defined below), the ACA's $0 mandate does not apply. 2. **The provider is in-network.** Out-of-network providers can charge whatever they charge. The ACA mandate runs through your plan's network. [HealthCare.gov](https://www.healthcare.gov/coverage/preventive-care-benefits/) is explicit on this. 3. **The preventive service is the primary purpose of the visit.** This is the condition that catches most patients. If the visit started as preventive but pivoted to evaluation of a separate problem, the problem-oriented portion is billed under your deductible. More on this below. 4. **Your plan is not exempt.** A handful of plan categories sit outside the ACA preventive rule entirely. Four conditions. All four must hold. Failure of any one moves you back into deductible territory. ## The three official preventive services lists The "preventive list" is actually three lists, maintained by three federal bodies: - The [U.S. Preventive Services Task Force](https://www.uspreventiveservicestaskforce.org/) publishes grade-A and grade-B recommendations for screening and counseling. Examples: colorectal cancer screening for adults 45 to 75, cervical cancer screening at recommended intervals, statin use for adults at elevated cardiovascular risk. - The Advisory Committee on Immunization Practices (ACIP) maintains the routine immunization schedule, including the standard childhood series, HPV, shingles, flu, and COVID-19. - The Health Resources and Services Administration (HRSA) publishes preventive services guidelines for women (contraception, well-woman visits, screening for intimate partner violence) and for children (newborn screening, developmental screening, vision, and hearing). The [KFF ACA Preventive Services Tracker](https://www.kff.org/aca-preventive-services-tracker/) is the single best place to check whether a given service is on one of these three lists, updated for the current plan year. ## Plans that are exempt entirely Not every plan in the US has to follow Section 2713. The exemptions: - Grandfathered plans. A "grandfathered" plan is one in existence on March 23, 2010 (when the ACA was signed) that has not significantly changed its terms since. These plans are exempt from many ACA requirements, including preventive cost-sharing. The grandfathered share has shrunk every year and now covers a small minority of insured workers. - Short-term limited-duration plans. Non-ACA-compliant plans sold for coverage gaps. They can exclude preventive services, exclude pre-existing conditions, and impose dollar limits. The 2024 federal rule cut the maximum duration to four months. Older plans sold before that change can still be in force. - Health-sharing ministries. Faith-based cost-sharing arrangements operating outside the ACA framework. They are not insurance, are exempt from ACA mandates, and have no obligation to cover any preventive service. If your coverage is one of these, the rules in this piece largely do not apply. Confirm before you assume. ## The preventive-to-diagnostic switch This is the single most common cause of "I thought my annual was free" bills. Here is the mechanic. You go in for a screening colonoscopy. Per USPSTF, this is a recommended preventive service for adults age 45 and over (grade A for ages 50 to 75, grade B for ages 45 to 49, both qualifying for $0 cost-sharing under the ACA). Your colonoscopy itself is $0. The gastroenterologist finds a polyp and removes it during the same procedure. The removal and the pathology on the polyp are diagnostic, not screening. Diagnostic services are not on the USPSTF preventive list. They run through your deductible and coinsurance. CMS, the Department of Labor, and Treasury addressed this scenario in [ACA Implementation FAQ Part 12](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/aca_implementation_faqs12), issued in 2013, with a related anesthesia clarification in subsequent FAQ guidance. The short version: if a colonoscopy starts as screening and turns into a polyp removal, the agencies told payers to treat the procedure itself as part of the screening (so the colonoscopy stays $0). Anesthesia, pathology fees, and follow-up testing may still be billed separately and may not be protected in every plan. Patient-side bills for "free" colonoscopies have been a documented and recurring pattern over the past decade. The same logic applies to: - Mammograms that surface a finding and require diagnostic follow-up imaging. - Annual physicals that surface a separate problem the doctor evaluates during the same visit. - Lab panels run for screening that produce a finding requiring a repeat test under a diagnostic code. The pattern repeats. The screening test is on the preventive list. The follow-up usually is not. ## Common services patients assume are covered but might not be A few specific traps: - Anesthesia for colonoscopies. Some plans cover the screening colonoscopy and related anesthesia at $0. Others apply cost-sharing to the anesthesia separately, especially when the anesthesia provider bills under their own NPI and is out-of-network. Verify both with the plan before scheduling. - Diagnostic follow-up after a screening finding. If your mammogram is abnormal and you need an ultrasound or biopsy, the follow-up is diagnostic. Some states have passed laws requiring follow-up breast imaging to be covered at $0. Most have not. Check your state. - Out-of-network providers at in-network facilities. A hospital-based pathologist or anesthesiologist outside your plan network can balance-bill in some scenarios. The No Surprises Act blocks balance billing in many of these situations but does not change cost-sharing for non-emergency, scheduled care if you knowingly chose the out-of-network provider. - Counseling vs. medication. A USPSTF recommendation might cover counseling for tobacco cessation. The actual prescription medication might be covered, or might run through the formulary at standard cost-sharing. - Provider-coded "office visit" alongside preventive. See [Modifier 25 Explained](/knowledge-base/modifier-25-explained/). The HealthCare.gov page itself includes the [caveat](https://www.healthcare.gov/coverage/preventive-care-benefits/) that $0 cost is "in some cases" and depends on plan and provider. It is worth reading the page in full before assuming any specific service will be free. ## How to verify before your visit Three steps that take ten minutes. 1. **Find the service on the [KFF ACA Preventive Services Tracker](https://www.kff.org/aca-preventive-services-tracker/).** Confirm it is on one of the three official lists (USPSTF, ACIP, HRSA) and note the exact age and population for which it is covered. 2. **Call your insurer's member services line.** Ask: "Is CPT code [X] covered as preventive at $0 cost-sharing under my plan, for my age and sex, performed by [provider name, in-network]?" Get a reference number for the call. 3. **Read your Summary of Benefits and Coverage** for the section on preventive care exclusions. Some plans note specific exclusions or limits the federal list does not. If the answer at step two is yes and a bill arrives anyway, the call reference number is your appeal evidence. ## How to appeal a billed "preventive" service The basic playbook: 1. **Request an itemized bill.** Get the line-item list with CPT codes, modifiers, and diagnosis codes. An EOB summary alone is not enough. 2. **Identify which line items are coded as preventive vs. diagnostic.** Preventive CPT codes for adult wellness include 99381 through 99387 (initial preventive medicine, new patient) and 99391 through 99397 (periodic preventive medicine, established patient). Compare the diagnosis codes attached to each line. 3. **File an internal appeal with your insurer.** State the specific ACA preventive service you believe applies. Cite the USPSTF, ACIP, or HRSA listing and the date of the recommendation. Attach the call reference if you have one. 4. **If denied internally, file for external review.** Most ACA-compliant plans must offer access to an independent external review process. [KFF data on ACA marketplace plans in 2024](https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/) shows about 34% of internal appeals get overturned, and the appeal rate is under 1%. The math is brutal in your favor if you actually file. Most patients who get billed pay without appealing. The reason is rarely that the case is weak. It is that the process is exhausting and the timeline is long. If you believe a charge was misclassified and the dollar amount justifies the time, consider appealing or requesting an itemized review before paying. ## Opinion The ACA preventive promise is real. Tens of millions of services that used to come with copays now do not. That is a genuine policy success. The conditions for the promise to apply are also real, and most patients only learn what they are after a bill arrives. The average patient does not know what modifier 25 is, what counts as "diagnostic" versus "screening," or that they have an appeal right at all. The information asymmetry is the actual problem. Fix it by reading your SBC, learning the four conditions, and calling your insurer before the visit instead of after the bill. For the most common surprise-bill mechanism in this category, see [Modifier 25 Explained](/knowledge-base/modifier-25-explained/). For the plan-type basics that determine what your network and deductible look like, see [The Five Health Insurance Plan Types Explained](/knowledge-base/five-health-insurance-plan-types/). On the operator side, [Denials 101](/knowledge-base/denials-101/) covers how the same rules show up from the billing perspective. > ### What this means for you > > 1. **Read the preventive care section of your SBC.** Note any plan-specific exclusions before scheduling. > 2. **Cross-check the service** on the [KFF ACA Preventive Services Tracker](https://www.kff.org/aca-preventive-services-tracker/) before the visit. > 3. **Call your insurer's member line in advance.** Ask the question with the specific CPT code and provider name. Get a reference number. > 4. **If a "free" service gets billed, request an itemized bill and appeal.** Overturn rates run around one in three for the patients who actually file. ## Sources - [HealthCare.gov, Preventive Care Benefits](https://www.healthcare.gov/coverage/preventive-care-benefits/) - [CMS, ACA Implementation FAQs Part 12](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/aca_implementation_faqs12) - [CMS, Background on ACA Preventive Care Rules](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/preventive-care-background) - [KFF, ACA Preventive Services Tracker](https://www.kff.org/aca-preventive-services-tracker/) - [KFF, Claims Denials and Appeals in ACA Marketplace Plans in 2024](https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/) - [USPSTF A and B Recommendations](https://www.uspreventiveservicestaskforce.org/) --- # AI in Prior Authorization: What It Means for Diagnostics and Molecular Labs URL: https://converus.ai/knowledge-base/ai-in-prior-authorization-diagnostics/ Updated: 2026-06-19 > **Educational use only.** This article is for general information and is not legal, compliance, billing, or coverage advice. The regulatory landscape around AI and prior authorization is changing quickly, and several items below are actively contested in 2026. Verify current law, regulations, and payer policy against primary sources and consult qualified professionals before acting. No outcome is guaranteed; use at your own risk. A molecular oncology test gets ordered for a patient with suspected recurrence. The order is clean, the medical record supports it, and the test is on the lab's menu for a reason. Weeks later the remittance comes back as a denial: not medically necessary. No one at the plan called the ordering physician. There may not have been a human in the loop at all until an appeal forced one. If that scenario feels familiar, you are living inside the central tension of prior authorization in 2026. Artificial intelligence is now on both sides of the table. Payers use it to screen, flag, and sometimes deny requests at scale. Providers and labs are racing to use it right back, to assemble documentation, predict denials, and appeal faster. And regulators, from Congress to state legislatures, are trying to draw a line between AI that makes the process faster and AI that simply makes "no" cheaper to produce. For a diagnostics or molecular lab, this is not an abstract policy debate. Your revenue depends on coverage decisions that are increasingly machine-mediated, against policies that change constantly, for tests that are among the hardest in all of medicine to authorize. Here is what is actually happening, what is verified, and what to watch. ## Physicians already believe payer AI is increasing denials Start with how the people on the receiving end see it. In its 2024 prior authorization physician survey of 1,000 practicing physicians, the American Medical Association found that 61% of physicians are concerned that health plans' use of AI is increasing prior authorization denials, and 75% reported that the number of denials had increased somewhat or significantly over the prior five years ([AMA, 2024](https://www.ama-assn.org/press-center/ama-press-releases/physicians-concerned-ai-increases-prior-authorization-denials)). That concern did not come from nowhere. In October 2024, the U.S. Senate Permanent Subcommittee on Investigations, then chaired by Senator Richard Blumenthal, released a report on Medicare Advantage prior authorization finding that major insurers were leaning on predictive technology to deny post-acute care. The report documented that in 2022, one insurer's denial rate for post-acute care was roughly 16 times higher than its overall denial rate ([Senate PSI report, via AHCA/NCAL, 2024](https://www.ahcancal.org/News-and-Communications/Press-Releases/Pages/ICYMI-Senate-Investigative-Report-Finds-Medicare-Advantage-Beneficiaries-Denied-Post-Acute-Care-Nations-Largest-Insurers.aspx)). The point for a lab operator is not to assign blame to any one insurer. It is to recognize that automated utilization management is now an established part of how coverage decisions get made, and that the scrutiny it has attracted is producing real rules you will have to operate under. ## The regulatory response is arriving in three layers ### Layer one: CMS sets the clock and the plumbing The most concrete federal change is the CMS Interoperability and Prior Authorization final rule, CMS-0057-F, issued January 17, 2024. For impacted payers, which include Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs and managed care plans, and most Qualified Health Plan issuers on the federally facilitated exchanges, the rule sets hard decision timeframes: expedited (urgent) requests must be answered within 72 hours and standard requests within 7 calendar days, generally beginning January 1, 2026. Payers must also give a specific reason for every denial. The FHIR-based API requirements, including a dedicated Prior Authorization API, generally carry a later compliance date of January 1, 2027 ([CMS-0057-F fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). Two caveats matter for labs. First, traditional fee-for-service Medicare and most commercial plans are not impacted payers under this rule, so the timeframes do not uniformly cover your book of business. Second, faster decisions are only as good as the data behind them. A 7-day clock on a wrong answer is still a wrong answer; it just arrives sooner. ### Layer two: states require a human behind the decision While CMS standardized the timing, states have gone after the substance, specifically the question of whether a machine can deny care by itself. California's SB 1120, the Physicians Make Decisions Act, took effect January 1, 2025 and prohibits health plans and insurers from denying, delaying, or modifying care based solely on AI; medical-necessity decisions must rest on the enrollee's clinical history and individual circumstances and be reviewed by a qualified human ([Fenwick analysis of SB 1120](https://www.fenwick.com/insights/publications/californias-sb-1120-regulates-ai-in-health-plan-utilization-review-and-management-activities-starting-in-january)). Maryland followed with a law effective October 1, 2025 that closely mirrors California's, requiring that AI tools support, rather than replace, clinician medical-necessity determinations based on the patient's full clinical picture, and adding reporting and audit obligations for carriers ([Alston & Bird, 2025](https://www.alston.com/en/insights/publications/2025/09/maryland-ai-health-care-utilization-management)). A further Maryland measure, HB 1563, effective June 1, 2026, adds quarterly transparency reporting to the Insurance Commissioner on adverse decisions and whether AI was used ([Holland & Knight, 2026](https://www.hklaw.com/en/insights/publications/2026/05/states-continue-efforts-to-regulate-ai-in-healthcare)). These state laws generally reach state-regulated plans, not self-funded ERISA plans or Medicare, so their practical effect on a given claim depends on the plan type. But the direction of travel is unmistakable: a human clinician, not an algorithm alone, is increasingly required to own an adverse medical-necessity decision. ### Layer three: the government tries AI itself, and Congress pushes back The most fast-moving item is the CMS Innovation Center's WISeR Model, short for Wasteful and Inappropriate Service Reduction. It began January 1, 2026 as a six-year pilot running through December 31, 2031 in six states (Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington), testing AI-assisted prior authorization on a defined set of higher-cost Part B services such as skin and tissue substitutes, electrical nerve stimulator implants, and certain knee procedures. CMS has stated that AI may flag requests but that no claim will be denied without review by a qualified human clinician ([Forvis Mazars, 2025](https://www.forvismazars.us/forsights/2025/12/cms-wiser-model-what-providers-need-to-know-by-january-2026)). WISeR drew immediate criticism over its incentive structure. According to the American Hospital Association, participating vendors stand to receive a share of the savings tied to reduced spending, which the AHA argued risks "a perverse incentive to deny care" even with a human-review requirement ([AHA comment letter, 2025](https://www.aha.org/lettercomment/2025-10-23-aha-comments-cms-wiser-model)). The model is now under active repeal pressure. On May 12, 2026, the Government Accountability Office determined that the WISeR notice is a "rule" subject to the Congressional Review Act ([GAO B-337994, 2026](https://www.gao.gov/products/b-337994)), and on May 20, 2026, members of Congress introduced a resolution of disapproval to repeal it, alongside separate legislation and an appropriations amendment aimed at blocking the pilot ([Congress.gov, S.J.Res.192](https://www.congress.gov/bill/119th-congress/senate-joint-resolution/192/text); [Georgetown Medicare Policy Initiative, 2026](https://medicare.chir.georgetown.edu/cmss-wiser-model-faces-potential-repeal-following-gao-determination/)). Treat WISeR as genuinely unsettled. As of mid-June 2026 it is operating, but its scope and survival are contested, and what it tests today may not be what it tests, or whether it exists at all, a year from now. For labs, the more durable lesson is the precedent: even when a payer is the federal government, applying AI to coverage triggers fierce debate about who reviews the machine and who profits from a denial. ## Why diagnostics and molecular labs sit at the sharp end of this Most coverage of AI in prior authorization is written for hospitals and post-acute care. Diagnostics is a harder case, for structural reasons. Molecular and genetic testing is documentation-dense in a way few other services are. Under Medicare's MolDX program, administered through Palmetto GBA, many tests must carry a registered Z-Code that is tied to a technical assessment of the test's analytical validity, clinical validity, and clinical utility, and payers increasingly use those identifiers to automate claim adjudication ([XiFin, MolDX Z-Codes](https://www.xifin.com/resource/blog-post/cracking-the-code-mastering-z-codes-for-molecular-and-genetic-tests/)). When adjudication is automated, the match between the test performed, the exact policy in force, and the codes submitted has to be precise. A registered identifier that is slightly off, a policy that quietly updated, or a clinical-utility requirement the documentation does not address, and an automated "not medically necessary" follows. Layer on top of this the pace of change. Molecular medical policies are revised frequently, coverage varies test by test and payer by payer, and new assays arrive faster than payer policy can settle. The same conditions that make automated payer review error-prone, ambiguous and shifting rules, make automated provider-side defense valuable, but only if the automation is reasoning over the policy that is actually in effect today. ## The real dividing line: grounded automation versus the black box Here is the strategic point, stated plainly. AI in prior authorization is neither savior nor villain. Its trustworthiness comes down to one question: what is it reasoning over? A payer system that produces denials from an opaque model, with rules you cannot inspect and reasoning you cannot trace back to published policy, is the thing regulators in California, Maryland, and Congress are reacting against. The fix the new laws keep reaching for is the same: ground the decision in the individual's clinical facts, keep a qualified human accountable, and make the basis auditable. The provider and lab side deserves the same standard. AI applied to reimbursement is only as good as the underlying payer rules it reasons over. If a tool generates a confident-sounding medical-necessity argument from stale, generic, or invented policy language, it is just a more articulate black box, and it will lose on appeal. The version worth trusting is grounded in real, currently published medical policy, with every assertion traceable to its source document, so that a human can verify it and a payer cannot wave it away. That is the approach Converus takes: structured, current payer medical policy and coverage rules delivered through an API and MCP interface, so the AI tools and revenue-cycle systems your lab already uses can reason over real, source-linked policy instead of guesses. The goal is not to out-automate the payer. It is to make sure that when a decision, on either side, is challenged, the rule it rests on is one you can actually point to. ## What to do with this now Map which of your payers fall under CMS-0057-F's 2026 decision timeframes and which do not, because your follow-up cadence should differ. Track the AI-oversight laws in the states where your patients are covered, since they shape what a defensible appeal can demand. Watch WISeR's status if you operate in its six states, but do not build around a pilot that Congress is actively trying to repeal. And whatever automation you adopt, insist that it cite its sources. In a world where the other side's machine may not, traceability is not a nice-to-have. It is the whole advantage. ## Sources - American Medical Association, "Physicians concerned AI increases prior authorization denials" (2024 prior authorization physician survey, n=1,000): https://www.ama-assn.org/press-center/ama-press-releases/physicians-concerned-ai-increases-prior-authorization-denials - U.S. Senate Permanent Subcommittee on Investigations report on Medicare Advantage prior authorization (Oct. 17, 2024), as summarized by AHCA/NCAL: https://www.ahcancal.org/News-and-Communications/Press-Releases/Pages/ICYMI-Senate-Investigative-Report-Finds-Medicare-Advantage-Beneficiaries-Denied-Post-Acute-Care-Nations-Largest-Insurers.aspx - CMS, "CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)" fact sheet: https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f - Fenwick, analysis of California SB 1120 (Physicians Make Decisions Act), effective Jan. 1, 2025: https://www.fenwick.com/insights/publications/californias-sb-1120-regulates-ai-in-health-plan-utilization-review-and-management-activities-starting-in-january - Alston & Bird, "New Maryland Law Regulates Use of AI in Health Care Utilization Management Reviews" (effective Oct. 1, 2025): https://www.alston.com/en/insights/publications/2025/09/maryland-ai-health-care-utilization-management - Holland & Knight, "States Continue Efforts to Regulate AI in Healthcare: A Review of Legislation Passed in 2026" (Maryland HB 1563, eff. June 1, 2026): https://www.hklaw.com/en/insights/publications/2026/05/states-continue-efforts-to-regulate-ai-in-healthcare - Forvis Mazars, "CMS WISeR Model: What Providers Need to Know by January 2026": https://www.forvismazars.us/forsights/2025/12/cms-wiser-model-what-providers-need-to-know-by-january-2026 - American Hospital Association, comment letter on the CMS WISeR Model (Oct. 23, 2025): https://www.aha.org/lettercomment/2025-10-23-aha-comments-cms-wiser-model - U.S. Government Accountability Office, B-337994, applicability of the Congressional Review Act to the WISeR Model notice (May 12, 2026): https://www.gao.gov/products/b-337994 - Congress.gov, S.J.Res.192, 119th Congress (resolution of disapproval of the WISeR Model rule): https://www.congress.gov/bill/119th-congress/senate-joint-resolution/192/text - Georgetown University Medicare Policy Initiative, "CMS's WISeR Model Faces Potential Repeal Following GAO Determination" (2026): https://medicare.chir.georgetown.edu/cmss-wiser-model-faces-potential-repeal-following-gao-determination/ - XiFin, "Cracking the Code: Mastering Z-Codes for Molecular and Genetic Tests" (MolDX / Palmetto GBA Z-Codes and technical assessment): https://www.xifin.com/resource/blog-post/cracking-the-code-mastering-z-codes-for-molecular-and-genetic-tests/ --- # Build vs. Buy: Keeping Payer Policy Current for a Molecular Lab URL: https://converus.ai/knowledge-base/build-vs-buy-payer-policy-monitoring/ Updated: 2026-06-19 Every molecular lab already has a payer-policy tracking system. It might be a senior biller who keeps the important changes in her head, a shared spreadsheet someone updates when they remember, a billing vendor whose rules you mostly trust, or a piece of software. The question is almost never whether to track payer policy. It is whether the way you track it now can keep pace with how fast it changes, and whether building a better version is smarter than buying one. This article is meant to make that decision clearly, without pretending the answer is the same for every lab. > **Disclaimer**: This is educational, not legal, financial, or procurement advice. The right approach depends on your organization's specifics, and vendor capabilities change over time. Evaluate any solution against your own requirements and consult qualified professionals before making a buying or building decision. Use this information at your own risk. ## First, be honest about what the job actually is "Tracking payer policy" sounds like a monitoring task. It is really four tasks stacked on top of each other, and most build-versus-buy conversations go wrong because they only price the first one. The first task is **detection**: noticing that something changed, across Medicare National and Local Coverage Determinations, MolDX requirements, and the medical policies of every commercial payer you bill. The second is **interpretation**: reading the change and understanding what it actually requires. The third is **translation**: turning that requirement into the specific rule that governs a given test, CPT code, indication, diagnosis, or documentation scenario. The fourth is **propagation**: getting that rule into the places where it has to act, your billing system, your work queues, your prior-authorization process, your staff's daily decisions, before a claim goes out under the old assumptions. A spreadsheet handles detection, badly. It does nothing for the other three. When people say payer-policy tracking is hard, what they usually mean is that the last three tasks are invisible, unglamorous, and never finished, because the policies never stop moving. ## The change never stops, and that is the whole point The case for taking this seriously is not theoretical. Look at just the last two years of changes a molecular lab had to absorb: - Medicare's NGS coverage determination (NCD 90.2) shifted in 2018 and again in 2020, each time adding criteria that a claim must satisfy. - The MolDX program turned the DEX Z-Code into a hard gate: as of **May 1, 2025**, MolDX claims submitted without the Z-Code in the correct claim field deny as unprocessable, with no clinical review at all (per Noridian guidance). - UnitedHealthcare extended a DEX Z-Code requirement to its commercial molecular claims, announced for April 1, 2024 and then **delayed to June 1, 2024**. - The federal prior-authorization rule (CMS-0057-F) introduced new payer decision timelines effective January 1, 2026, with API requirements following in 2027. None of these was front-page news inside a lab. Each one quietly changed the conditions a clean claim must meet, and each one created a fresh denial pattern for any lab that did not catch it in time. That is the real shape of the work: not a few big events you can plan around, but a constant drip you have to stay ahead of. Whatever you build or buy has to be built for the drip, not the headline. ## The case for building Building your own payer-policy capability has genuine advantages, and they are worth stating plainly so the decision is fair. You get **control**. The rules are yours, shaped exactly to your test menu, your payer mix, and your interpretations. You get **institutional knowledge**: the analyst who has tracked a payer for three years understands its quirks in ways no generic tool encodes. And you avoid a vendor dependency for something central to your revenue. The cost of building is not the initial setup. It is the maintenance, and it is permanent. Detection, interpretation, translation, and propagation are not a project you finish; they are a process you staff forever, because the policies keep changing. The expense is mostly skilled labor, and it is easy to underestimate because it hides inside headcount and inside the denials that leak through whenever a change is missed during a vacation, a turnover, or a busy quarter. Building is the right call when payer-policy operations is a competency you want to own and resource as a permanent function, not a side duty bolted onto a billing team that already has a day job. ## The case for buying Buying turns a permanent internal process into someone else's permanent process. The advantages are speed and breadth: a dedicated platform tracks far more sources, far more continuously, than most labs can justify staffing for, and it spreads that cost across many customers. But "buy" is not one thing, and this is where labs get the decision wrong. The tools in this space differ enormously in what they actually deliver, and the differences map directly onto the four tasks above: - Some tools stop at **detection and alerting**, they tell you a policy changed and leave interpretation, translation, and propagation to you. Useful, but you still own three of the four jobs. - Some are oriented toward **pharmaceutical market access** rather than the operational reality of a diagnostics lab, so the data is real but framed for a different buyer. - Some deliver **structured, usable rules** rather than just notifications, which is the difference between knowing a policy moved and having the new requirement actually applied to the right test and indication. - Some expose that rule layer through an **API or programmatic interface** so it can flow into your own systems, billing, work queues, and even AI agents, instead of living in a dashboard a human has to check. When you evaluate a "buy" option, those are the axes that matter: which sources it covers, how quickly it detects change, and how far down the chain it carries the work. A tool that only alerts you has handed back the hard part. A tool that delivers current, structured rules you can act on, ideally programmatically, has actually absorbed the burden. ## The decision, distilled Strip away the noise and the choice comes down to a few honest questions. How many payers and tests do you have to keep current, and how often do those policies change? The higher the volume and velocity, the worse spreadsheets and tribal knowledge scale, and the stronger the case for a dedicated capability, built or bought. Is payer-policy operations a core competency you want to own and staff permanently, or a commodity you want handled so your people can focus elsewhere? Be honest about whether you will actually fund the in-house version through turnover and busy seasons, or whether it will quietly degrade. And if you buy, does the tool carry the work all the way to an actionable, current rule, or does it just tell you something changed? The whole value is in how much of detection, interpretation, translation, and propagation it genuinely takes off your plate. ## What "good" looks like, and where this points The reason this decision matters is that the cost of getting it wrong is measurable. A 2025 *JAMA Network Open* study found that **23.3% of Medicare cancer-NGS claims were denied**, climbing to **27.4%** after coverage expanded in 2020, with a **median denied charge of $3,800**. Most molecular denials are operational, which is another way of saying they are produced by claims that did not match a current rule. Stale policy tracking is not a tidy inconvenience; it is the upstream source of a meaningful share of your denial rate. The strongest position a lab can be in is to treat payer policy as live data, detected at the source, translated into the specific rules that govern each test and indication, kept current automatically, and delivered into the systems and workflows where it has to act, including through an API or MCP so your own tools and agents can use it directly. That is the bar to hold any option against, build or buy. It is also, candidly, the standard Converus was designed to meet: a maintained rule layer over payer policy, contracts, fee schedules, and mandates, usable across your team, your systems, and your AI workflows. Whether you build that capability or buy it, the goal is the same, your claims should reflect today's rules, not last year's. ## Sources - Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare — *JAMA Network Open*, April 18, 2025 (doi:10.1001/jamanetworkopen.2025.5785; PubMed 40249617) - Proper Submission of DEX Z-Code for Molecular Diagnostic Services (MolDX) Claims — Noridian Healthcare Solutions (effective May 1, 2025) - Make Sure Molecular Tests Have a Z-Code Assigned — UnitedHealthcare (commercial Z-Code requirement, 2024) - CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) — Centers for Medicare & Medicaid Services - National Coverage Determination (NCD 90.2): Next Generation Sequencing — Centers for Medicare & Medicaid Services --- # CMS-0057-F: What the Prior Authorization Final Rule Actually Changes for Diagnostic and Molecular Labs URL: https://converus.ai/knowledge-base/cms-0057-f-prior-authorization-labs/ Updated: 2026-06-19 If you run a molecular or diagnostic lab, you have probably already heard CMS-0057-F described as an "interoperability rule," filed it under someone else's problem, and moved on. That instinct is understandable. The Federal Register text reads like an IT procurement document, full of FHIR APIs, implementation guides, and content standards. But buried inside that health-plan and engineering framing are a handful of operational changes that land directly on your prior authorization and appeals desk, and on the oncology and specialty practices that order your tests. > **Disclaimer:** This article is educational and is not legal, compliance, or billing advice. Regulatory requirements and timelines change, and the summaries here are simplified. Always verify the current text against CMS's published guidance and consult qualified legal, compliance, or revenue-cycle professionals before acting. Use this information at your own risk. So let us translate the rule out of payer-IT language and into the reality of submitting a PA for a comprehensive genomic profile and fighting a denial when it comes back. ## What CMS-0057-F Is, in Plain Terms CMS finalized the Interoperability and Prior Authorization Final Rule, CMS-0057-F, in early 2024, with the rule published in the Federal Register on February 8, 2024 ([CMS press release](https://www.cms.gov/newsroom/press-releases/cms-finalizes-rule-expand-access-health-information-improve-prior-authorization-process)). It does two broad things: it speeds up and adds transparency to prior authorization, and it requires payers to build standardized data pipes (FHIR APIs) so clinical and PA information can move electronically. The first thing to nail down is scope, because it determines whether any given denial on your aging report is even touched by this rule. The impacted payers are Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan (QHP) issuers on the Federally Facilitated Exchanges ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). That is a meaningful slice of a typical molecular lab's payer mix, especially if you carry significant Medicare Advantage volume. But notice what is missing: standalone commercial PPOs and self-insured employer (ERISA) plans are not directly bound by CMS-0057-F. In practice, several of the largest national payers run MA, Medicaid managed care, and exchange business under the same roof, so the workflows and portals they build to comply often bleed into how they handle other lines too. Still, when you cite this rule in an appeal, cite it only against an in-scope plan. The second thing to nail down, and it matters enormously for labs, is that the prior authorization provisions generally **exclude drugs** ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). The faster clocks, the specific-denial-reason mandate, the public metrics, and the dedicated PA API all apply to medical items and services other than drugs. For a diagnostic lab that is good news: the tests you bill, your molecular panels, your CGP, your hereditary cancer panels, your MRD assays, are medical services, squarely the kind of item the rule is designed to move faster. CMS handled drug prior authorization separately in a later proposed rule, CMS-0062-P ([CMS-0062-P overview](https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p)). If a practice that orders your companion diagnostic is also chasing PA for the targeted therapy itself, that drug-side authorization is a different regulatory animal. ## The Decision Clock: 72 Hours and 7 Days Here is the change you will feel first. Effective January 1, 2026, impacted payers, excluding QHP issuers on the FFEs, must send prior authorization decisions within **72 hours for expedited (urgent) requests** and **7 calendar days for standard (non-urgent) requests** ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). For some payers, CMS notes this represents roughly a 50% improvement over prior standard-request timelines. Translate that into your PA queue. If your lab or an ordering oncology practice submits a standard PA for an NGS panel to a Medicare Advantage plan, the clock the plan is working against is now seven calendar days, not the open-ended limbo that has historically forced your team to call, hold, and re-call. That cuts both ways. The upside is a more predictable turnaround that you can build into specimen handling and test-launch timing. The catch is that a faster decision is only as good as the completeness of what you submit, because an incomplete packet still gets bounced, just faster. A tighter clock rewards labs that send a clean, fully documented request the first time: the right CPT and HCPCS codes, the specific cancer diagnosis (ICD-10 code, not a generic "malignant neoplasm" placeholder), the clinical indication, and the medical-necessity documentation the payer's policy actually demands. The labs that win the seven-day clock are the ones who already know, before they hit submit, exactly what that payer requires for that test and that indication. One nuance worth flagging for your billing leads: QHP issuers on the Federally Facilitated Exchanges are carved out of these specific decision timeframes ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). They are still subject to the denial-reason and metrics provisions below, but do not assume a 72-hour or 7-day clock applies to an exchange QHP plan. ## Specific Denial Reasons: The End of "Not Medically Necessary" Beginning in 2026, impacted payers must provide a **specific reason** for denied prior authorization decisions, regardless of how the decision is communicated, whether by portal, fax, email, mail, or phone ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). On paper this is a transparency requirement. In your appeals workflow, it is a lever. Anyone who has worked molecular denials knows the maddening pattern: a PA comes back denied with nothing more than "does not meet medical necessity" or a bare denial code, and your appeals coordinator is left guessing whether the problem was the diagnosis code, a missing prior-test result, a coverage policy the test simply does not fit, or a documentation gap. You cannot efficiently rebut a reason you cannot see. A requirement that the payer state the specific reason for the denial means your team should increasingly be able to target the appeal at the actual deficiency rather than throwing the whole chart back over the wall and hoping. For a lab, that changes the economics of appeals. When you know the specific reason, you can sort denials into the ones genuinely worth appealing (the payer misread your documentation, or you can supply exactly what was missing) versus the ones where the test truly falls outside the policy and your energy is better spent on patient financial counseling or a coverage pathway that fits. It also makes denial-reason data far more useful in aggregate: if a specific payer keeps denying a given assay for the same stated reason, that is a signal about a policy interpretation you can address upstream, in how you build the PA in the first place, rather than one appeal at a time. ## Public Metrics: Your Payers Now Have to Show Their Work The rule also requires impacted payers to publicly report certain aggregated prior authorization metrics, posted on their public-facing websites annually. The first reporting cycle covers calendar year 2025 data, due to be posted by **March 31, 2026** ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f); [CMS Prior Authorization API FAQ](https://www.cms.gov/priorities/burden-reduction/overview/interoperability/frequently-asked-questions/prior-authorization-api)). These metrics cover medical items and services subject to prior authorization, again excluding drugs, and include things like the list of items and services that require PA, approval and denial rates, and how often denials were overturned on appeal. For a revenue-cycle leader, this is reconnaissance that simply did not exist before. When a Medicare Advantage plan publishes how often it denies and how often those denials are overturned, you gain an external benchmark for your own experience with that plan. If a payer overturns a large share of appeals, that tells you appealing is worth the effort. If your overturn rate badly trails the published average, that is a prompt to examine your own submission and appeal quality. Used well, these public numbers help you decide where to invest scarce appeals capacity instead of treating every payer the same. ## The Four APIs: Plumbing That Will Reshape PA Submission The interoperability half of the rule requires impacted payers to build and maintain four FHIR-based APIs, generally with compliance beginning **January 1, 2027** (phrased around rating periods and plan years on or after that date for managed care and QHP issuers) ([CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)). The four are the Patient Access API, the Provider Access API, the Payer-to-Payer API, and a dedicated **Prior Authorization API** ([CMS-0057-F final rule](https://www.cms.gov/files/document/cms-0057-f.pdf)). The Prior Authorization API is the one to watch. It is designed to let a provider's system query, electronically, whether a given item or service requires prior authorization and what documentation the payer needs, then submit the request and receive the decision through a standardized pipe rather than a fax queue or a portal designed for office visits. For a molecular lab, the promise is structured, machine-readable answers to the two questions that govern every PA you touch: does this test, for this patient and indication, require authorization, and exactly what does this payer want to see. That is a meaningful step away from PDFs, policy hunts, and phone trees, and toward requirements you can query and act on programmatically. Note again that this API, like the rest of the PA provisions, excludes drugs. ## What This Adds Up To for Labs and the Practices That Order You Step back and the three operational changes point in the same direction. Decision clocks are getting shorter, so a clean first submission matters more than ever. Denials must now carry a specific reason, so the value of knowing precisely which requirement you missed goes up. And the Prior Authorization API is being built to deliver payer requirements in structured form. Each of these raises the premium on one thing: knowing, in structured and current form, exactly what each in-scope payer requires for each test and each indication, before the request goes out. That is harder than it sounds, because payer policies are scattered across coverage documents, medical policies, PA lists, and benefit-management vendor pathways, and they change on rolling schedules. Maintaining that knowledge by hand, per payer, per test, is exactly the kind of work that does not scale. This is the category Converus works in, turning payer prior-authorization and coverage requirements into structured, queryable form, and it is a natural consumer of the very PA APIs CMS-0057-F is bringing online. As those pipes come up in 2026 and 2027, the labs positioned to benefit are the ones that already treat "what does this payer require" as structured data rather than tribal knowledge. CMS-0057-F is not the end of prior authorization for molecular testing. But it does change the terms of the game, and labs that read it as an operations rule rather than an IT footnote will be the ones who turn the new clocks, the new transparency, and the new plumbing into fewer denials and faster cash. ## Sources - [CMS Interoperability and Prior Authorization Final Rule CMS-0057-F, CMS Fact Sheet](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f) - [CMS Press Release: CMS Finalizes Rule to Expand Access to Health Information and Improve the Prior Authorization Process](https://www.cms.gov/newsroom/press-releases/cms-finalizes-rule-expand-access-health-information-improve-prior-authorization-process) - [CMS Prior Authorization API FAQ](https://www.cms.gov/priorities/burden-reduction/overview/interoperability/frequently-asked-questions/prior-authorization-api) - [CMS-0057-F Final Rule (full text PDF)](https://www.cms.gov/files/document/cms-0057-f.pdf) - [Federal Register: Advancing Interoperability and Improving Prior Authorization Processes (Feb 8, 2024)](https://www.federalregister.gov/documents/2024/02/08/2024-00895/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-advancing-interoperability) - [CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P) overview](https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p) --- # Why an FDA Companion Diagnostic Is the Cleanest Path to Medicare Coverage for an NGS Test URL: https://converus.ai/knowledge-base/companion-diagnostic-medicare-coverage/ Updated: 2026-06-19 A molecular lab can run two technically identical next-generation sequencing panels on two Medicare patients and watch one claim sail through while the other lands in an appeals queue. The difference often is not the science in the assay. It is whether the test carries FDA companion-diagnostic standing and is being used for the cancer the FDA cleared it for. That single distinction is the most reliable lever a lab or oncology practice has over Medicare coverage of an NGS test, and it is worth understanding precisely why. > **Disclaimer**: This article is educational and is not medical, legal, or billing advice, nor a coverage determination for any specific patient, test, or claim. Coverage rules change, Medicare Administrative Contractors apply their own local policies, and the only authoritative sources are the current NCD and applicable LCD language. Verify against CMS's current policy and consult qualified clinical, billing, and compliance professionals before making coverage, billing, or treatment decisions. Use this information at your own risk. ## What a companion diagnostic actually is A companion diagnostic, or CDx, is a test the FDA reviews and authorizes alongside a specific therapy. The FDA's own definition is narrow and deliberate: a companion diagnostic is an in vitro diagnostic device or imaging tool that provides information that is essential for the safe and effective use of a corresponding therapeutic product ([FDA](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)). In oncology this usually means identifying patients whose tumors carry a particular biomarker, an EGFR mutation, a BRAF V600E alteration, microsatellite instability, so a clinician can match them to a drug that works for that biomarker. The key point is that a companion diagnostic is not just a good test. It is a test the FDA has formally tied to a drug and an indication. The FDA maintains a public, regularly updated list of cleared or approved companion diagnostic devices, which is the authoritative place to confirm whether a given assay holds CDx status and for which therapies and tumor types ([FDA](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)). That regulatory anchoring is precisely what Medicare's coverage framework leans on. ## The rule that ties CDx status to coverage: NCD 90.2 Medicare's national coverage rule for cancer NGS is National Coverage Determination 90.2, first finalized in March 2018 and later amended ([CMS NCD 90.2](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372); [CMS press release](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients)). The rule is often summarized as "Medicare covers NGS for advanced cancer," but that summary hides the structure that matters most. NCD 90.2 does two different jobs at once. For some tests it establishes a national coverage pathway. For others it hands the decision to local Medicare Administrative Contractors. Companion-diagnostic status is what determines which door a test comes through. The companion-diagnostic door is the cleaner one. Under NCD 90.2, an NGS diagnostic laboratory test has a defined national coverage pathway when it meets a specific set of conditions ([CMS NCD 90.2 Decision Memo](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=296)): - The test is performed in a **CLIA-certified laboratory** and is **ordered by the treating physician**. - The patient has **recurrent, relapsed, refractory, metastatic, or advanced (stage III or IV) cancer**, has **not been previously tested** with the same NGS test for the same primary cancer diagnosis, and **has decided to seek further cancer treatment**. - The test has **FDA approval or clearance as a companion in vitro diagnostic**. - The test has an **FDA-approved or cleared indication for use in that patient's cancer** (this is the on-label requirement). - **Results are provided to the treating physician** for management of the patient, using a report template to specify treatment options. When all of those hold, you are inside the national pathway. CMS put the consequence plainly: tests that gain FDA approval or clearance as an in vitro companion diagnostic receive full coverage under the final NCD, provided the other coverage criteria are also met ([CMS press release](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients)). That is as close to a predictable national "yes" as Medicare offers for an NGS assay, and it is the throughline of this whole discussion. ## Why "on-label" is the load-bearing word Read the criteria again and notice that FDA companion-diagnostic status alone is not enough. The rule requires an FDA-approved or cleared indication for use *in that patient's cancer*. That is the on-label requirement, and it is the part labs most often gloss over. Many modern NGS panels are approved as companion diagnostics for several drug-and-tumor combinations at once while also reporting a much wider set of genomic findings. FoundationOne CDx, for example, received FDA approval on November 30, 2017 as the first NGS-based companion diagnostic to incorporate multiple companion-diagnostic indications across solid tumors ([FDA, FoundationOne CDx P170019](https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048); [NCI](https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer)). Guardant360 CDx, a liquid-biopsy panel, was FDA-approved in 2020 ([Guardant Health investor relations](https://investors.guardanthealth.com/press-releases/press-releases/2020/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers/default.aspx)). Both keep adding companion-diagnostic indications over time as new drug approvals arrive. The CDx label is therefore specific, not blanket. Running an FDA-approved companion diagnostic for a tumor type or purpose that falls outside its cleared indications is, for coverage purposes, an off-label use, and off-label use does not ride the national companion-diagnostic pathway. The same physical test can be on-label for one patient and off-label for the next. Coverage predictability lives in that match between the patient's cancer and the test's cleared indication, as of the date of service, which is why any specific claim should be checked against current FDA labeling and current NCD and LCD policy rather than assumed. ## The other door: contractor discretion So what happens to NGS tests that are not FDA-approved or cleared companion diagnostics, or that are used off-label? NCD 90.2 does not cover them nationally. It leaves coverage to the Medicare Administrative Contractors when the same clinical criteria are met ([CMS NCD 90.2](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372)). In much of the country that determination runs through the MolDX program, administered by contractors including Palmetto GBA, Noridian, CGS, and Wisconsin Physicians Service ([Precision Medicine Online](https://www.precisionmedicineonline.com/reimbursement-news/medicare-contractors-final-coverage-decision-ngs-cancer-testing-appeases)). MolDX maintains its own billing and coding articles distinguishing targeted panels from comprehensive genomic profiling, with CGP expected to yield clinically relevant information beyond a targeted panel, such as identifying clinical trials or possible therapeutic interventions for off-label use ([CMS, MolDX article A56518](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56518)). This is meaningful coverage, but it is local coverage. It can differ by contractor and jurisdiction, it can change, and it requires meeting contractor-specific criteria. As one industry analysis put it, the national rule covers FDA-approved companion diagnostics but leaves laboratory-developed NGS tests without FDA approval to the MACs, so coverage for those tests continues to vary by jurisdiction ([Precision Medicine Online](https://www.precisionmedicineonline.com/reimbursement-news/medicare-contractors-final-coverage-decision-ngs-cancer-testing-appeases)). That variability is the whole reason CDx, on-label status is the cleaner lever. One door is a defined national pathway. The other is a shifting patchwork. ## A quick way to triage a test When you are trying to predict how a Medicare NGS claim will be treated, the same handful of questions sort most cases: 1. **Is the test FDA-approved or cleared as a companion in vitro diagnostic?** Confirm on the FDA's public CDx list, not on marketing copy. 2. **Is the patient's cancer within the test's FDA-cleared indication on the date of service?** This is the on-label check, and it is per patient, per indication. 3. **Does the patient meet the NCD's clinical gate?** Advanced or metastatic disease, treating-physician order, CLIA lab, no duplicate prior NGS for the same diagnosis, seeking further treatment. 4. **Are results returned to the treating physician** to guide management? If the answer to all four is yes, you are in the national companion-diagnostic pathway, the most predictable position available. If any answer is no, you are likely in contractor-discretion territory, where the analysis is real but local and variable. ## The limits worth stating plainly The companion-diagnostic pathway is the cleanest route, not a universal one, and it is worth being honest about where it stops. It is conditional, not automatic. Even an on-label companion diagnostic still has to clear the clinical criteria; CMS's language is full coverage *provided the other coverage criteria are also met* ([CMS press release](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients)). It is bounded by stage. The somatic pathway is built around advanced and metastatic disease, so it does not by itself reach most early-stage testing. Germline testing follows its own track: a 2020 amendment added a national pathway for certain inherited-cancer testing, effective for dates of service on and after January 27, 2020, again subject to defined criteria ([CMS NCD 90.2](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372)). And coverage in principle is still not a paid claim: documentation that the criteria were met, accurate coding, and avoidance of duplicate testing all decide whether an otherwise-covered test is actually reimbursed. Report CPT and PLA codes by number and confirm the current descriptor and any contractor billing rules rather than relying on memory. None of this is static. Companion-diagnostic indications expand as new drugs are approved, FDA labeling changes, and contractor policies are revised. A test that is on-label and covered for an indication today may have a broader, or differently defined, footprint next quarter. Treat every specific determination as a point-in-time answer to verify, never a permanent one. ## Where this leaves a lab or practice The strategic takeaway is simple to state and easy to underweight. The most reliable thing you can do to make an NGS test's Medicare coverage predictable is to keep it inside the FDA companion-diagnostic, on-label lane, because that lane is governed by a defined national pathway. Everything outside it, off-label use of a CDx, non-CDx panels, comprehensive genomic profiling for trial-matching or off-label drug exploration, lives in a patchwork of local and commercial policy that shifts by contractor, by indication, and over time. That per-test, per-indication coverage logic is exactly what is hard to track by hand and exactly what [Converus](https://converus.ai) is built to monitor, so labs and revenue-cycle teams can see which uses sit on the clean national pathway and which depend on local discretion before the claim goes out. The article you are reading is a starting point, not a determination; confirm the current FDA labeling and the current NCD and LCD policy for any specific test and patient. ## Sources - [CMS, National Coverage Determination (NCD) 90.2: Next Generation Sequencing (NGS)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372) - [CMS, NCA Decision Memo, Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=296) - [CMS press release, CMS finalizes coverage of Next Generation Sequencing tests](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients) - [FDA, List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools) - [FDA, FoundationOne CDx (F1CDx) P170019/S048](https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048) - [NCI, FDA Approves Two Genomic Profiling Tests for Cancer](https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer) - [Guardant Health, Guardant360 CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers](https://investors.guardanthealth.com/press-releases/press-releases/2020/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers/default.aspx) - [CMS, MolDX: Targeted and Comprehensive Genomic Profile Testing in Cancer (Billing and Coding Article A56518)](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56518) - [Precision Medicine Online, Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders](https://www.precisionmedicineonline.com/reimbursement-news/medicare-contractors-final-coverage-decision-ngs-cancer-testing-appeases) --- # Denials 101: A Taxonomy of Denial Reasons and How to Escalate Each URL: https://converus.ai/knowledge-base/denials-101/ Updated: 2026-05-06 ## Why Denial Taxonomy Matters When a prior authorization or claim comes back denied, the worst thing a revenue cycle team can do is launch a generic appeal. Payers process thousands of appeals; a letter that doesn't directly address the denial reason reads as noise and fails at a high rate. The first step in every denial workflow should be the same: identify the specific denial reason code and the policy basis the payer cited. That information tells you exactly what argument you need to make, which documentation to gather, and which escalation pathway to pursue. This article maps the most common denial categories for genetic testing and oncology and provides a practical escalation guide for each. ## Category 1: Medical Necessity Denial **What it means**: The payer's reviewer determined that the submitted clinical information did not satisfy the coverage criteria for the requested service. This is the most common denial type in genetic testing and oncology, and it is also the most frequently overturned on appeal. **Why it happens**: Medical necessity denials often reflect documentation gaps rather than a genuine lack of clinical appropriateness. The ordering provider's notes may support the service clearly, but if the PA submission did not include the right ICD-10 code combination, the treating physician's specific clinical reasoning, or the applicable guideline reference (e.g., NCCN category designation), the reviewer cannot make the connection. **Escalation pathway**: 1. **Request a peer-to-peer review immediately**. Most payers allow 5–14 business days post-denial. A physician-to-physician conversation is the highest-yield intervention for medical necessity denials. The ordering physician should be prepared to walk through the clinical rationale, guideline support, and why alternatives are inappropriate. 2. **First-level administrative appeal**: If peer-to-peer fails or is unavailable, submit a formal appeal with enhanced documentation, a detailed letter of medical necessity from the treating physician, the specific NCCN guideline page with the applicable category designation, and any relevant peer-reviewed literature. 3. **External review**: If internal appeals are exhausted, request an independent external review under state or federal law. Independent reviewers approve at materially higher rates than payer internal reviewers for oncology services. ## Category 2: Missing or Insufficient Documentation **What it means**: The payer received the request but indicated that required supporting documentation was absent or incomplete. This is technically a "pend" or "hold" rather than a true denial, but it functions like one if the deadline to respond is missed. **Why it happens**: Payers publish specific documentation checklists in their PA guidelines that differ by service. For genetic testing, common missing elements include: ordering provider NPI, treating diagnosis with supporting clinical notes, prior testing results (especially for reflex or companion testing), family history documentation, and, for MolDX-managed tests, the DEX Z-code. **Escalation pathway**: 1. **Respond within the payer's stated timeframe**, typically 10–14 business days. Missing this window converts a pend to a denial with stricter appeal rights. 2. **Submit the complete documentation package**, not just the missing item. Payers often identify only one gap in the initial request; a complete resubmission prevents another round-trip. 3. If denied due to missed deadline, appeal on procedural grounds and simultaneously resubmit as a new PA request if clinically timely. ## Category 3: Non-Covered Service **What it means**: The payer determined that the requested service is simply not a covered benefit under the patient's plan, regardless of medical necessity. **Why it happens**: Benefit exclusions are common for certain categories of genetic testing, particularly when laboratory-developed tests (LDTs) are not included in a payer's contracted test menu, or when a molecular test has not yet been added to the payer's covered services list. **Escalation pathway**: 1. **Verify the denial is truly a benefit exclusion** and not a miscoded medical policy denial. Request the specific contract language or benefit document the payer relied on. 2. **Check for exceptions**: Some plans exclude genetic testing categorically but include exceptions for companion diagnostics required by FDA-approved therapies or for NCCN Category 1 indications. 3. **File a coverage determination request**: If you believe the service should be covered based on parity laws, state mandates, or the ACA's preventive care provisions, file a formal coverage determination challenge. 4. **Patient assistance pathway**: If the service is genuinely excluded and the patient has a compelling clinical need, engage the treating physician to explore manufacturer patient assistance programs. ## Category 4: Prior Authorization Not Obtained **What it means**: The service was delivered before PA was obtained, and the payer is denying the claim on that basis. This is a process failure, not a clinical one. **Why it happens**: Emergency or urgent clinical situations, rapid turnaround requirements for time-sensitive oncology decisions, or breakdowns in the PA workflow between the ordering provider and the lab. **Escalation pathway**: 1. **Retro-authorization**: Many payers accept retroactive PA requests for services rendered in emergent or urgent circumstances. Submit within the payer's retro-auth window (often 24–72 hours post-service for emergencies; some allow up to 30 days). 2. **Document the clinical urgency**: The appeal should explain why obtaining PA prior to service delivery was clinically not feasible, for example, a biopsy result that necessitated immediate next-generation sequencing to guide treatment decisions with a narrow window. 3. **Review the provider agreement**: Some provider contracts limit or waive PA requirements for certain service types. Confirm whether the denial has any contractual basis. ## Category 5: Experimental or Investigational **What it means**: The payer classified the requested service as experimental or investigational (E&I), meaning it does not yet meet their evidentiary standards for coverage. **Why it happens**: This denial is particularly common for novel biomarker assays, laboratory-developed tests, and emerging companion diagnostics. Payers typically require FDA approval, consistent peer-reviewed evidence, and often MolDX or NCCN endorsement before reclassifying a test from investigational to covered. **Escalation pathway**: 1. **Build the evidentiary case**: Compile peer-reviewed publications demonstrating clinical utility (not just analytical validity), FDA clearance or approval documentation, NCCN guideline listings, and any positive coverage determinations from other payers or CMS. 2. **Challenge the classification**: If the test has FDA approval and NCCN Category 1 or 2A designation, the E&I classification is often legally challengeable. File an appeal citing these authorities directly. 3. **Clinical trial coverage**: If the patient is enrolled in a clinical trial, the ACA mandates coverage of routine costs for qualifying trials. File under this provision if applicable. 4. **Medical necessity + E&I combination appeal**: Some payers will approve a service under E&I exception criteria when standard therapy has failed and no covered alternative exists. Frame the appeal around treatment necessity and lack of alternatives. ## Category 6: Duplicate Claim or Service **What it means**: The payer flagged the claim as a duplicate of a previously processed claim or of a service delivered within a defined service frequency period. **Why it happens**: Molecular testing can trigger this denial when a reflex or reflexed-to test uses the same CPT code family as a prior test, or when billing for a panel and individual components occurs simultaneously. **Escalation pathway**: 1. **Review for coding errors**: Confirm the claim was not a true duplicate. If it was, correct and resubmit. 2. **Document clinical distinction**: If the new test is clinically distinct (e.g., a somatic panel following a germline test, or a repeat test after a clinically significant interval), the appeal should clearly articulate the clinical differentiation and cite the specific policy basis that permits repeat testing. ## Category 7: Benefit Coordination / Other Insurance Primary **What it means**: The payer is indicating that another insurer is primary and should be billed first. **Escalation pathway**: Verify COB (coordination of benefits) information with the patient. Bill the correct primary payer first, then submit the secondary claim with the EOB from the primary payer attached. ## Building a Denial Management Program Effective denial management is a system, not a firefighting exercise. At a minimum, your team should: - Track denial reasons by category, payer, and test type to identify patterns - Establish time-sensitive peer-to-peer request triggers (within 48 hours of medical necessity denial) - Maintain a library of clinical literature and guideline citations indexed by test and indication - Monitor appeal overturn rates by denial type and payer to prioritize effort The data consistently shows that 60–70% of prior authorization denials that go to appeal are overturned. The bottleneck is not the outcome, it is the bandwidth and process to pursue them systematically. --- # eviCore Guidelines for Oncology: What Practices Need to Know in 2026 URL: https://converus.ai/knowledge-base/evicore-guidelines-oncology/ Updated: 2026-05-06 When Cigna or Aetna tells you a PA request for oncology testing is "managed by eviCore," you're entering a different process, different portal, different clinical criteria, different appeal pathway. It trips up practices that assume it's the same as going through the payer directly. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## What eviCore Is and Who Uses It eviCore healthcare (now part of Evernorth, Cigna's health services subsidiary) is a specialty benefits management company that payers contract with to conduct clinical reviews for high-cost services. Rather than building internal clinical review capacity for oncology imaging, radiation oncology, and molecular testing, payers outsource the review to eviCore, which uses its own set of evidence-based clinical guidelines. As of 2026, eviCore manages oncology-related PA reviews for: Cigna commercial and Medicare Advantage plans, Aetna commercial plans in select markets, multiple Blue Cross Blue Shield affiliates, and UnitedHealthcare Medicare Advantage plans for certain testing categories. The specific services they manage differ by payer, one payer might route only oncology imaging through eviCore while routing molecular testing through their own clinical team. Verify which services are eviCore-managed for each payer by checking the payer's PA list or calling provider services. ## How to Submit Through the eviCore Portal Go to evicore.com, select your payer from the dropdown, and log in with your provider credentials. Each payer routes to its own submission queue within the same platform. You'll enter: the member ID, plan information, ordering provider NPI, CPT code(s), ICD-10 diagnosis codes, and clinical information. The clinical questionnaire is dynamic, it changes based on the CPT code and the diagnosis you enter. Answer each question specifically. eviCore reviewers flag vague answers. "Patient has advanced cancer" will not satisfy a question asking for specific staging and prior treatment history. For molecular testing (NGS panels, biomarker testing, comprehensive genomic profiling), eviCore's clinical pathways require: tumor type confirmed with pathology, disease stage (specific, not "metastatic" alone, but which metastatic sites and whether the disease is newly diagnosed or recurrent), prior systemic treatments with response data, and the specific clinical question the test is intended to answer. Save your case number the moment you submit. eviCore doesn't send confirmation emails reliably. The case number is how you track status and initiate peer-to-peer requests. ## eviCore's Oncology Clinical Pathways eviCore uses its own clinical pathways for oncology that draw on NCCN guidelines, ASCO recommendations, and the medical literature. Their pathways are published (look for "Clinical Guidelines" on the eviCore website), but they're updated frequently and can lag behind or differ from NCCN in specific areas. For comprehensive genomic profiling of solid tumors, eviCore's criteria generally align with NCD 90.2 (CMS's national coverage determination for NGS in cancer). They require: advanced cancer (recurrent, relapsed, refractory, metastatic, or stage 3/4), use in a Medicare-certified lab, and that the test is being used to guide patient management. If you're submitting for an NGS panel on a stage 2 solid tumor, you're fighting an uphill battle with eviCore, their criteria typically require advanced disease. For liquid biopsy and circulating tumor DNA testing, eviCore's coverage is more selective. They generally require a specific clinical rationale for why a tissue-based test isn't feasible (patient not biopsy-eligible, insufficient tissue) rather than covering liquid biopsy as a first-line equivalent. ## What Happens When eviCore Denies When eviCore issues a denial, the denial letter comes from eviCore but on the payer's letterhead (or vice versa, depending on the arrangement). Read it carefully to understand whether you're appealing to eviCore or to the payer, this varies. **Peer-to-peer**: Request it immediately through the eviCore portal or by calling their peer-to-peer line. The window is typically 5 business days from the denial. eviCore's medical directors are clinical, they respond well to specific clinical arguments tied to their published guidelines. Don't call to argue in general; call with the specific guideline section that supports coverage and the specific clinical facts that meet it. **First-level appeal**: If peer-to-peer fails, submit a formal appeal. For most payer arrangements, the first-level appeal goes to eviCore. Include the ordering physician's letter of medical necessity, the relevant NCCN guideline pages, and any supporting peer-reviewed literature. If the denial cites a specific eviCore criterion, address it by name. **Escalation to the payer**: If the eviCore appeal is upheld, the next step depends on whether the plan is fully insured (escalate to the payer's internal appeals department, then external review) or self-insured ERISA (the plan administrator governs the process). This is where you need to know your plan type. ## The Most Common eviCore Denial Reasons for Oncology 1. Staging insufficient, "advanced disease" not adequately documented 2. Test ordered without specifying treatment decision it will guide 3. Repeat NGS panel without documented clinical rationale for retesting 4. Liquid biopsy requested without documentation of tissue biopsy failure 5. CGP ordered for a tumor type where eviCore's pathway doesn't support it Each of these is fixable with the right documentation at the time of submission, not after denial. ## Sources - eviCore Clinical Guidelines, evicore.com (verify current version for your specific payer) - CMS NCD 90.2 (next-generation sequencing in cancer, referenced in eviCore's oncology criteria) - NCCN Clinical Practice Guidelines (NCCN.org), category designations by tumor type - 45 CFR §147.136 (internal claims and appeals for fully insured ACA-compliant plans) - 42 CFR §422.578 (Medicare Advantage coverage determination appeals) - 29 USC §1133 (ERISA full and fair review for self-insured plans) --- # The Five Health Insurance Plan Types Explained URL: https://converus.ai/knowledge-base/five-health-insurance-plan-types/ Updated: 2026-05-19 > ### At a glance > > US employer health plans cluster into five common types. PPO, HMO, HDHP, POS, and EPO. The label on your insurance card decides whether you need a referral, whether out-of-network care is covered, how big your deductible runs, and how much of each visit you pay before insurance even starts. Per the [KFF 2025 Employer Health Benefits Survey](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/), 46% of covered US workers are on a PPO, 33% are on an HDHP, 12% are on an HMO, and 9% are on a POS. > ### Disclaimer > > This article is general educational content and is not medical, legal, tax, or financial advice. Plan rules, payer policies, and federal and state regulations change. Coverage outcomes depend on your specific plan, provider, diagnosis, and circumstances. Dollar amounts in this article are illustrative examples, not quotes for any particular plan. For decisions about your care, coverage, or finances, consult a qualified professional (your insurer's member services, your benefits administrator, a tax professional, a healthcare attorney, or your physician, as appropriate). Use this information at your own risk. ## Why your plan type matters more than the brand name on your card The logo on your insurance card is the part you remember. Aetna. Blue Cross. United. None of that is the part that controls your bill. Four characters underneath the logo do. PPO, HMO, HDHP, POS, or EPO. That is the plan type. It determines whether you can see a specialist without a referral, whether your visit at a clinic across town counts as out-of-network, and how much of the visit comes out of your pocket before the carrier owes a dollar. Two people with cards from the same insurer can have completely different experiences. One pays $30 to see a dermatologist. The other pays $480 because the dermatologist is technically out-of-network. Same logo. Different plan type. This piece walks through the five types you are most likely to see in employer coverage, what each one actually does, and which trade-offs are baked in. ## HMO (Health Maintenance Organization) An HMO is the cheapest of the common plan types on premium, and the most controlled on access. - Lowest monthly premium of the five. - Narrow network. You see in-network doctors only. Going outside the network is generally not covered except for emergencies. - Primary care physician (PCP) requirement. You pick a PCP and they coordinate your care. - Referral required to see a specialist. Per [KFF's 2025 data](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/), about 12% of covered US workers have an HMO. That share has been shrinking for two decades as PPO and HDHP products have taken share. HMOs work well if your PCP is good and your specialists already sit inside the network. If you travel often, see physicians across state lines, or want to bypass the PCP gate, an HMO will friction you. ## PPO (Preferred Provider Organization) The PPO is the most common employer plan in the United States. 46% of covered workers per KFF 2025. - Higher premium than an HMO. - Wide network. You get a discounted rate inside the network and partial coverage outside it. - No PCP requirement. No referral required for specialists. The PPO trades higher monthly premiums for flexibility. You can see any provider you want. The insurer just pays less if that provider is out-of-network, leaving you with a bigger share of the bill. The catch most patients miss: "in-network facility" does not always mean "in-network provider." A hospital can be in your PPO network while the anesthesiologist or radiologist working inside it bills under a separate, out-of-network contract. The federal No Surprises Act blocks balance billing in many emergency and out-of-network-at-in-network-facility scenarios. The protection is narrower than most patients assume. Always confirm both the facility and the individual provider. ## HDHP (High Deductible Health Plan) The HDHP is the plan type that quietly took over the employer market over the last decade. - Lowest premium of the bunch, often paired with employer HSA contributions to soften the trade-off. - Large deductible. The IRS sets the minimums. For 2026, an HDHP has a minimum deductible of $1,700 individual / $3,400 family, with maximum out-of-pocket ceilings of $8,500 individual / $17,000 family (per IRS Revenue Procedure 2025-19). Real-world employer HDHP deductibles often sit between $3,000 and $8,000. - Pairs with a Health Savings Account (HSA). You can put pre-tax money in, invest it, and pull it out for qualified medical expenses tax-free. The 2026 HSA contribution limit is [$4,400 for individual coverage and $8,750 for family coverage](https://www.irs.gov/pub/irs-pdf/p969.pdf), per IRS Publication 969 and Revenue Procedure 2025-19. Catch-up contributions for HSA holders age 55 and over remain at $1,000. - The HDHP label only describes cost-sharing. The network underneath the HDHP can be PPO-style or HMO-style. The trend numbers are striking. Per KFF, HDHP enrollment jumped from 27% of covered workers in 2024 to 33% in 2025. That is the largest year-over-year shift in plan-type mix in the survey's recent history. Here is the opinion. Most workers do not realize the employer plan menu has been quietly shifting toward HDHPs. The premium is lower, so they say yes during open enrollment. Then the first hospital visit comes through, the deductible is $6,000, and the math starts to look very different. If your employer's open enrollment is around the corner, read the Summary of Benefits and Coverage (SBC) before clicking renew. The deductible and out-of-pocket maximum are where the real money lives, not the premium. ## POS (Point of Service) A POS plan is the HMO-PPO hybrid. - PCP and referrals required, like an HMO. - Out-of-network coverage available, like a PPO, at a higher cost. About 9% of covered workers per KFF 2025. POS plans work for patients who want the lower premium of an HMO with a safety valve for out-of-network care. The trade-off is real: the referral gate still applies for the in-network discount, and out-of-network reimbursement at higher coinsurance is rarely cheap. ## EPO (Exclusive Provider Organization) An EPO is essentially a PPO without the out-of-network coverage. - No referral required for specialists, unlike an HMO. - No out-of-network coverage except for emergencies, unlike a PPO. - Premiums sit between HMO and PPO levels. EPOs are common in some regional markets and rare in others. KFF rolls EPO enrollment into PPO or HMO categories depending on the year. If you have one, treat the network like an HMO would and the referral rules like a PPO would. ## Side-by-side comparison | Plan type | Premium tier | Deductible range | Network width | Referrals required | Out-of-network covered | % US workers (KFF 2025) | | --- | --- | --- | --- | --- | --- | --- | | HMO | Low | Low to moderate | Narrow | Yes | Emergency only | 12% | | PPO | High | Moderate | Wide | No | Yes, at a lower benefit | 46% | | HDHP | Lowest | $3,000 to $8,000 | Varies (PPO or HMO underneath) | Depends on underlying network | Depends on underlying network | 33% | | POS | Moderate | Moderate | Narrow in-network, wider out-of-network at higher cost | Yes | Yes, at a lower benefit | 9% | | EPO | Moderate | Moderate | Moderate | No | Emergency only | Rolled into PPO/HMO mix | ## Plan types not covered in depth here A few you might run into that this piece does not walk through: - Catastrophic plans. ACA marketplace plans for people under 30 or with hardship exemptions. Very low premium, very high deductible. Cover preventive services and three primary care visits before the deductible kicks in. - Traditional indemnity plans. Fee-for-service. The plan pays a percentage of the bill from any provider. Rare in employer coverage today. - Direct primary care (DPC). A monthly membership to a primary care practice for unlimited visits. DPC is not insurance and a separate plan is still needed for hospitalizations and specialty care. - Faith-based health-sharing ministries. Members pool money and share medical bills under faith-aligned rules. Exempt from ACA mandates. Coverage rules differ by ministry and are discretionary. ## How to figure out which plan type you have Two places to check. 1. **Your insurance card.** The plan type is usually printed underneath the carrier logo: "HMO," "PPO," "HDHP-HSA," "POS," "EPO." If it just says something like "Choice Plus" or "Open Access," read the fine print or call member services. 2. **Your Summary of Benefits and Coverage (SBC).** Every ACA-compliant plan is required to provide an SBC. It is a standardized summary with deductible, out-of-pocket maximum, coverage examples, and plan-type label. Your HR portal or your insurer's member website has it. The SBC is the single most useful document for understanding your plan. ## The trade-off that applies to all of them Every plan type is some version of the same equation. Pay more every month, or pay more when you actually get sick. HMO: cheap month-to-month, restricted access. PPO: more flexibility, higher premium. HDHP: lowest premium, the deductible eats the difference the first time you have a real medical event. POS and EPO: middle paths with different friction profiles. There is no plan that lets you pay less in both directions. The carriers know what they are doing. The question is which trade-off matches your actual usage pattern over the next year, which means doing a little math instead of picking by name recognition. If you have just gotten a confusing bill and are trying to understand which rules applied to it, the plan type is the first thing to identify. The second is whether the service should have been covered as preventive under the ACA. We cover that in [What's Actually Covered as "Preventive" Under the ACA](/knowledge-base/aca-preventive-services-explained/). And if the bill came after what was supposed to be a "free" annual visit, [Modifier 25 Explained](/knowledge-base/modifier-25-explained/) walks through the most common mechanism that turns a no-cost preventive visit into a billed one. For the operator-side view of the same questions, see [What Is Prior Authorization?](/knowledge-base/what-is-prior-authorization/) and [Denials 101](/knowledge-base/denials-101/). > ### What this means for you > > 1. **Find your SBC** before next open enrollment and read the deductible, out-of-pocket maximum, and coverage example pages. Ignore the premium for one minute. > 2. **Check the plan type on your card.** If it says "HDHP," budget for a $3,000-plus first-event deductible before benefits kick in. > 3. **For HMO and POS plans,** confirm your PCP is the gatekeeper for specialist referrals. Going around the PCP is the fastest way to a denied claim. > 4. **Verify both the facility and the individual provider** are in-network before a scheduled procedure. An in-network hospital does not guarantee an in-network anesthesiologist. ## Sources - [KFF, 2025 Employer Health Benefits Survey](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/) (premium, deductible, and plan-type enrollment) - [IRS Publication 969, Health Savings Accounts](https://www.irs.gov/pub/irs-pdf/p969.pdf) (HDHP and HSA limits) - [HealthCare.gov, Preventive Care Benefits](https://www.healthcare.gov/coverage/preventive-care-benefits/) (plan exemption rules) --- # Genetic Testing Prior Authorization: A Step-by-Step Playbook URL: https://converus.ai/knowledge-base/genetic-testing-prior-authorization-playbook/ Updated: 2026-05-06 Genetic testing prior authorization has its own failure modes. The clinical criteria are test-specific and payer-specific. The coding requires DEX Z-codes for MolDX. The documentation burden is heavier than for most services. Get one thing wrong and you're starting over. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## Step 1: Identify What You're Requesting and Who the Payer Is Start here, not at the portal. The payer and the specific test determine everything that comes next. First, confirm the test type: hereditary (germline) panel, somatic tumor profiling, pharmacogenomics, or a single-gene test. These categories are reviewed under different policies, different clinical criteria, and sometimes different external reviewers. Next, identify the payer and plan type. Commercial fully insured, self-insured employer (ERISA), Medicare, Medicare Advantage, or Medicaid? The plan type determines which policies apply and which appeal rights you have if things go wrong. Then look up whether PA is required for this specific CPT code under this specific payer and plan. Don't assume. UnitedHealthcare's PA list differs by employer group. A self-insured client of Cigna may not require PA for a test that Cigna's standard commercial plan requires it for. Check the payer's provider portal or call. For Medicare patients, check whether the test has an applicable LCD from the MAC covering your region or a National Coverage Determination. For MolDX-managed tests (most molecular diagnostics billed to Medicare in states where Palmetto GBA is the MAC), the test needs a DEX Z-code before billing. If you don't have one, get it through the MolDX technical assessment process before submitting to payer. ## Step 2: Find the Coverage Criteria and Map Your Patient Against Them Pull the payer's current medical policy for the test type. Read the coverage position section, not the background, not the references, the coverage position. Write down every criterion listed. For hereditary cancer panels, you're typically looking at: personal history of cancer at qualifying age, number of affected first- or second-degree relatives, specific cancer types (ovarian, triple-negative breast, colorectal, uterine), ethnic background criteria, prior genetic test results, or meeting a validated risk assessment threshold. The criteria vary by payer. Aetna, Cigna, and UHC each have different thresholds. For somatic tumor profiling (NGS of tumor tissue): confirmed malignancy, cancer type, disease stage (usually advanced/metastatic), and that the result will guide treatment selection. Some policies require documentation that targeted therapy options exist for the cancer type. For pharmacogenomics: this is the hardest category. PGx coverage is narrow across most payers. Most policies cover a limited set of drug-gene pairs for specific clinical situations (pre-transplant medication management, specific psychiatric drug selection). Many policies list PGx as E&I for most indications. Write out the criteria your patient meets. If they don't meet all criteria, decide now whether to proceed with a documentation-strengthening conversation with the ordering physician or whether this is a case that'll need to go to appeal. ## Step 3: Assemble the Documentation Package Don't submit and then chase documentation. Assemble everything before you open the portal. **For hereditary panels**: - Clinical notes documenting the specific qualifying criterion (personal history, family history, risk assessment score) - Pathology reports if personal cancer history is the qualifying criterion - For family history criteria: documentation of the specific relative's diagnosis and relationship, ideally from the patient's chart or a pedigree drawn by a genetic counselor **For somatic tumor profiling**: - Pathology report confirming tumor type, grade, and stage - Clinical notes documenting advanced or metastatic disease - Prior treatment history with dates and response - Statement from the ordering physician explaining what treatment decision the results will inform **For MolDX-managed tests billed to Medicare**: - The test's DEX Z-code (obtained through Palmetto GBA's MolDX program) - ICD-10 diagnosis codes matching the LCD's covered indications - Ordering provider's NPI on the ABN if coverage is uncertain ## Step 4: Submit, and Track Submit through the payer's designated channel. Availity handles most commercial payers. Some payers use their own portals. eviCore manages reviews for some payers' NGS panels. When you submit, record: submission date and time, case/reference number, channel used (portal, fax, EDI), and who submitted. Set a calendar reminder for the expected decision date. Standard PA timelines under federal rules: 15 calendar days for standard non-urgent requests, 3 business days (72 hours) for urgent/expedited, under ACA-compliant commercial plans and Medicare Advantage. If you don't have a decision by day 14, follow up. If the payer requests additional information (a "pend"), respond within their stated deadline. Missing it turns a pend into a denial with stricter appeal rights. ## Step 5: If You Get a Denial Read the denial reason before doing anything else. It tells you whether this is a documentation problem (missing criteria), a policy problem (test is E&I or excluded), or a process problem (wrong CPT code, missing NPI). Documentation problems are the easiest to fix. Get the missing information and file the appeal with a complete clinical package within the appeal deadline. Policy denials (E&I or benefit exclusion) take longer. You'll need to build an evidentiary case, peer-reviewed literature, FDA clearance status, NCCN listing, positive coverage determinations from other payers. This is a weeks-long process, not days. Request a peer-to-peer review for medical necessity denials. The ordering physician speaking directly to the payer's medical director is the highest-yield intervention. Don't skip it to go straight to written appeal. ## Sources - CMS NCD 90.2 (next-generation sequencing in cancer) - Palmetto GBA / MolDX program (DEX Z-code technical assessment requirements) - 42 CFR §410.32 (Medicare ordering and referring requirements) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans) - ACA §2719 (independent external review) - ASCO/CAP HER2 Testing Guidelines, joint guideline - NCCN Clinical Practice Guidelines (NCCN.org) --- # Gold Carding: What It Is, Which Payers Offer It, and How to Qualify URL: https://converus.ai/knowledge-base/gold-carding/ Updated: 2026-05-06 ## What Gold Carding Is Gold carding, also called provider exemption, PA waiver, or prior authorization exemption, is a payer program under which qualifying providers are granted automatic approval for specified services without having to submit a prior authorization request each time. Instead of going through the standard PA workflow for a covered service, the provider's request is either automatically approved at the point of order or bypassed entirely. The term "gold card" comes from the metaphor of a premium credential: providers who have demonstrated a consistently high approval rate and appropriate utilization pattern earn a standing authorization that replaces the per-request review process. For genetic laboratories and oncology practices, gold carding represents a meaningful operational opportunity. High-volume providers who routinely meet payer criteria are spending significant staff time on PA submissions that will almost certainly be approved. A gold carding program converts that cost center into recovered time. ## Why Payers Offer Gold Carding Gold carding programs serve payer interests as much as provider interests. When a provider has a documented track record of submitting clinically appropriate cases, per-request review adds administrative cost on the payer's side without improving utilization outcomes. Exempting high performers allows payers to concentrate their review resources on higher-risk claims and newer providers. There is also a legislative dimension. A growing number of states have enacted gold carding laws that require insurers to offer exemption programs to providers who meet defined performance thresholds. Texas passed the first such law in 2021; similar legislation has passed or is advancing in states including Arkansas, West Virginia, Oklahoma, and others. Some state laws also apply to managed Medicaid plans. Federal legislation has been proposed but has not yet passed as of this writing. ## Which Payers Offer Gold Carding Programs Gold carding availability and terms vary substantially by payer and market: **State-mandated programs**: In states with gold carding laws, commercial plans and sometimes managed Medicaid plans operating in that state are legally required to offer exemption programs. The qualification thresholds and covered services are often defined in the statute or implementing regulations. **Voluntary commercial programs**: Several major commercial payers operate voluntary gold carding programs independent of state mandates. Cigna's "Embarc" program and Anthem's provider collaboration initiatives include PA exemption components. UnitedHealthcare has piloted exemption arrangements in certain markets. Terms vary by region, product line, and negotiation. **Medicare Advantage**: Medicare Advantage plans are regulated by CMS and are increasingly subject to federal guidance on PA use. CMS has taken administrative steps to reduce prior authorization burden in MA plans, and some MA plans have voluntarily expanded gold carding or PA exemption programs for high-performing practices. **Traditional Medicare (Fee-for-Service)**: Traditional Medicare does not use prior authorization for most services in the same way commercial plans do, but MolDX technical assessment approvals function similarly, once a lab's test has received a positive coverage determination and a DEX Z-code assignment, billing proceeds without a per-case PA. ## Who Qualifies Qualification criteria differ by payer and program, but common thresholds include: - **Approval rate**: The provider or lab must demonstrate a PA approval rate above a defined threshold, commonly 90% or higher, over a lookback period (typically 6–18 months). - **Volume floor**: Most programs require a minimum number of PA submissions during the lookback period to establish a statistically meaningful track record. Low-volume providers generally do not qualify even with a 100% approval rate. - **Denial and appeal rate**: Some payers factor in the rate of medical necessity denials, not just the overall approval rate. A provider with a high approval rate but a pattern of appealable denials may not qualify. - **Scope of exemption**: Gold carding is service-specific and sometimes indication-specific. A lab might be gold-carded for a specific hereditary cancer panel but still require PA for somatic tumor profiling. Review the exact scope of any exemption carefully. - **Provider type and specialty**: Most programs are specialty-specific. Oncology practices and high-volume genetic testing labs are among the most common candidates. ## What Gold Carding Changes About the Workflow When a gold carding exemption is in place, the standard PA workflow for covered services is replaced by a streamlined process: **Ordering**: The ordering provider includes documentation that the gold carding exemption applies (payer-specific, may be an attestation code, a specific modifier, or simply a notation in the order). **Submission and billing**: The lab submits the claim without a pending PA number, using whatever payer-specific billing indicator designates the exemption. Some payers issue a blanket authorization number that applies to all exempt services from that provider. **Documentation requirements**: Gold carding does not eliminate documentation requirements, it eliminates the pre-service review step. Clinical documentation still needs to support coverage criteria and must be available if the payer conducts post-payment review or audit. **Post-payment review risk**: Payers that offer gold carding programs typically retain the right to conduct retrospective audits. Providers who see their approval rate drop below the qualifying threshold after being exempted may be removed from the program and subject to increased scrutiny. Maintaining consistent documentation practices is therefore essential even when PA is not required pre-service. ## Strategic Considerations for Labs and Oncology Teams **Negotiate proactively**: Gold carding programs are not always prominently advertised. If your lab or practice has a strong approval track record, proactively raise gold carding with your payer contracting contact during contract negotiations or renegotiations. **Track your data**: You cannot qualify for what you cannot document. Maintain detailed records of PA submission outcomes by payer, service type, and indication. This data is your primary asset in a gold carding conversation. **Understand the limits**: Gold carding is a risk management tool, not a coverage guarantee. Post-payment audits still happen, and a claim denied in audit is worse than a denial at the PA stage. Operational discipline must accompany any exemption. **State law as leverage**: If you are in a state with a gold carding mandate and your payer is not offering the program, that is a compliance issue, not a negotiation. Know your state's law and use it. Gold carding represents the long-term endpoint of what effective PA management looks like: a demonstrated track record of clinical appropriateness that earns a structural reduction in administrative burden. For teams building toward that outcome, the path runs through consistent, well-documented submissions and a systematic approach to denial avoidance. --- # How to Get a Molecular Test Covered: A Practical Market-Access Roadmap URL: https://converus.ai/knowledge-base/how-to-get-a-molecular-test-covered/ Updated: 2026-06-19 # How to Get a Molecular Test Covered: A Practical Market-Access Roadmap > **Educational disclaimer.** This article is for general educational purposes only. It is not legal, billing, regulatory, or reimbursement advice. Coding, coverage, and payer processes change frequently, and requirements differ by Medicare Administrative Contractor, by payer, and by test. Verify current MolDX, DEX, and individual payer requirements directly with the relevant source, and consult qualified professionals before acting. CPT and PLA codes are referenced by number only. Use this information at your own risk. You have a validated assay. The analytical work is done — limits of detection nailed down, reproducibility studies signed off, the whole binder of validation data sitting on a shared drive. Clinicians who have seen the data want to order it. And then someone in finance asks the question that stops the celebration cold: *how, exactly, do we get paid for this?* It turns out that developing a molecular test and getting a molecular test reimbursed are two almost entirely separate disciplines. The first is science. The second is a market-access process with its own registry, its own dossiers, its own coding rules, and dozens of payers who each decide for themselves. Labs that treat reimbursement as an afterthought routinely run claims for months and collect almost nothing. This is the roadmap from "developed" to "covered and paid." It runs through five stages: registering the lab and test in the DEX Diagnostics Exchange, completing a MolDX technical assessment, obtaining a DEX Z-Code, sorting out coding and pricing, and finally pursuing commercial payer coverage and contracting. None of these stages is a formality, and the order matters. ## Stage 1: Register the lab and test in DEX For most molecular tests, the front door is the **MolDX Program** — the Molecular Diagnostic Services program Palmetto GBA developed in 2011 to identify molecular diagnostic tests and establish coverage and reimbursement for them ([Palmetto GBA](https://palmettogba.com/palmetto/moldxv2.nsf/DID/D30FL2NZ3F)). MolDX provides uniform policies across four Medicare Administrative Contractors (MACs): Palmetto GBA, Noridian Healthcare Solutions, CGS, and WPS, covering a large block of states ([Noridian](https://med.noridianmedicare.com/web/jeb/topics/claim-submission/reason-code-guidance/missing-incorrect-dex-z-code-identifier)). The mechanism MolDX uses to identify each test is the **DEX Diagnostics Exchange**, a web-based registry that Palmetto GBA administers ([dexzcodes.com](https://www.dexzcodes.com/)). Labs in the impacted MACs are required to register their tests through DEX — particularly laboratory-developed tests (LDTs) and expanded panels that test for more than five targets ([Lighthouse Lab Services](https://www.lighthouselabservices.com/what-is-moldx-and-when-do-i-need-a-z-code/)). You create an account at dexzcodes.com, register the laboratory, and submit the specific test. It helps to frame this stage correctly: registration catalogs your test so it can be tracked and so a claim can later be processed. It is the entry point, not the finish line. The substantive review that decides whether Medicare will pay comes next. ## Stage 2: Complete the MolDX technical assessment The technical assessment is where coverage is actually won or lost. MolDX reviews the clinical information for a new test to determine whether it meets Medicare's reasonable-and-necessary requirement ([Palmetto GBA Technical Assessment](https://palmettogba.com/palmetto/moldxv2.nsf/DID/9W2LPH1487)). In MolDX's own words, the program will only cover and reimburse tests that demonstrate **analytical validity, clinical validity, and clinical utility** at a level that meets that standard ([MolDX FAQ via Streamline](https://www.streamlinesci.com/moldx-faq)). CMS has directed MolDX to follow the **ACCE framework** the CDC developed — analytical validity, clinical validity, clinical utility, and the associated ethical, legal, and social implications. Those first three terms are worth slowing down on, because payers everywhere — not just Medicare — organize their thinking around them: - **Analytical validity** asks whether the test accurately measures what it claims to measure. This is most of your validation binder: sensitivity, specificity, reproducibility, the boundary conditions of the assay. MolDX expects analytical validation that establishes those boundary conditions, generally using clinical specimens — samples from patients with the relevant disorder — rather than only contrived or purchased reference material ([MolDX FAQ via Streamline](https://www.streamlinesci.com/moldx-faq)). - **Clinical validity** asks whether a result actually correlates with the disease, risk, or outcome it claims to predict ([Managed Healthcare Executive](https://www.managedhealthcareexecutive.com/view/coverage-policy-genetic-tests-should-reflect-clinical-utility)). - **Clinical utility** asks the harder question: does using this test lead to measurable improvements in how the patient is managed or how they fare? ([Managed Healthcare Executive](https://www.managedhealthcareexecutive.com/view/coverage-policy-genetic-tests-should-reflect-clinical-utility)). The gap between the last two is where a surprising number of well-built tests stall. A test can be beautifully valid — it predicts exactly what it says it predicts — and still fail to show that acting on the result changes anything for the patient. Payers consistently weigh tests with both clinical validity *and* utility more favorably than tests with validity alone, because actionability rises when a result informs management rather than merely confirming a diagnosis already in hand ([Managed Healthcare Executive](https://www.managedhealthcareexecutive.com/view/coverage-policy-genetic-tests-should-reflect-clinical-utility)). Practically, this stage means assembling a **dossier**. MolDX expects a table of contents of all submitted materials, a summary of the test's background and intended use — who should be tested, when, and why — and any professional-society or clinical guidelines addressing the test's use ([Palmetto GBA Technical Assessment](https://palmettogba.com/palmetto/moldxv2.nsf/DID/9W2LPH1487)). MolDX also offers a pre-submission process that lets developers get feedback on dossier materials before a formal technical assessment, though it does not change the requirements or the review timeline ([Palmetto GBA Technical Assessment](https://palmettogba.com/palmetto/moldxv2.nsf/DID/9W2LPH1487)). One structural detail can save you months. MolDX maintains **foundational LCDs**, sometimes called umbrella policies, that lay out general criteria for a class of tests. A foundational LCD can cover future tests on a rolling basis when MolDX determines they show "equivalent or superior performance to covered tests" with similar indicated uses ([Discoveries in Health Policy](https://www.discoveriesinhealthpolicy.com/2021/05/moldx-new-lcds-and-lcd-proposals-may.html)). If your test fits an existing foundational policy, your path can be considerably shorter than starting from a blank coverage determination. Timelines for technical assessment vary by test and by the completeness of your dossier, so treat any duration you hear as approximate and verify the current expectation. ## Stage 3: Obtain the DEX Z-Code — and understand what it does not do Once a test is registered, DEX assigns it a **DEX Z-Code**: a unique five-character alphanumeric identifier that pins down exactly which test was performed, on a claim, at your specific lab ([dexzcodes.com](https://www.dexzcodes.com/)). On a molecular claim, the Z-Code is how a payer knows that the CPT code in front of them refers to *your* specific assay and not one of the dozens of other tests that might share the same CPT code. Here is the single most important thing to internalize about the Z-Code: **it identifies your test; it does not establish coverage.** A Z-Code can be assigned within roughly two weeks of submission, but it is not effective for claims until the DEX clinical team reviews the application, determines coverage, and assigns the appropriate CPT code ([Lighthouse Lab Services](https://www.lighthouselabservices.com/what-is-moldx-and-when-do-i-need-a-z-code/)). The Z-Code alone does not make a test payable; coverage and reimbursement are assigned *to* the Z-Code only after that review ([dexzcodes.com General FAQs](https://www.dexzcodes.com/palmetto/dex.nsf/DID/6E6ZYSDLUU)). Plenty of labs have celebrated receiving a Z-Code only to discover that the actual coverage decision was still ahead of them. ## Stage 4: Sort out coding and pricing With identity and coverage taking shape, the test needs a code that carries a price. Two families matter here. Standard **CPT** molecular pathology codes describe categories of testing. **PLA** (Proprietary Laboratory Analyses) codes are a specialized addition to the CPT set, created after CMS's June 2016 final rule, that let a specific lab or manufacturer uniquely identify its advanced diagnostic or FDA-cleared test rather than share a generic code ([AMA](https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes)). If your test is distinctive enough, a PLA code can describe it precisely; if not, you may land on an existing CPT code that DEX recommends during registration. Pricing on the **Clinical Laboratory Fee Schedule** generally follows one of two methods. A new code is **crosswalked** when its payment rate is set by comparison to a similar existing code. When no comparable assay exists, CMS uses **gapfill**: the MACs individually price the test in the first year, and in the second year CMS adopts the median of those contractor-specific prices to set a national limitation amount ([Association for Molecular Pathology](https://www.amp.org/advocacy/advocacy-resources/coverage-and-reimbursement/)). In setting a rate, MACs consider charges and routine discounts, the cost of resources to perform the test, amounts other payers pay, and the pricing of comparable tests. The takeaway for planning: a price is not a fixed number you can assume in advance. Crosswalk and gapfill can produce very different outcomes, and gapfill in particular plays out over a multi-year cycle. Build your financial model around a range, and verify current pricing rather than anchoring on a figure you saw last year. ## Stage 5: Pursue commercial payer coverage and contracting Medicare is rarely the whole story. Commercial payers run their own show, and getting paid by them is its own multi-front campaign. The encouraging news is that the MolDX infrastructure increasingly extends beyond Medicare. Commercial payers including UnitedHealthcare and Humana have adopted the DEX and Z-Code framework for certain molecular tests nationwide, regardless of MAC region ([Lighthouse Lab Services](https://www.lighthouselabservices.com/molecular-test-reimbursement-moldx-z-codes-payer-reform/)), and many commercial medical policies reference MolDX-style criteria — the same analytical validity, clinical validity, and clinical utility tests you assembled evidence for in Stage 2. The work you did for Medicare is not wasted; it is the foundation of your commercial dossier. But each payer still maintains its own medical policy and decides coverage on its own terms, and being *covered* is not the same as being *in network*. Two distinct tracks run here. The first is **coverage**: persuading the payer's medical policy team that the test is medically necessary for a defined population, again with that validity-versus-utility distinction front and center. The second is **contracting and credentialing**: negotiating an in-network agreement and a rate, and completing the payer's credentialing of your lab. These processes take time and vary widely by payer and by test; rather than promise a specific number of weeks, plan for an ongoing, multi-payer effort and staff it accordingly. When the evidence base is genuinely promising but not yet conclusive, there is an interim path worth knowing. **Coverage with Evidence Development (CED)** lets Medicare cover an item or service on the condition that data gathered through a clinical study or registry will determine its effectiveness, used when available evidence is insufficient to support coverage outright ([CMS](https://www.cms.gov/medicare/coverage/evidence)). CED coverage is typically time-limited, and CMS encourages sponsors to build interim analyses into their study design to ease the transition to full coverage ([CMS CED Guidance](https://www.cms.gov/files/document/ced-guidance2024pdf.pdf)). It is not a shortcut — it is a structured way to keep generating the utility evidence payers want while patients get access. ## Getting covered is the start, not the finish Walk the full roadmap and you arrive somewhere that feels like a destination: a registered test, a Z-Code, a coverage determination, a price, and a handful of payer contracts. It is a real milestone. It is also the moment the maintenance problem begins. Coverage is not static. MolDX policies get revised. Commercial payers update medical policies, tighten medical-necessity language, change which indications they will pay for, and revise documentation requirements — each on its own schedule. A test that is reliably paid this quarter can start denying next quarter because one payer rewrote one policy for one indication, and nobody on the revenue-cycle side caught the change until the denials piled up. The hard part of reimbursement, in other words, is not getting covered once. It is **staying paid** as every payer's criteria drift, per test and per indication. That is the gap **Converus** is built to close: keeping each payer's evolving coverage criteria encoded and current for every test and every indication, so the policy reality your claims meet today is the one your team is actually working from. The roadmap gets you covered. Keeping the criteria current is how you stay paid. ## Sources - Palmetto GBA — MolDX Program Overview: https://palmettogba.com/palmetto/moldxv2.nsf/DID/D30FL2NZ3F - Palmetto GBA — MolDX Technical Assessment: https://palmettogba.com/palmetto/moldxv2.nsf/DID/9W2LPH1487 - DEX Diagnostics Exchange (dexzcodes.com): https://www.dexzcodes.com/ - DEX — General FAQs: https://www.dexzcodes.com/palmetto/dex.nsf/DID/6E6ZYSDLUU - Noridian — Missing/Invalid MolDX DEX Z-Code Identifier (participating MACs): https://med.noridianmedicare.com/web/jeb/topics/claim-submission/reason-code-guidance/missing-incorrect-dex-z-code-identifier - Lighthouse Lab Services — What is MolDX and When Do I Need a Z-Code?: https://www.lighthouselabservices.com/what-is-moldx-and-when-do-i-need-a-z-code/ - Lighthouse Lab Services — Molecular Test Reimbursement: MolDX, Z-Codes & Payer Reform: https://www.lighthouselabservices.com/molecular-test-reimbursement-moldx-z-codes-payer-reform/ - MolDX FAQ (via Streamline Scientific): https://www.streamlinesci.com/moldx-faq - Managed Healthcare Executive — Coverage policy for genetic tests should reflect clinical utility: https://www.managedhealthcareexecutive.com/view/coverage-policy-genetic-tests-should-reflect-clinical-utility - American Medical Association — CPT PLA Codes: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes - Association for Molecular Pathology — Coverage and Reimbursement (crosswalk and gapfill): https://www.amp.org/advocacy/advocacy-resources/coverage-and-reimbursement/ - Discoveries in Health Policy — MolDX New LCDs and Foundational LCDs: https://www.discoveriesinhealthpolicy.com/2021/05/moldx-new-lcds-and-lcd-proposals-may.html - CMS — Coverage with Evidence Development: https://www.cms.gov/medicare/coverage/evidence - CMS — Coverage with Evidence Development Guidance (2024): https://www.cms.gov/files/document/ced-guidance2024pdf.pdf --- # How to Write a Prior Authorization Appeal Letter That Actually Works URL: https://converus.ai/knowledge-base/how-to-write-a-pa-appeal-letter/ Updated: 2026-05-06 A UnitedHealthcare denial lands on your desk citing "medical necessity not established." Your instinct is to write a thorough letter explaining everything. That instinct will produce a 4-page letter that gets ignored. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## Match Your Letter to the Exact Denial Reason This sounds obvious, but most appeal letters fail because they argue the wrong thing. Payers categorize denials, medical necessity, non-covered service, experimental/investigational, documentation insufficient. Each requires a different argument. Pull the denial notice and find the specific reason code. If it's CO-50 (medical necessity), your letter needs to show clinical appropriateness using the payer's own coverage criteria. If it's CO-197 (pre-certification absent), you're making a procedural argument about why retro-auth applies, not a clinical one. Conflating these is the most common appeal mistake. For genetic testing and oncology claims, you're most often fighting a medical necessity denial. The payer's reviewer said the clinical information you submitted didn't satisfy their policy. That means your appeal has one job: show that the clinical information *does* satisfy their policy, or that their policy is inconsistent with accepted clinical standards. ## The Structure That Gets Read Appeals reviewers process dozens of letters a day. They skim. Your letter needs to lead with the conclusion, not build to it. **First paragraph**: State what you're appealing, reference the denial date, and assert your conclusion upfront. Example: "We are appealing the January 14, 2026 denial of CPT 81479 for [patient initials, DOB, member ID]. The denial should be reversed because the submitted documentation satisfies the criteria set forth in [payer]'s Molecular Diagnostic Testing Policy, effective [date], and is consistent with NCCN Clinical Practice Guidelines Category 2A." **Second paragraph**: Lay out the clinical facts, diagnosis code(s), the specific clinical indication that justifies the test or drug, any prior treatments and outcomes, and the treating physician's clinical rationale. Keep this to a paragraph or two. Use bullet points for test history or prior treatment steps. Don't editorialize. **Third section**: Cite the policy. Quote the relevant coverage criteria verbatim from the payer's published medical policy or LCD. Then show, criterion by criterion, that the patient meets each one. This is where most letters fall short, they describe the patient's situation in general terms instead of walking through the payer's own checklist. **Fourth section (if applicable)**: Cite external authority. NCCN guideline designation (category and indication), NCD coverage criteria, peer-reviewed literature. Attach the specific pages, not just the full document. If you're citing NCD 90.2 for next-generation sequencing in cancer, include the exact coverage criteria text. **Closing**: State what you're requesting and the timeline you expect a response within. Reference the applicable federal or state appeal rights (42 CFR §405.960–405.978 for Medicare; 45 CFR §147.136 for ACA-compliant plans; 29 USC §1133 for ERISA plans). ## What to Attach - The payer's denial letter (to establish the administrative record) - The treating physician's letter of medical necessity, specific to this patient, not a form letter - The relevant pages from the payer's own coverage policy (highlight the criteria you're addressing) - NCCN guideline pages with the indication highlighted - Pathology or lab results that establish clinical context - Prior treatment documentation if step therapy or failure of alternatives is relevant Don't attach a 200-page academic literature dump. Attach the two or three studies that directly support the specific indication, and cite them in the letter body. ## Cigna and Aetna Have Different Preferences Cigna's internal appeal process goes through Cigna's Appeals and Grievances team, and they are strict about submission format and deadlines. If you're using Cigna for HCP (their provider portal), you can submit appeals electronically. They will bounce an incomplete submission, missing member ID, missing treating physician signature, on procedural grounds before a reviewer ever reads it. Aetna's process is similar but they've published specific documentation requirements by service category. For genetic testing appeals, Aetna's oncology medical policies cite MCG (Milliman Care Guidelines) criteria heavily. If you know the MCG reference they're applying, address it directly. For Medicare Advantage plans, the appeals process follows Part C timelines (generally 60 days from denial to request a redetermination). The plan must decide within 7 days for standard appeals and 72 hours for expedited. Miss that distinction and you'll get a procedural rejection. ## Checklist Before You Submit - Denial reason code identified and letter addresses it directly - Member ID, date of service, CPT code, and treating provider NPI all match the denial notice exactly - Payer's coverage criteria quoted verbatim and addressed point-by-point - Physician letter is patient-specific (not a template) - NCCN or other guideline citation attached with relevant pages - Submission deadline confirmed and met (typically 60–180 days from denial date) - Delivery method documented (portal confirmation number, fax confirmation, certified mail receipt) ## Sources - 42 CFR §405.960–405.978 (Medicare administrative appeals process) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans) - 29 USC §1133 (ERISA full and fair review) - ACA §2719 (independent external review for non-grandfathered plans) - CMS NCD 90.2 (next-generation sequencing in cancer) - NCCN Clinical Practice Guidelines (NCCN.org), category designations by indication --- # The 14-Day Rule, Plain English: Who Bills Medicare for a Molecular Test, and When URL: https://converus.ai/knowledge-base/lab-14-day-rule-date-of-service/ Updated: 2026-06-19 A specimen leaves a hospital outpatient clinic on a Tuesday. A patient came in, blood was drawn or a tissue block was pulled, and the physician decided that a molecular panel was warranted to guide what comes next. The patient goes home. Three days later the order reaches your reference lab, you run a complex molecular assay, you produce a report, and you send a bill. The clinical part went perfectly. Now answer one deceptively simple question: who is supposed to receive that bill, you or the hospital, and as of what date? That question is the entire substance of Medicare's laboratory date-of-service policy, the rule the industry has long called the "14-Day Rule." It does not decide whether a test is covered or medically necessary. It decides something more basic and more easily fumbled: which party holds the right to bill Medicare, and on what date the service is considered to have occurred. Get it wrong in one direction and you bill Medicare for a service you had no standing to bill. Get it wrong in the other and you do unpaid work while the hospital never pays you either. This article walks through the rule in plain language, with the molecular and ADLT exception that changed the landscape in 2018, and why it remains one of the quieter sources of revenue leakage for labs that handle hospital-outpatient specimens. > **Disclaimer**: This article is educational and is not medical, legal, or billing advice. It is not a coverage or payment determination for any specific test, specimen, or claim. Medicare policies change, Medicare Administrative Contractors apply local rules, and the only authoritative sources are the current regulation, CMS guidance, and your contractor's policy. Always verify against current CMS date-of-service guidance and consult qualified billing, coding, compliance, and legal professionals before acting. Use this information at your own risk. ## The default rule: date of service equals date of collection Start with the baseline, because the exceptions only make sense against it. Under Medicare's laboratory date-of-service policy, codified at [42 CFR 414.510](https://www.law.cornell.edu/cfr/text/42/414.510), the date of service (DOS) for a clinical diagnostic laboratory test is generally the date the specimen was collected. That single default carries surprising weight, because the date of service is tied to the encounter, and the encounter determines who bills. When a specimen is collected during a hospital encounter, the test tends to be treated as part of that hospital service rather than as a freestanding lab service. In practical terms, the hospital bills Medicare for the encounter and its associated services, and the performing laboratory, if it is a separate reference or molecular lab, looks to the hospital for payment rather than to Medicare. This is the bundling logic that sits underneath everything else here. ([CMS, Laboratory Date of Service Policy](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy)) ## Where the "14 days" comes from The "14-Day Rule" nickname describes the hinge in that default. The general policy is that the DOS is the date of specimen collection unless the ordering physician orders the test at least 14 days after the patient is discharged from the hospital. If the order comes 14 or more days after discharge, the date of service shifts to the date the test was actually performed, the test is effectively unbundled from the hospital encounter, and the performing laboratory bills Medicare directly under the Clinical Laboratory Fee Schedule (CLFS). ([CMS](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy); [Houston Harbaugh](https://hh-law.com/blogs/health-care/cms-publishes-revision-to-laboratory-14-day-rule/)) So the 14-day window is really a timing test that flips the billing party. Inside the window, with the date of service pinned to collection, the test rides with the hospital encounter, and the lab seeks payment from the hospital. Outside the window, the lab can go straight to Medicare. The rule did not start as a molecular-testing rule at all. It traces back to the mid-2000s and was initially shaped around chemosensitivity testing on tumor samples, which became effective for the 2007 calendar year, where fresh tissue was required and results rarely affected an inpatient's immediate treatment. ([Discoveries in Health Policy](https://www.discoveriesinhealthpolicy.com/2025/08/medicares-14-day-rule-where-did-it-come.html)) The mechanics were built for a different era of testing, and that mismatch is exactly what created problems once molecular medicine arrived. ## Why molecular labs hit a wall before 2018 Here is the practical bind that the original framework created. Modern molecular pathology and advanced diagnostic testing is frequently ordered soon after a patient is seen, not two weeks later. A physician sees a patient, decides a complex genomic assay is warranted, and orders it promptly. Under the default rule, a specimen collected during a hospital outpatient encounter with the order arriving inside the 14-day window meant the test was treated as a hospital service. Before 2018, that left reference and independent laboratories unable to bill Medicare directly for many molecular pathology tests ordered less than 14 days after a hospital outpatient discharge. Instead, the lab had to seek reimbursement from the hospital, and the hospital billed Medicare. ([APS Medical Billing](https://apsmedbill.com/whitepapers/new-year-rings-change-cms-14-day-rule-its-laboratory-date-service-policy)) That arrangement was awkward for everyone. Hospitals were billing for sophisticated send-out tests they did not perform and could not always price, labs were dependent on hospital payment for highly specialized work, and patients and physicians sometimes waited or maneuvered around the calendar. Stakeholders argued the rule was throttling access to precision medicine. ([GenomeWeb](https://www.genomeweb.com/reimbursement/cms-14-day-rule-revisions-ease-precision-medicine-access-patients-stakeholders-say)) ## The 2018 exception that changed who bills CMS responded in the CY 2018 Hospital Outpatient Prospective Payment System (OPPS) final rule, published December 14, 2017, by creating an exception to the laboratory date-of-service policy. Effective January 1, 2018, for Advanced Diagnostic Laboratory Tests (ADLTs) and molecular pathology tests that are excluded from OPPS packaging, the date of service is the date the test was performed, rather than the date of collection, when specific conditions are met. ([CMS](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy); [Quadax](https://blog.quadax.com/opps-2018-revisions-outpatient-14-day-rule-changes-to-laboratory-dos-policy)) The effect is the part to internalize. When the exception applies, the performing laboratory bills Medicare directly under the CLFS for those tests, even when they were ordered within 14 days of a hospital outpatient discharge. ([APS Medical Billing](https://apsmedbill.com/whitepapers/new-year-rings-change-cms-14-day-rule-its-laboratory-date-service-policy)) The molecular or genomic lab that actually ran the assay is the party that bills, instead of routing the work through the hospital. That is a meaningful shift in standing, and it only holds when the conditions below are satisfied. ## The conditions, stated precisely The exception is conditional, and the conditions matter because missing any one of them can put you back on the wrong side of the billing line. As CMS and Medicare Administrative Contractor guidance describe it, the molecular pathology and ADLT exception for hospital outpatient specimens applies when: - The test is performed **following** the hospital outpatient's discharge from the hospital outpatient department. - The specimen was collected from a hospital **outpatient** during an encounter. - It was **medically appropriate** to have collected the sample during that hospital outpatient encounter. - The **results do not guide treatment** provided during that hospital outpatient encounter. - The test was **reasonable and medically necessary** for the treatment of an illness. ([CMS](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy); [Noridian, Laboratory Date of Service — ADLT and Molecular Pathology Tests](https://med.noridianmedicare.com/web/jea/cert-reviews/cert/cert-articles-and-resources/laboratory-date-of-service-adlt-and-molecular-pathology-tests)) Two qualifiers deserve emphasis. First, the exception is for **outpatient** specimens. It does not extend to specimens collected from a hospital inpatient; inpatient testing is handled under separate bundling rules and generally flows through the hospital. ([CMS](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy)) Second, the "results do not guide treatment during the encounter" condition is doing real work. If the molecular result was meant to direct care during that same outpatient encounter, the logic of the exception, which assumes the test informs later management, no longer fits, and you should treat the billing question as unresolved until you confirm the specifics. It is also worth knowing what an ADLT is, since the term carries weight in this rule. CMS generally describes an ADLT as a test furnished by a single laboratory that analyzes multiple biomarkers (such as DNA, RNA, or proteins) and, through a unique algorithm, yields new clinical diagnostic information that cannot be obtained from any other test or combination of tests, or a test that is cleared or approved by the FDA, among other criteria. ([GenomeWeb](https://www.genomeweb.com/reimbursement/cms-14-day-rule-revisions-ease-precision-medicine-access-patients-stakeholders-say)) The distinction matters because ADLTs and molecular pathology tests excluded from OPPS packaging are the categories the 2018 exception was built around. ## A note on storage, and on the inpatient line A couple of adjacent rules tend to surface in the same conversations, and they are easy to trip on. Medicare's DOS policy also addresses archived specimens: if a specimen is stored more than 30 calendar days before testing, it is generally considered to have been archived, and the date of service becomes the date the specimen was obtained from storage rather than the date of original collection. ([CMS](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy)) That can independently change the analysis for tests run long after collection. And the inpatient line is its own world. The bundling rules for inpatient specimens are distinct, the molecular/ADLT outpatient exception does not reach them, and conflating the two is a common way that otherwise careful billing operations get the party wrong. When you are unsure whether a specimen counts as inpatient or outpatient for these purposes, that ambiguity is itself a reason to slow down and verify, not to assume. ## Where the money leaks None of this is academic. The 14-Day Rule decides who bills, and a rule that decides who bills is a rule that decides who gets paid and who eats the cost when the answer is wrong. The leakage runs in both directions. In one direction, a lab bills Medicare directly for a test that should have been billed by the hospital because the conditions for the exception were not actually met. That is not just a denied claim, it is a compliance exposure. In January 2025, reporting described a False Claims Act settlement in which a laboratory and health system resolved allegations, for roughly $388,667, that physician orders for certain lab testing were delayed until 14 days after discharge specifically to sidestep the bundling rule. ([Hall Render](https://hallrender.com/2025/01/29/medicare-14-day-rule-enforcement-action/)) Whatever the specifics of that matter, the signal for operators is clear: timing the order to manufacture a billing right is the kind of thing the government pursues, and the DOS policy is being actively enforced. In the other direction, a lab that is genuinely entitled to bill Medicare under the 2018 exception sometimes fails to, or routes the work through a hospital arrangement that pays slowly or incompletely, simply because the staff applying the rule did not realize the exception applied. That is quieter leakage, but it is leakage all the same: real molecular work performed, with payment left on the table or trapped in a hospital pass-through. The performing lab had standing to bill Medicare directly and did not use it. What makes this category so slippery is that the right answer depends on a stack of moving facts: the specimen setting, the specific test type and its OPPS-packaging status, the discharge timing, whether results drove same-encounter care, and whatever your Medicare Administrative Contractor currently says. Each of those can change, and CMS has revisited the DOS policy more than once. A rule you "know" from 2019 is not necessarily the rule today. ## Confirm before you bill If you operate a molecular or genetic-testing lab, or an oncology practice that sends specimens out, the disciplined move is to treat the billing-party decision as its own checkpoint, not an afterthought to the clinical result. Identify the specimen setting, confirm the test category and its packaging status, walk the timing and the same-encounter-treatment condition, and only then decide whether you bill Medicare directly or look to the hospital. And because this is technical billing policy that genuinely changes, confirm the specifics of any uncertain case against current CMS date-of-service guidance and your MAC's published policy rather than relying on institutional memory. This is precisely the kind of payer and CMS logic that quietly goes stale. Date-of-service rules, packaging exclusions, ADLT determinations, and contractor guidance are constantly maintained documents, and the gap between what a rule said two years ago and what it says now is exactly where labs lose money or take on risk without noticing. Keeping that logic current, so the billing decision reflects today's policy rather than yesterday's, is the category Converus works in. The clinical work is hard enough; the rule about who gets paid for it should not be the part that leaks. ## Sources - [42 CFR 414.510 — Laboratory date of service for clinical laboratory and pathology specimens (Cornell LII)](https://www.law.cornell.edu/cfr/text/42/414.510) - [CMS — Laboratory Date of Service Policy](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy) - [Noridian (MAC) — Laboratory Date of Service: ADLT and Molecular Pathology Tests](https://med.noridianmedicare.com/web/jea/cert-reviews/cert/cert-articles-and-resources/laboratory-date-of-service-adlt-and-molecular-pathology-tests) - [APS Medical Billing — The New Year Rings In Change to CMS' "14 Day Rule"](https://apsmedbill.com/whitepapers/new-year-rings-change-cms-14-day-rule-its-laboratory-date-service-policy) - [APS Medical Billing — Update to the 14-Day Rule Exception for Outpatient Molecular Tests & ADLTs](https://apsmedbill.com/whitepapers/update-14-day-rule-exception-outpatient-molecular-tests-advanced-diagnostic-lab-tests) - [Houston Harbaugh, P.C. — CMS Publishes Revision to Laboratory "14-Day Rule"](https://hh-law.com/blogs/health-care/cms-publishes-revision-to-laboratory-14-day-rule/) - [Quadax — OPPS 2018 Revisions: Outpatient 14-Day Rule Changes to Lab DOS Policy](https://blog.quadax.com/opps-2018-revisions-outpatient-14-day-rule-changes-to-laboratory-dos-policy) - [GenomeWeb — CMS 14-Day Rule Revisions Ease Precision Medicine Access](https://www.genomeweb.com/reimbursement/cms-14-day-rule-revisions-ease-precision-medicine-access-patients-stakeholders-say) - [Hall Render — Medicare 14-Day Rule Enforcement Action (Jan 2025)](https://hallrender.com/2025/01/29/medicare-14-day-rule-enforcement-action/) - [Discoveries in Health Policy — Medicare's 14-Day Rule: Where Did It Come From?](https://www.discoveriesinhealthpolicy.com/2025/08/medicares-14-day-rule-where-did-it-come.html) --- # Lab Billing 101: CPT, MAAA, and Z-Codes for Molecular Diagnostics URL: https://converus.ai/knowledge-base/lab-billing-cpt-codes-explained/ Updated: 2026-05-06 Billing a next-generation sequencing panel isn't like billing a CBC. The code selection for molecular diagnostics involves CPT tiers, MAAA codes, unlisted codes, and a MolDX Z-code layer that doesn't exist anywhere else in healthcare billing. Get it wrong and you'll have a clean claim that pays zero. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## CPT Tier 1 vs. Tier 2 vs. Unlisted, Know the Difference The AMA CPT code set divides molecular pathology codes into two tiers. **Tier 1 codes** (81200–81383) are gene-specific. Each code maps to a single gene or a defined gene variant. 81162 is BRCA1 and BRCA2 combined analysis. 81213 is BRCA1/2 uncommon variant. 81479 is an unlisted molecular pathology procedure, which matters because when no Tier 1 code exactly describes what you're doing, 81479 is your code. **Tier 2 codes** (81400–81408) are organized by the level of analytical complexity, not by gene. They're categorized into stacked levels (Level 1 through Level 9) based on the technical difficulty of the analysis. These are less commonly used for commercial labs now that Tier 1 codes have expanded, but they still apply to some analyses. **81479 (Unlisted molecular pathology procedure)** is the fallback. Many laboratory-developed tests, novel NGS panels, and multi-gene assays that don't match an existing Tier 1 code bill under 81479. Payers require detailed documentation with 81479 claims, you can't just drop it on a claim without a description. Most payers want a written description of the test methodology and the clinical indication. The key point: if a Tier 1 code exists and specifically describes your test, use it. Using 81479 when a more specific code applies is a billing error that triggers review. The CPT code needs to be accurate and specific. ## MAAA Codes and What They Cover Multianalyte Assays with Algorithmic Analysis (MAAA) codes sit in their own section of CPT (81500–81599 and proprietary codes above 81599). These cover tests that combine results from multiple analytes, often multiple genes or biomarkers, into a single algorithmic score or risk stratification. Examples: Oncotype DX Breast Recurrence Score (81519), the Decipher Prostate test (81541), Prosigna Breast Cancer Prognostic Gene Signature (81520). These are distinct CPT codes tied to specific commercially available tests, often with FDA clearance or clinical validation behind them. Some MAAA tests also have PLA (Proprietary Laboratory Analyses) codes, specific codes assigned by the AMA to single-manufacturer tests. A PLA code identifies a unique test offered by a single lab. If the test you're billing has a PLA code, use it. Payers increasingly look for PLA codes for specific tests rather than accepting generic MAAA codes. Coverage for MAAA codes varies significantly by payer. Medicare's coverage for some MAAA codes runs through Palmetto GBA under MolDX; you need a positive coverage determination and Z-code. Commercial payers have their own coverage policies. Don't assume that because a MAAA code exists it's covered, check the payer's specific policy. ## DEX Z-Codes: What They Are and When You Need Them The DEX Z-code system is Palmetto GBA's mechanism for identifying specific molecular tests under the MolDX program. It's not part of CPT or HCPCS. It's a supplemental billing requirement specific to Medicare claims processed by Palmetto GBA and its affiliates. Here's how it works: before a lab can bill Medicare for a molecular test managed under MolDX, the lab must submit the test for technical assessment through the MolDX portal. If the assessment is positive, MolDX assigns the test a DEX Z-code, a unique identifier that looks like "ZZ000-0" and is appended to the claim in a specific field. Without the Z-code, the claim edits out. Not every test requires a Z-code. Single-gene Tier 1 tests with established Medicare coverage may not require one. Multi-gene panels and novel molecular tests almost always do. Check the MolDX covered test list (available on the Palmetto GBA website) to determine your test's Z-code status. For commercial payers, Z-codes aren't required. But having a positive MolDX technical assessment can be valuable in commercial PA and appeals situations, it's a coverage determination from a CMS contractor that demonstrates the test has been evaluated and approved for clinical use. ## Companion Diagnostics and Biomarker Testing Codes Companion diagnostic tests, those tied to FDA-approved therapies, have their own coding considerations. Tests like PD-L1 expression (often billed under 88360 for IHC), HER2 IHC (88360) or FISH (88377), and MSI/MMR testing (IHC under 88342 or 88344; PCR under 81301) have established CPT codes and generally clearer coverage than novel LDTs. The billing challenge comes when a test is ordered as part of a comprehensive genomic profile but the companion diagnostic is also separately ordered. Don't double-bill. If the CGP result includes the biomarker status, billing the standalone companion diagnostic separately on the same encounter will get flagged under NCCI edits. J-codes (HCPCS Level II J-codes) apply to oncology drug infusions, not to testing. J9355 is pertuzumab; J9354 is ado-trastuzumab emtansine. These are claim-level codes for drug administration, but they tie to the companion diagnostic in terms of coverage, payer policies covering J9355 often reference HER2 testing requirements, so your biomarker test documentation supports both the test claim and the downstream drug claim. ## Getting ICD-10 Codes Right Molecular test claims are sensitive to ICD-10 code specificity. Generic codes fail. For somatic testing: specify the cancer type and laterality. C50.911 (malignant neoplasm of right breast, unspecified) is better than C50.9 (malignant neoplasm of breast, unspecified). For lymphoma, distinguish between Hodgkin and specific subtypes. Payers' LCD and NCD coverage criteria often list specific ICD-10 codes, if your code isn't on the covered list, the claim edits out automatically. For hereditary testing: the ICD-10 codes are often Z-codes (family history codes) or personal history codes, not active malignancy codes. Z84.81 is family history of cancer (among others). These need to pair correctly with the test and the policy criteria. ## Sources - AMA CPT Code Set, current edition (Tier 1, Tier 2, MAAA, PLA codes) - HCPCS Level II Code Set, CMS.gov (J-codes for oncology drugs) - Palmetto GBA / MolDX Program, DEX Z-code technical assessment requirements - CMS NCD 90.2 (next-generation sequencing in cancer, coverage criteria and applicable codes) - 42 CFR §410.32 (Medicare ordering and documentation requirements) - ASCO/CAP HER2 Testing Guidelines, coding and testing methodology reference --- # LCD vs. NCD: How Medicare's Two Coverage Determinations Actually Decide Your Claim URL: https://converus.ai/knowledge-base/lcd-vs-ncd-medicare-coverage/ Updated: 2026-06-19 A molecular lab gets two claims denied for the exact same test on the exact same week. One patient lives in North Carolina, the other in Ohio. Same CPT code, same documentation, same clinical story. One denial cites a national rule; the other cites a local one the billing team had never read. Nothing was wrong with the lab. What was wrong was the assumption that Medicare coverage is one thing. It is not. Medicare coverage runs on two parallel tracks, and a claim has to clear whichever ones apply to it. Understanding the difference between a National Coverage Determination and a Local Coverage Determination is the difference between predicting your denials and being surprised by them. > **Disclaimer**: This article is educational and is not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. Coverage policies change, contractors interpret them differently, and the only authoritative sources are the current NCD, LCD, and Article language in the CMS Medicare Coverage Database. Always verify against current policy and consult qualified clinical, billing, and compliance professionals before making coverage, billing, or treatment decisions. Use this information at your own risk. ## The shared foundation: "reasonable and necessary" Both kinds of determination answer the same underlying question. Under Section 1862(a)(1)(A) of the Social Security Act, Medicare generally cannot pay for items or services that are not "reasonable and necessary for the diagnosis or treatment of illness or injury." ([CMS](https://www.cms.gov/medicare/coverage/determination-process); [SSA §1862](https://www.ssa.gov/OP_Home/ssact/title18/1862.htm)) An NCD and an LCD are simply two different mechanisms for deciding what counts as reasonable and necessary, at two different levels of government. The level matters because it determines who decides, how far the decision reaches, and how the two decisions stack. ## NCDs: the national floor A National Coverage Determination is a coverage policy issued by the Centers for Medicare & Medicaid Services (CMS) that sets, on a nationwide basis, the extent to which Medicare will cover a specific item, service, or technology. ([CMS](https://www.cms.gov/medicare/coverage/determination-process)) An NCD is the closest thing Medicare has to a single national answer. Two features make NCDs powerful. First, they are **binding on all Medicare contractors** and entities; under Section 1869(f) of the Social Security Act, NCDs bind the contractors that process claims, and administrative law judges may not disregard them. ([CMS transmittal](https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r59ncd.pdf); [SSA §1869](https://www.ssa.gov/OP_Home/ssact/title18/1869.htm)) Second, they are **slow and deliberate to make or change**. For a request that does not require an external technology assessment or advisory committee review, CMS must issue a proposed decision within 6 months; requests that do require that review get 9 months. A proposed decision then posts for a 30-day public comment period, with the final decision due within 60 days after comments close. ([CMS](https://www.cms.gov/medicare/coverage/determination-process)) An NCD is a major, infrequent event. For molecular labs, NCD 90.2 (next-generation sequencing for cancer) is the textbook example of a national rule that sets the floor for a whole category of testing. ## LCDs: local detail where the national rule stops A Local Coverage Determination is a decision by a Medicare Administrative Contractor (MAC) about whether a particular item or service is reasonable and necessary, and therefore covered, **within that contractor's jurisdiction only**. ([CMS](https://www.cms.gov/medicare/coverage/determination-process/local)) MACs are the private companies CMS contracts with to administer Medicare claims region by region; each one covers a defined set of states. Crucially, MACs develop an LCD **when there is no NCD on the topic, or when an existing NCD needs to be further defined for the local jurisdiction.** ([CMS](https://www.cms.gov/medicare/coverage/determination-process/local)) That is the heart of the relationship. LCDs fill gaps and add specificity; they do not override the national layer. The Medicare Program Integrity Manual is explicit that LCDs must not conflict with statutes, regulations, CMS rulings, or national coverage policy. ([CMS PIM Ch. 13](https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf)) LCDs also move on their own clock. A proposed LCD must be published on the Medicare Coverage Database and open for public comment for a minimum of 45 days, with an open meeting during that window; the final LCD then carries a notice period of at least 45 days before it takes effect. ([CMS PIM Ch. 13](https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf); [Epstein Becker Green](https://www.ebglaw.com/insights/publications/cmss-new-process-for-issuing-local-coverage-determinations)) Because every MAC runs that process independently, the same test can gain, lose, or change coverage in one jurisdiction while staying untouched in another. ## LCD vs. NCD at a glance | Dimension | NCD (National Coverage Determination) | LCD (Local Coverage Determination) | | --- | --- | --- | | Who issues it | CMS | A Medicare Administrative Contractor (MAC) | | Geographic scope | All of Medicare, nationwide | Only the issuing MAC's jurisdiction(s) | | What it governs | Whether an item/service is reasonable and necessary, set as a national policy | Whether an item/service is reasonable and necessary within that jurisdiction; often adds local detail where no NCD exists | | Precedence / relationship | Binding on all contractors; LCDs cannot conflict with it | Must stay consistent with NCDs, statutes, and regulations; operates in the space an NCD leaves open | | How it's found | CMS Medicare Coverage Database (national coverage updated in real time) | CMS Medicare Coverage Database (local coverage captured weekly, displayed the following Thursday) | | How often it changes | Infrequent; formal multi-month process with a 30-day comment period | More frequent and varies by MAC; minimum 45-day comment period plus a 45-day notice period | Sources for the table values are listed in the Sources section below. ([CMS coverage process](https://www.cms.gov/medicare/coverage/determination-process); [CMS local](https://www.cms.gov/medicare/coverage/determination-process/local); [MCD intro](https://www.cms.gov/Outreach-and-Education/MLN/Educational-Tools/MLN901347-How-to-MCD/mcd/mcd/chapter_1_introduction/); [CMS PIM Ch. 13](https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf)) ## How they interact on a real claim The cleanest way to think about it: the NCD is the national floor, and the LCD is the local detail built on top of it where the floor allows. A claim has to clear every determination that applies to it. Three common situations follow from that: - **An NCD exists and settles the question.** The national rule controls, and any LCD in the picture has to be consistent with it. Here, knowing the NCD is most of the work. - **No NCD exists.** The MAC's LCD (and its companion coding Article) is the operative policy, and it can differ from one jurisdiction to the next. Two labs running the identical test can face different rules purely because of where the patient's claim is adjudicated. - **An NCD exists but leaves room.** Some NCDs explicitly defer parts of the coverage decision to the contractors. The NCD sets the frame; the LCD fills in local specifics like covered indications, documentation expectations, and coding. NCD 90.2 works this way for many non-FDA-approved tests, which is exactly why MolDX policy carries so much weight in molecular diagnostics. One subtlety worth flagging: the coding and billing instructions you actually need to get a claim right often live not in the LCD itself but in an associated **Article**. CMS guidance directs that coding guidelines are not part of the LCD and should be published in Articles instead. ([CMS PIM Ch. 13](https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf)) Reading the LCD without its Article is a frequent way teams miss the requirement that denies them. ## Why this distinction decides molecular and diagnostic payment For diagnostic, genetic-testing, and specialty labs, the LCD layer is where most coverage action happens, because so many molecular tests have no dedicated NCD. That is the gap the **MolDX program** was built to fill. MolDX was developed by Palmetto GBA to set coverage and reimbursement standards for molecular diagnostic tests, and several other MACs, including Noridian, WPS, and CGS, have adopted MolDX policies in their own jurisdictions. ([CMS LCD L35025](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35025); [Palmetto GBA](https://palmettogba.com/palmetto/moldxv2.nsf/DID/9A7MFG4181)) The practical result is that whether your test is covered, and under what conditions, frequently turns on which MAC adjudicates the claim and what that MAC's current MolDX LCD and Article say. This is where the two tracks become an operational problem rather than a trivia question. A national rule can stay frozen for years while a relevant MolDX LCD is revised, retired, or replaced on a 45-day cycle in one jurisdiction and not another. Your coverage picture for a single test is the sum of an NCD that changes rarely and a set of LCDs that change independently, on different calendars, in different regions. Tracking only the national layer, or only your "home" MAC, leaves blind spots that show up as denials. That per-jurisdiction coverage logic, every applicable NCD plus the relevant local LCD and Article, on their own changing schedules, is exactly what [Converus](https://converus.ai) monitors so labs can see where a given test is payable and what each jurisdiction currently requires, rather than discovering it one denial at a time. ## The takeaway NCDs and LCDs are not competing answers to the same question; they are two layers of one system. The NCD sets a binding national floor. The LCD, written by a MAC, adds local detail where the national rule is silent or deferential, and it can never conflict with the national rule above it. To get paid, a claim must satisfy whichever determinations apply, national and local, and those determinations change on independent schedules. For molecular and diagnostic labs especially, the local layer is often the one that actually decides the claim, which is why "Is it covered by Medicare?" is rarely a single national yes or no. ## Sources - CMS, Medicare Coverage Determination Process — https://www.cms.gov/medicare/coverage/determination-process - CMS, Local Coverage Determinations — https://www.cms.gov/medicare/coverage/determination-process/local - CMS, Pub. 100-03 Medicare National Coverage Determinations (transmittal, NCD binding effect) — https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r59ncd.pdf - CMS, Medicare Program Integrity Manual, Chapter 13 — Local Coverage Determinations (LCD/NCD consistency, comment and notice periods, Articles) — https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c13.pdf - CMS, How to Use the Medicare Coverage Database — Introduction (document types; update timing) — https://www.cms.gov/Outreach-and-Education/MLN/Educational-Tools/MLN901347-How-to-MCD/mcd/mcd/chapter_1_introduction/ - Social Security Act §1862 (reasonable and necessary) — https://www.ssa.gov/OP_Home/ssact/title18/1862.htm - Social Security Act §1869 (NCD binding effect, review limits) — https://www.ssa.gov/OP_Home/ssact/title18/1869.htm - CMS Medicare Coverage Database, LCD — MolDX: Molecular Diagnostic Tests (L35025) — https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35025 - Palmetto GBA, MolDX Frequently Asked Questions — https://palmettogba.com/palmetto/moldxv2.nsf/DID/9A7MFG4181 - Epstein Becker Green, CMS's New Process for Issuing Local Coverage Determinations (45-day comment and notice periods) — https://www.ebglaw.com/insights/publications/cmss-new-process-for-issuing-local-coverage-determinations --- # Liquid Biopsy and ctDNA Reimbursement: How Medicare Covers (and Denies) Plasma-Based Genomic Profiling URL: https://converus.ai/knowledge-base/liquid-biopsy-ctdna-medicare-coverage/ Updated: 2026-06-19 # Liquid Biopsy and ctDNA Reimbursement: How Medicare Covers (and Denies) Plasma-Based Genomic Profiling A metastatic lung cancer patient walks into your affiliated clinic on a Friday. The oncologist needs a genomic answer fast, the tissue block is thin, and a re-biopsy means another procedure and another two weeks. So the physician orders a blood draw instead. The liquid biopsy comes back in days, names an actionable alteration, and the patient starts targeted therapy. Clinically, this is a win. Then the claim posts, and it denies. If you run a lab, an oncology practice, or a revenue-cycle function, you have lived some version of that story. Liquid biopsy is one of the fastest-moving categories in molecular oncology, and the gap between "clinically appropriate" and "reimbursed" is wide and shifting. The good news: there is real, durable Medicare coverage here. The catch: it is conditional, test-specific, and indication-specific, and the conditions change as the FDA approves new companion-diagnostic claims and Medicare contractors revise their policies. Getting paid depends less on whether liquid biopsy is "covered" in the abstract and more on whether *this assay*, for *this patient's cancer and stage*, lines up with a current policy. > **Educational disclaimer.** This article is for general educational purposes only. It is not medical, legal, billing, or reimbursement advice, and it does not guarantee coverage or payment. Coverage policies, codes, and criteria change frequently and vary by payer, contractor, and date of service. Statements here reflect sourced information as of the dates cited; always verify against the current policy and consult qualified professionals before making clinical, coding, or billing decisions. Use at your own risk. ## The line that decides everything: companion diagnostic vs. everything else The single most useful mental model for liquid biopsy reimbursement is a fork in the road. On one side sit FDA-approved companion-diagnostic (CDx) liquid assays used on-label. On the other side sit broader, earlier-stage, monitoring, and screening uses. The two sides have very different coverage stories. Start with the favorable side. Two plasma-based comprehensive genomic profiling tests anchor the FDA-approved companion-diagnostic category. **Guardant360 CDx** was the first FDA-approved liquid biopsy for comprehensive genomic profiling, analyzing circulating tumor DNA (ctDNA) from a blood draw, and it carries multiple companion-diagnostic indications across tumor types including lung and colorectal cancer ([Guardant Health](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx)). **FoundationOne Liquid CDx** is an FDA-approved next-generation sequencing (NGS) test that analyzes circulating cell-free DNA from plasma in patients with advanced cancer, with multiple companion-diagnostic claims across biomarkers and therapies ([Foundation Medicine](https://www.foundationmedicine.com/test/foundationone-liquid-cdx); [FDA](https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers)). Why does that FDA status matter so much for Medicare? Because of a national policy hook. Under the National Coverage Determination for Next Generation Sequencing (**NCD 90.2**), Medicare covers diagnostic NGS lab tests for patients with advanced cancer (recurrent, relapsed, refractory, metastatic, or stage III/IV) when the test has FDA approval or clearance as a companion in vitro diagnostic, has an FDA-approved or cleared indication for use in *that patient's* cancer, and is ordered by a treating physician with results returned for patient management ([CMS NCD 90.2](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372)). CMS has stated that tests gaining FDA approval or clearance as an in vitro companion diagnostic automatically receive coverage under the NCD when the other criteria are met ([CMS](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients)). That is the cleanest pathway in this whole landscape. An FDA-approved CDx, used on-label, in a patient with advanced disease, ordered appropriately, in a CLIA-certified lab. When all of those align, the coverage question is largely answered at the national level. The operational discipline is making sure every one of those elements is actually true and documented for the claim in front of you, because the denial-prone failures are subtle: the assay was run for an indication outside its on-label CDx claim, or the patient's documented stage does not meet the "advanced cancer" definition. ## MolDX and the plasma-based genomic profiling framework National policy is only half the picture. Most molecular lab claims route through a Medicare Administrative Contractor (MAC), and for molecular diagnostics that usually means the **MolDX** program run by Palmetto GBA and adopted by several MACs. MolDX maintains a Local Coverage Determination specifically for **plasma-based genomic profiling in solid tumors** ([CMS LCD L38043](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38043); related billing article [A57867](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57867)). This is the framework that governs whether a liquid biopsy is covered as a limited-coverage benefit and under what conditions. Per the policy, patients can be eligible when they are candidates for treatment with a drug that is FDA-approved for their cancer or carries an NCCN category 1 or 2A recommendation tied to a biomarker the assay tests, and when tissue-based comprehensive genomic profiling is infeasible or has not revealed actionable mutations ([CMS LCD L38043](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38043)). The policy also contemplates that other liquid biopsies can be covered for the same indications if they demonstrate comparable performance to the established assay in their intended-use applications. Two practical points fall out of this. First, the framework is explicitly therapy-linked: coverage flows from whether the result can guide an approved or guideline-supported treatment, not from genomic curiosity. Second, MolDX coverage is not automatic for every plasma test; a new assay typically has to establish its analytical and clinical validity and complete the MolDX technical assessment to qualify. NeoGenomics' PanTracer LBx, for example, was reported to qualify for Medicare coverage under the MolDX plasma-based profiling policy ([Clinical Lab Products](https://clpmag.com/lab-management/company-news/medicare-grants-coverage-blood-based-genomic-profiling-test-advanced-solid-tumors/)). The lesson for operators bringing a test to market, or relying on a sendout: coverage is earned per assay, and the MolDX Z-code and billing-article details matter as much as the clinical story. Note also that MACs have latitude. The local-coverage section of NCD 90.2 expands MAC discretion, including for germline NGS testing across cancer diagnoses ([Epstein Becker Green](https://www.ebglaw.com/insights/publications/medicare-expands-access-to-genetic-diagnostic-tests-for-certain-ovarian-and-breast-cancers)). MACs may cover beyond the NCD's national floor but cannot contradict it. So two patients with identical clinical pictures can land differently depending on jurisdiction and the policy in force on the date of service. ## Tissue or blood? The clinical decision shapes the claim Liquid biopsy did not replace tissue; it joined it, and the coverage logic reflects that. In advanced non-small cell lung cancer, ctDNA testing has shown high concordance with tissue for guideline-recommended biomarkers and a markedly faster turnaround ([PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9881738/)). That speed is the clinical case for blood-first or concurrent testing. But concordance is not identity. Studies show that when a plasma result is negative and the ctDNA tumor fraction is low, reflexing to tissue can surface previously unidentified alterations in a substantial share of cases ([ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1556086424018057)), and complementary ctDNA testing can add information in many patients while still missing some alterations detectable on tissue ([PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858142/)). Why does a clinical nuance belong in a reimbursement article? Because the MolDX plasma framework bakes the tissue relationship into coverage. The policy's eligibility language leans on whether tissue profiling is infeasible or uninformative, and it points clinicians toward tissue genotyping when no alteration is detected in plasma or ctDNA is insufficient. In other words, the documentation that supports medical necessity is the same documentation that records the clinical reasoning: insufficient tissue, prior tissue testing without actionable findings, the need for a rapid result to start therapy. A liquid biopsy ordered without that rationale in the record is not just clinically thinner; it is a weaker claim. Build the chart so the "why blood" answer is explicit, and the coverage case largely writes itself. ## The investigational side of the fork: screening and (still-maturing) monitoring Now the other side of the road, where enthusiasm has outrun coverage. **Multi-cancer early detection (MCED).** Blood tests that aim to screen asymptomatic people for many cancers at once are scientifically exciting and, for Medicare reimbursement purposes, largely not there yet. As of 2026, no MCED test is FDA-approved, and these tests are not routinely covered by Medicare; one prominent test is available through CLIA pathways and marketed without payer coverage ([Prevent Cancer Foundation](https://preventcancer.org/policy-advocacy/multi-cancer-early-detection/coverage-and-legislation/)). CMS and the FDA approved an Investigational Device Exemption study enrolling roughly 50,000 Medicare beneficiaries to evaluate clinical impact ([GRAIL](https://grail.com/press-releases/grail-to-initiate-reach-study-to-evaluate-clinical-impact-of-galleri-multi-cancer-early-detection-mced-test-among-the-medicare-population/)). Congress has moved as well: the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law in February 2026, creating a benefit-category mechanism so Medicare *could* cover such tests once FDA-approved ([AJMC](https://www.ajmc.com/view/bipartisan-support-secures-mced-coverage-in-medicare)). That is a runway, not a coverage decision. Treat MCED as a watch-this-space category, not a billable line today. **Molecular residual disease (MRD).** ctDNA-based MRD testing, detecting trace tumor DNA after treatment to flag recurrence early, sits in a middle zone that has been moving toward coverage. MolDX maintains an LCD for minimal/molecular residual disease testing for cancer ([CMS LCD L38835](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38835); billing article [A58456](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58456)), and specific assays have qualified for coverage in defined settings. Exact Sciences' Oncodetect, for instance, was reported to receive Medicare coverage through MolDX for serial use in stage II–III and resectable stage IV colorectal cancer in adjuvant and recurrence-monitoring settings ([Exact Sciences](https://www.exactsciences.com/news-events/press-releases/exact-sciences-announces-medicare-coverage-for-oncodetect-molecular-residual-disease-test)). The pattern mirrors plasma CGP: coverage is assay-specific and indication-specific, often limited to particular tumor types, stages, and serial-testing schedules. Do not assume MRD coverage in one cancer extends to another. ## Why clean-looking claims still deny, and what to do about it Put the pieces together and a denial taxonomy emerges. Liquid biopsy claims most often fail not because the science is weak but because of an alignment problem between the test as run and the policy as written: - **Indication mismatch.** The assay was used outside an FDA-approved on-label companion-diagnostic claim, or for a cancer type the policy does not cover. - **Stage mismatch.** The patient's documented stage does not meet the "advanced cancer" definition under NCD 90.2, or the early-stage use is not within MAC discretion. - **Documentation gaps.** The record does not establish medical necessity, treating-physician order, or the clinical rationale for plasma over tissue. - **Stale policy.** The claim relied on a coverage understanding that has since changed because the FDA added or modified a CDx claim, or a MAC revised its LCD or billing article. - **Coding precision.** The proprietary laboratory analysis (PLA) code billed must correctly identify the specific assay (these tests are reported with test-specific PLA codes), and pricing for such codes is frequently contractor-priced rather than nationally set ([CMS CLFS test code list](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)). Reference CPT and PLA codes by number against current AMA and CMS sources rather than from memory. The throughline across every one of these failure modes is currency. The covered indication for a given liquid biopsy is not a fixed fact; it is a moving target that updates each time the FDA approves a new companion-diagnostic claim, a MAC posts a revised LCD, or a billing article changes its covered code list. A test that was investigational last year can become covered this year for a specific indication, and a policy can narrow as well as expand. Labs and practices that treat coverage rules as a one-time setup and revisit them only when denials spike are, structurally, always slightly behind the policy. ## The operating discipline this category demands If there is one durable takeaway for a lab director, clinic owner, or revenue-cycle leader, it is this: in liquid biopsy, getting paid is a function of keeping payer coverage rules current per test and per indication. The clinical value of ctDNA is no longer the question. The operational question is whether your order sets, medical-necessity documentation, coding, and payer-policy references reflect what each MAC and commercial plan actually covers *today* for the specific assay and the specific patient population you serve. That is precisely the work that is easy to under-resource and expensive to neglect. It means tracking NCD 90.2's national floor, the MolDX plasma-CGP and MRD LCDs and their billing articles, the FDA's evolving list of companion-diagnostic claims, and the commercial medical policies that often lag or diverge from Medicare. It means knowing when a sendout assay has cleared MolDX technical assessment and what indications it is covered for. This is the category **Converus** works in: keeping reimbursement intelligence current across tests and indications so that coverage rules are tracked deliberately rather than discovered at the remittance. However you resource it, the principle holds. Coverage in liquid biopsy is real but conditional, and the conditions move. Make tracking them a standing process, not an afterthought. ## Sources - CMS, National Coverage Determination (NGS) 90.2: https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372 - CMS, "CMS finalizes coverage of Next Generation Sequencing tests": https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients - CMS, LCD — MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043): https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38043 - CMS, Billing and Coding Article — MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A57867): https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57867 - CMS, LCD — MolDX: Minimal Residual Disease Testing for Cancer (L38835): https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38835 - CMS, Billing and Coding Article — MolDX: MRD Testing for Solid Tumor Cancers (A58456): https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58456 - CMS, Advanced Diagnostic Laboratory Tests Under the Medicare CLFS (test code list): https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf - FDA, "FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers": https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers - Foundation Medicine, FoundationOne Liquid CDx: https://www.foundationmedicine.com/test/foundationone-liquid-cdx - Guardant Health, FDA approval of Guardant360 CDx (BRAFTOVI/colorectal): https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx - Clinical Lab Products, NeoGenomics PanTracer LBx qualifies for Medicare coverage under MolDX: https://clpmag.com/lab-management/company-news/medicare-grants-coverage-blood-based-genomic-profiling-test-advanced-solid-tumors/ - Epstein Becker Green, Medicare Expands Access to Genetic Diagnostic Tests (ovarian/breast, MAC discretion): https://www.ebglaw.com/insights/publications/medicare-expands-access-to-genetic-diagnostic-tests-for-certain-ovarian-and-breast-cancers - Exact Sciences, Medicare Coverage for Oncodetect MRD Test: https://www.exactsciences.com/news-events/press-releases/exact-sciences-announces-medicare-coverage-for-oncodetect-molecular-residual-disease-test - Prevent Cancer Foundation, Multi-Cancer Early Detection Coverage & Legislation: https://preventcancer.org/policy-advocacy/multi-cancer-early-detection/coverage-and-legislation/ - GRAIL, REACH study (Galleri in Medicare population): https://grail.com/press-releases/grail-to-initiate-reach-study-to-evaluate-clinical-impact-of-galleri-multi-cancer-early-detection-mced-test-among-the-medicare-population/ - AJMC, "Bipartisan Support Secures MCED Coverage in Medicare": https://www.ajmc.com/view/bipartisan-support-secures-mced-coverage-in-medicare - Liquid Biopsy for Guiding Treatment Decisions in Advanced NSCLC (concordance/turnaround), PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9881738/ - Concurrent Liquid and Tissue Biopsy / reflex testing, ScienceDirect: https://www.sciencedirect.com/science/article/abs/pii/S1556086424018057 - Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing in Advanced NSCLC, PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858142/ --- # MCED Coverage Reality Check: Where Galleri and Multi-Cancer Screening Actually Stand With Payers URL: https://converus.ai/knowledge-base/mced-galleri-coverage-status/ Updated: 2026-06-19 A patient walks into an oncology clinic having read that a single blood draw can screen for more than fifty cancers at once. They want the Galleri test. The physician is willing. The lab can run it. And then the practical question lands on whoever manages your revenue cycle: who pays for this? For multi-cancer early detection (MCED) testing in mid-2026, the honest answer is almost always the patient, out of pocket. Understanding why that is the case, and what would have to change for it to be otherwise, is the difference between setting realistic expectations and writing off claims you never should have submitted. > **Disclaimer**: This is educational content, not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. This topic is moving quickly: FDA review timelines, federal legislation, and payer policies can change after this was written. The dates and statuses below are stated as of mid-2026 and you should verify the current FDA status, legislative status, and each payer's current policy directly before relying on any of it. Consult qualified clinical, billing, regulatory, and legal professionals before making coverage, treatment, or compliance decisions. Use this information at your own risk. ## What MCED tests are, and why coverage is the hard part Multi-cancer early detection tests look for signals shared across many cancer types, typically by analyzing circulating tumor DNA and related markers in a blood sample. Galleri, made by GRAIL, is the best-known example and the only widely available MCED test in the United States. The American Cancer Society describes these as multi-cancer detection tests that are not yet recommended for routine screening and notes that none has been approved by the FDA. The clinical pitch is genuinely compelling. The trouble for anyone who has to get paid is that a compelling test and a covered test are two different things. Coverage decisions turn on a specific, unglamorous question that every payer asks: is there sufficient evidence that using this test changes what clinicians do and improves outcomes, enough to call it medically necessary rather than investigational? For MCED screening in asymptomatic people, payers have largely concluded the answer is "not yet." To see why, you have to look at three things at once: FDA status, the evidence base, and the structure of the Medicare benefit itself. ## The FDA status: a lab-developed test, with a PMA now pending Galleri has been on the market since 2021, but not as an FDA-approved product. It is offered as a laboratory-developed test (LDT) under CLIA regulations, the framework that lets a single high-complexity lab develop and run a test it offers as a service. That distinction matters enormously for reimbursement, because the absence of FDA approval is the first thing most payer policies cite when they decline to cover MCED testing. That status is now in motion. On January 29, 2026, GRAIL announced it had submitted a premarket approval (PMA) application to the FDA for Galleri, completing a modular submission and supporting it with data from the PATHFINDER 2 study and the NHS-Galleri trial ([GRAIL, January 2026](https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/)). The FDA had previously granted Galleri Breakthrough Device designation. A PMA submission, though, is the beginning of an FDA review, not the end. As of mid-2026 the FDA had not issued a decision, and you should treat any timeline you hear as an estimate rather than a fact. This is precisely the kind of status that can change between when this was written and when you read it, so verify it directly with the FDA or GRAIL's current communications before you assume anything about approval. ## The evidence question payers keep returning to Even setting FDA status aside, commercial payers apply their own evidence standard, and MCED testing has not yet cleared it for screening use. The familiar three-part test runs through nearly every relevant medical policy: analytic validity (does the test measure what it claims, reliably), clinical validity (does the result correlate with a real clinical condition), and clinical utility (does acting on the result actually improve outcomes). MCED tests tend to show strong analytic performance and high specificity, but the clinical-utility piece, the proof that earlier detection through MCED leads to better outcomes at the population level, is the part still being established through large trials. The professional and guideline landscape reflects that caution. The U.S. Preventive Services Task Force has grade A or B screening recommendations for only a handful of single cancers, breast, cervical, colorectal, and lung cancer in high-risk individuals, and does not currently recommend MCED screening ([ASCO Educational Book, 2025](https://ascopubs.org/doi/10.1200/EDBK-25-473834)). GRAIL's own PATHFINDER 2 results, presented in October 2025, were framed as showing what Galleri adds *on top of* USPSTF-recommended screening rather than as a replacement, reporting a more than seven-fold increase in cancers found within a year when Galleri was added to recommended screenings ([GRAIL/PR Newswire, October 2025](https://www.prnewswire.com/news-releases/grail-pathfinder-2-results-show-galleri--multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings-302588036.html)). Promising, and explicitly positioned as additive to, not a substitute for, established screening. ## How that translates into payer policy When you read the actual medical policies, the pattern is consistent. Blue Cross Blue Shield of Massachusetts classifies the use of multi-cancer early detection tests, naming Galleri, as **investigational**, and treats it as not a covered service ([BCBS MA medical policy](https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/124%20Multicancer%20Early%20Detection%20Testing.pdf)). Blue Shield of California maintains a comparable multicancer early detection testing policy citing the lack of FDA approval among its rationale ([Blue Shield of California medical policy](https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Multicancer-Early-Detection-Testing.pdf)). "Investigational" is not a soft word in this context. It is a defined coverage status that places the test outside the medical-necessity benefit, which is why these claims are routinely denied rather than processed and paid. The practical reality for patients shows up in price. GRAIL lists Galleri at a self-pay price, and the company itself states that insurance does not currently cover the test, while noting that certain employer programs, life insurers, and some military-affiliated channels have offered access ([Galleri patient cost page](https://www.galleri.com/patient/the-galleri-test/cost)). If you are setting patient expectations or designing an order-to-cash workflow around MCED, plan for self-pay and financial counseling as the baseline, not for third-party reimbursement. ## The Medicare structure problem, and the bill meant to fix it Here is the part that surprises people: even if MCED testing had a robust evidence base today, traditional Medicare would still face a structural obstacle. Medicare pays for screening tests through defined statutory benefit categories. Colorectal cancer screening, mammography, and the like each exist because Congress or CMS created a category and pathway for them. Until 2026 there was no equivalent dedicated benefit category for multi-cancer early detection screening in an asymptomatic population, and absent that category, CMS did not have a straightforward route to cover MCED screening nationally, regardless of the data. That gap is exactly what the **Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act** was written to close, and as of early 2026 it is law. Introduced in the 119th Congress as H.R. 842 and S. 339, it was folded into the Consolidated Appropriations Act of 2026, which the House passed on January 23, 2026, and it was signed into law on February 3, 2026 ([H.R. 842, congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/842); [Rep. Sewell, House press release, February 2026](https://sewell.house.gov/2026/2/on-world-cancer-day-rep-sewell-celebrates-signing-of-the-nancy-gardner-sewell-multi-cancer-early-detection-act)). It creates a Medicare benefit category for MCED screening tests and allows CMS to begin an evidence-based coverage process, but only for tests that have received FDA approval. Read that mechanism carefully, because it is widely misunderstood. The law does not order Medicare to cover Galleri or any other test. It builds the pathway. FDA approval still has to come first, and then CMS still has to run its own coverage process before any MCED test is paid for. So even now that the enabling law exists, this remains a multi-step sequence stretched over years: FDA approval of a specific test, then a CMS coverage determination, with the statute's coverage mechanism phased in rather than switched on at signing. Confirm the implementation timeline and any CMS rulemaking directly, since those details govern when coverage could actually begin. A direct caution, because this is the fastest-moving corner of the topic: although the enabling law is now on the books, that is not the same as coverage, and the operative questions have simply moved downstream to FDA approval and CMS implementation. Verify the current FDA decision status and any CMS coverage rulemaking before you tell anyone that an MCED test is, or is about to be, covered. Do not let either a stale "still in committee" headline or a premature "it's the law, so it's covered" headline drive a coverage assumption. ## What a settled coverage pathway looks like, by contrast To appreciate how early MCED is, compare it to an established screening test that traveled the full road. Cologuard, the multi-target stool DNA test for colorectal cancer, is FDA-approved, is included in USPSTF colorectal screening guidance, and is covered by Medicare Part B at a defined interval for average-risk beneficiaries in the eligible age range, without cost-sharing as a preventive service ([American Cancer Society, screening coverage](https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html)). Line those two tests up and the difference is not subtle. Cologuard has FDA approval, a guideline recommendation, and an existing Medicare benefit category for colorectal screening to slot into. Galleri, as of mid-2026, has a pending FDA submission, no USPSTF screening recommendation, an investigational status across major commercial policies, and a Medicare benefit category that exists only on paper, newly created by statute but unusable until an MCED test is FDA-approved and CMS acts. Every element that makes Cologuard payable is, for MCED, either in progress or not yet started. That is the whole story of why one is covered and the other generally is not. ## What this means for how you operate If you are a lab offering MCED, an oncology practice fielding patient requests, or the person who owns market access, a few things follow directly. Set patient and referrer expectations toward self-pay today; submitting MCED screening to most payers as if it were a covered benefit will generate denials and rework. Track FDA status as its own variable, because it is the gating event for almost everything downstream, including the federal legislation. And treat the Sewell Act for what it is: a newly enacted pathway to monitor, not a present-day coverage win, since no MCED test can be reimbursed under it until the FDA approves one and CMS acts. The deeper lesson generalizes well beyond Galleri. Coverage for an emerging diagnostic is not a single fact you can learn once. It is a moving relationship among FDA status, evidence accumulation, individual payer medical policies, and statute, and each of those moves on its own clock and per test and per indication. A policy can flip from investigational to covered the quarter after an approval, or stay put for years. The operators who get paid on the right tests at the right time are the ones treating that change as something to be tracked continuously rather than rediscovered at denial. Building that monitoring discipline, whether internally or through a service like Converus that watches payer policy by test and indication, is what turns a fast-moving coverage landscape from a liability into something you can actually plan around. For MCED specifically, the practical instruction is simple: verify the current FDA status, the current legislative status, and each payer's current policy at the moment you need to act, because all three are still in motion. ## Sources - GRAIL, "GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test" (January 2026): https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/ - GRAIL / PR Newswire, "GRAIL PATHFINDER 2 Results Show Galleri Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings" (October 2025): https://www.prnewswire.com/news-releases/grail-pathfinder-2-results-show-galleri--multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings-302588036.html - Galleri, "How Much Does the Galleri Test for Cancer Screening Cost?" (patient cost page): https://www.galleri.com/patient/the-galleri-test/cost - Blue Cross Blue Shield of Massachusetts, Medical Policy 124, "Multicancer Early Detection Testing": https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/124%20Multicancer%20Early%20Detection%20Testing.pdf - Blue Shield of California, "Multicancer Early Detection Testing" medical policy: https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Multicancer-Early-Detection-Testing.pdf - American Cancer Society, "Multi-cancer Detection (MCD) Tests": https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html - ASCO Educational Book, "Multicancer Early Detection Tests at a Crossroads: Commercial Availability Ahead of Definitive Evidence" (2025): https://ascopubs.org/doi/10.1200/EDBK-25-473834 - U.S. Congress, H.R. 842 (119th Congress), Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act: https://www.congress.gov/bill/119th-congress/house-bill/842 - U.S. Congress, S. 339 (119th Congress), Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act: https://www.congress.gov/bill/119th-congress/senate-bill/339 - Rep. Terri Sewell, "On World Cancer Day, Rep. Sewell Celebrates Signing of the Nancy Gardner Sewell Multi-Cancer Early Detection Act" (February 2026): https://sewell.house.gov/2026/2/on-world-cancer-day-rep-sewell-celebrates-signing-of-the-nancy-gardner-sewell-multi-cancer-early-detection-act - American Cancer Society, "Insurance Coverage for Colorectal Cancer Screening": https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html --- # Modifier 25 Explained: Why Your "Free" Checkup Got a Bill URL: https://converus.ai/knowledge-base/modifier-25-explained/ Updated: 2026-05-19 > ### At a glance > > Modifier 25 is a two-character code added to an office visit to flag that the doctor handled a separately identifiable medical problem on the same day as another service (often a preventive checkup). It is legitimate billing. It is also the single most common reason a patient walks out of a "free" annual visit and gets a bill two weeks later. > ### Disclaimer > > This article is general educational content and is not medical, legal, tax, or financial advice. CPT codes, modifier rules, and payer policies change, and the appropriateness of any specific billing code is a determination for licensed coders, providers, and payers based on the documentation in your chart. Dollar amounts in this article are illustrative examples, not quotes for any particular plan or visit. Inclusion of an example does not imply that any specific provider, payer, or plan has billed incorrectly. For decisions about a specific bill, appeal, or coverage question, consult a qualified professional (your insurer's member services, a patient advocate, a healthcare attorney, or your provider's billing office, as appropriate). Use this information at your own risk. ## What modifier 25 actually is A modifier, in plain English, is a two-digit suffix attached to a CPT code to add information about how a service was performed. The official AMA definition of [modifier 25](https://www.ama-assn.org/practice-management/cpt) is "Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service." Translated: the doctor performed a separate, billable evaluation on the same day as something else (usually a preventive visit or a minor procedure), and that separate work should be paid separately. The CPT code an E/M (evaluation and management) visit uses depends on visit type and complexity. Common ones: - 99213, 99214. Established patient office visit, lower or moderate complexity. - 99203, 99204. New patient office visit, lower or moderate complexity. - 99396, 99397. Established patient periodic preventive visit (adult, age-banded). When a doctor performs both a preventive visit and a separately billable problem-oriented visit on the same day, the claim might look like: - 99396 (preventive medicine, established patient, age 40 to 64) - 99213-25 (office visit, problem-focused, with modifier 25 attached) The "-25" tells the payer: yes, this is in addition to the preventive code, and yes, the documentation supports a separate evaluation. The first code (99396) is on the ACA preventive list. The second (99213) is not. The second runs through your deductible and coinsurance. ## Why modifier 25 exists at all It exists because doctors sometimes do two genuinely different things in one visit, and the billing system has to capture both. Without modifier 25, a payer's claims engine sees two E/M codes from the same provider on the same patient on the same day and bundles them as a duplicate. The modifier tells the payer that the second code represents distinct work requiring its own history-taking, examination, and medical decision-making. Used appropriately, it is fair compensation for clinical work that actually happened. ## How it shows up on your EOB The Explanation of Benefits is a post-claim summary from your insurer. It records what the doctor billed, what the insurer adjusted, and what you owe. The actual bill comes from the provider. On an EOB after a visit with modifier 25, you will typically see two line items. The amounts below are illustrative examples to show the structure, not real numbers from any specific plan: | CPT code | Modifier | Description | Allowed amount (illustrative) | Patient responsibility | | --- | --- | --- | --- | --- | | 99396 | (none) | Periodic preventive visit, age 40 to 64 | $250 | $0 | | 99213 | 25 | Established patient office visit, problem-focused | $150 | Up to $150, depending on deductible and coinsurance | The preventive code lands at $0 because of the ACA Section 2713 rules. (See [What's Actually Covered as "Preventive" Under the ACA](/knowledge-base/aca-preventive-services-explained/) for the full set of conditions.) The problem-focused E/M lands wherever your deductible is. If you have not met your deductible yet, the full allowed amount is on you. ## Why it turns "free" annuals into billed visits Patients schedule "an annual." They are thinking about the preventive list: blood pressure check, blood work, screening reminders, vaccinations. They expect $0. During the visit, the doctor asks how things have been. The patient mentions a stiff shoulder. Or a headache. Or trouble sleeping. The doctor takes a moment, asks follow-up questions, examines the shoulder, jots a few notes, suggests a stretch or a medication or a referral. That short detour is what the doctor's billing staff later codes as 99213-25. It was, in the doctor's clinical judgment, a separately identifiable evaluation. It happened during the same visit. It is billable. The patient experienced one appointment. The biller submitted two services. The EOB lists two services. The bill arrives. The patient is confused. This is rarely a fraud problem. It is a communication problem. The doctor did the work, documented the work, and coded per CPT guidelines. The patient just did not know in real time that a question had become a billable separate visit. ## Other mechanisms with similar effect Modifier 25 is the most common but it is not the only path to a surprise charge after a "free" service: - Z-code vs. E-code diagnosis swap on lab tests. A blood panel ordered with a screening Z-code (for example, Z00.00 general adult medical exam) can be recoded under a diagnostic ICD-10 code after the lab matches the order against actual findings. The diagnostic code runs through the deductible instead of the preventive benefit. - Out-of-network labs at in-network facilities. Your doctor's office is in-network, but the lab they send your blood draw to may not be. Some plans cover any in-network reference lab. Others restrict to specific contracted labs. - Frequency limits. ACA preventive coverage applies at the recommended frequency only. If USPSTF recommends one screening every five years and you got two in three years, the second one is not free. - Provider counted as out-of-network within the encounter. A clinic-employed PA or a covering physician may not share the in-network status of the practice's lead doctor. ## When modifier 25 is used appropriately CPT and CMS guidance are consistent. The modifier is appropriate when: - A separate problem was evaluated. - The evaluation required its own history-taking and examination. - The evaluation required medical decision-making, documented in the chart. - The documentation is enough that the evaluation could stand as a separately billable service on its own. A worked example. Patient comes in for a periodic preventive visit (CPT 99396). The doctor finds a new skin lesion that looks suspicious, takes a focused history, conducts a focused dermatologic exam, decides on biopsy, and documents the work. The 99213-25 alongside the 99396 is the right code combination. The patient gets one annual at $0 and one problem-focused visit billed under the deductible. ## When it is used questionably The trickier zone is when a brief patient comment does not actually require its own evaluation but gets coded as one anyway. If a patient says "my knee has been a little sore lately, but not too bad" and the doctor responds "we can talk about that more if it gets worse" and moves on, the documentation may not support a 99213-25 if the claim is later audited. Whether a specific use of modifier 25 was appropriate is ultimately a determination made by coders, providers, and reviewers based on the chart. CMS has identified modifier 25 as a known audit-risk area, and the HHS Office of Inspector General has published reports examining patterns of modifier 25 use. The risk to providers and patients alike is having a charge stand or fall on whether the underlying documentation supports a separately billable visit. ## What patients can do Four concrete moves: 1. **Ask the front desk before the annual.** "Will today's visit be billed as a single preventive visit, or could it generate additional charges if I bring up an unrelated problem?" Good practices give a clear answer in advance. 2. **Scan the EOB for modifiers.** If you see a CPT code with "-25" appended, recall what was discussed at the visit. If the modifier looks unwarranted, you have a basis for an appeal. 3. **Request an itemized bill.** Get the line-item statement showing every CPT code, modifier, and diagnosis code. Some clinics will not send this automatically. 4. **Appeal if it does not look right.** Per [KFF's 2024 marketplace data](https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/), internal appeal overturn rates run around 34%, with fewer than 1% of denied claims actually appealed. Patients who file have one-in-three odds. Patients who do not file have zero. ## What providers can do to reduce surprise bills Two changes on the provider side have outsized effect: 1. **Real-time communication when a conversation becomes a separately billable visit.** If the patient mentions a knee problem and the doctor decides to evaluate it, the doctor can say in plain language that this is now a separate evaluation with its own billing, and offer to either evaluate today or schedule a follow-up sick visit. Patients overwhelmingly choose to know in advance. 2. **Front-desk script during scheduling.** "If you have specific problems you want addressed, mention them now. Annual visits are designed for preventive care. Other problems may be billed separately." Practices that do this consistently see fewer billing complaints and fewer abandoned balances. ## Opinion Modifier 25 is legitimate and necessary. Doctors who handle two real medical issues in one visit deserve to be paid for two. On paper, the system works. It is also one of the most common sources of patient surprise bills, because clinics rarely tell patients in real time that a conversation has become a billable separate visit. That communication gap is fixable on the provider side and not particularly hard to fix. The clinics that have fixed it see it pay back in patient satisfaction and collections. The asymmetry is the patient not knowing. For related context, see [What's Actually Covered as "Preventive" Under the ACA](/knowledge-base/aca-preventive-services-explained/) for the rules behind the "free" visit, [The Five Health Insurance Plan Types Explained](/knowledge-base/five-health-insurance-plan-types/) for how your plan type shapes the deductible the billed portion runs through, and [Denials 101](/knowledge-base/denials-101/) for how the same modifier shows up on the billing side. > ### What this means for you > > 1. **Ask before the annual** whether bringing up unrelated problems will trigger a separate bill. Get the answer in writing if you can. > 2. **Read the EOB line by line.** Look for any CPT code with "-25" attached. > 3. **Request the itemized bill.** Confirm the documentation supports a separately billable visit before paying. > 4. **Appeal.** Internal appeal overturn rates run around 34%. Most patients who pay these charges never file an appeal. ## Sources - [AMA CPT codes and modifiers](https://www.ama-assn.org/practice-management/cpt) (modifier 25 official definition) - [CMS, Background on ACA Preventive Care Rules](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/preventive-care-background) - [CMS, ACA Implementation FAQs Part 12](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/aca_implementation_faqs12) - [KFF, Claims Denials and Appeals in ACA Marketplace Plans in 2024](https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/) --- # The MolDX Z-Code, Explained: When You Need One and How the Process Works URL: https://converus.ai/knowledge-base/moldx-z-code-explained/ Updated: 2026-06-19 A few years ago, the DEX Z-Code was the kind of administrative detail a lab could be a little late on. That era is over. As of May 1, 2025, a molecular claim that reaches a MolDX contractor without a Z-Code in the right field does not get reviewed, debated, or partially paid. It is rejected as unprocessable. The clinical merit of the test never enters the conversation. If you bill molecular diagnostics, the Z-Code has quietly become one of the highest-leverage details on the claim, and it is worth understanding properly. > **Disclaimer**: This is educational, not billing, legal, or medical advice. MolDX and DEX requirements, jurisdictions, and processes change over time, and your situation may differ from the general description here. Always verify current requirements against MolDX, the DEX Diagnostics Exchange, and the applicable Medicare Administrative Contractor before acting. Use this information at your own risk. ## What a Z-Code actually is A DEX Z-Code is a unique identifier, assigned through the DEX Diagnostics Exchange, that tells a payer exactly which molecular test was performed. That sounds trivial until you remember how molecular billing works: a single broad CPT code can represent dozens of completely different assays from different labs, with different methods, gene content, and evidence. The CPT code says "a molecular test of roughly this type." It does not say *which* one. That ambiguity is the problem the Z-Code solves. By pairing the broad CPT code with a specific Z-Code, the lab tells the payer precisely which test is on the claim, which in turn lets the payer apply the coverage policy that belongs to that specific test. The Z-Code is, in effect, the test's fingerprint in the reimbursement system. The program behind it is MolDX, administered by Palmetto GBA on behalf of Medicare and applied across the participating Medicare Administrative Contractor jurisdictions, roughly half the country. Within those jurisdictions, the Z-Code is how molecular tests are identified, tracked, and adjudicated. ## When you need one The clean version of the rule is this: if you are billing molecular diagnostic tests in a jurisdiction where MolDX applies, you are operating in Z-Code territory, and the requirement is most consistently and strictly enforced for laboratory developed tests (LDTs) and similar assays. What has changed recently is that the Z-Code is no longer only a Medicare concern. Commercial payers have started adopting the same identifier. UnitedHealthcare extended a DEX Z-Code requirement to its commercial molecular claims, a change announced for April 1, 2024 and then **delayed to June 1, 2024**, under which claims are denied when the Z-Code is missing, invalid, or does not match the service billed. The significance is the direction of travel: an identifier that began as a MolDX-specific Medicare mechanism is becoming a broader expectation across payers, which means more of your book of business depends on getting it right. ## How a test gets a Z-Code Obtaining a Z-Code is not a single form. It is a registration lifecycle, and understanding the sequence helps explain why the timing can surprise labs that treat it as a last-minute step. First, the **laboratory** registers with MolDX through the DEX Diagnostics Exchange. Then each individual **test** is registered, because the Z-Code attaches to a specific assay, not to the lab in general. For tests that require it, the lab then completes a **technical assessment**: a dossier in which MolDX reviewers, experts in clinical molecular genetics and molecular genetic pathology, evaluate the test against three standards, analytical validity (does the test accurately measure what it claims to), clinical validity (does the result correlate with the clinical condition), and clinical utility (does the result actually change patient management). MolDX will only cover and reimburse tests that meet these standards at the level of Medicare's reasonable-and-necessary requirement. After the initial review, DEX assigns the Z-Code. Initial assignment is often relatively quick, but, and this is the part labs most often misread, the Z-Code arriving in your inbox is not the same as the test being payable. Build in time for the full process, and do not assume a newly registered test is ready to bill the moment its identifier appears. ## The distinction that trips everyone up: a Z-Code is not coverage Here is the single most important point in this article. **Having a Z-Code does not mean the test is covered.** The Z-Code identifies the test. Coverage is a separate determination. A test can be fully registered, carry a valid Z-Code, and still be denied because it does not meet the coverage criteria for a particular patient and indication, the wrong cancer stage, insufficient documentation of medical necessity, an indication the policy excludes, or a technical assessment that has not established utility to the payer's satisfaction. Labs get burned by conflating the two. They obtain a Z-Code, treat the test as "approved," and are then surprised when claims deny on medical-necessity or coverage grounds. The Z-Code clears the *identification* hurdle. The *coverage* hurdle is still there, and it is governed by the applicable Local or National Coverage Determination and the test's technical assessment, not by the existence of the identifier. ## What happens when the Z-Code is missing or wrong This is where the recent enforcement change bites. **Effective May 1, 2025, MolDX claims submitted without the DEX Z-Code in the required claim field deny as unprocessable**, per Noridian guidance. There is no clinical review and no partial adjudication; the claim is rejected on the spot. The same logic applies to commercial adopters: under UnitedHealthcare's commercial policy, claims are denied when the Z-Code is missing, invalid, or mismatched to the service. A mismatch is its own trap, submitting a Z-Code that does not correspond to the test actually represented by the CPT code can be as fatal to the claim as submitting none at all. The practical takeaway is that the Z-Code has become a structural gate that sits in front of everything else. A clinically perfect order, performed correctly, documented well, will still be rejected if the identifier is missing or wrong. It is the cheapest denial to prevent and one of the most expensive to ignore, because it costs you the entire claim for a purely administrative reason. ## Why this keeps getting harder to manage If this were a one-time setup, it would be a project, not a problem. It is a problem because it never holds still. Test registrations have to be maintained. Z-Code-to-CPT relationships change as codes update. Coverage policies tied to those tests, the LCDs, the technical-assessment expectations, the commercial medical policies, get revised on their own schedules. And the list of payers requiring Z-Codes is expanding from Medicare into the commercial world. For a lab running a real menu of molecular tests across multiple payers, keeping every registration current, every Z-Code correctly mapped, and every linked coverage policy up to date is not a clerical task. It is an ongoing operational discipline, and it is exactly the kind of work that erodes quietly: a registration lapses, a code relationship changes, a policy updates, and the first sign of trouble is a denial report. ## The strategic takeaway The Z-Code is a useful lens on a bigger truth about molecular reimbursement: getting paid increasingly depends on a chain of specific, current details, the right identifier, mapped to the right code, tied to the right coverage policy, for the right indication, and the chain breaks at its weakest link. A missing Z-Code breaks it administratively. A stale coverage rule breaks it clinically. Either way the claim is lost. That is why leading labs are moving away from treating these as isolated billing chores and toward treating them as a maintained system, registrations, identifiers, and the coverage rules attached to them kept current together, so the claim that goes out reflects today's requirements. Keeping that web of test identifiers and payer rules accurate and current, per test and per payer, is the problem Converus was built to solve, and the Z-Code is a good example of why it matters: in molecular billing, the small current detail is often the difference between a paid claim and an automatic rejection. ## Sources - Proper Submission of DEX Z-Code for Molecular Diagnostic Services (MolDX) Claims — Noridian Healthcare Solutions (effective May 1, 2025) - MolDX: Technical Assessment and Technical Assessment FAQs — Palmetto GBA - DEX Diagnostics Exchange — Z-Code registration and program information - Make Sure Molecular Tests Have a Z-Code Assigned — UnitedHealthcare (commercial Z-Code requirement, 2024) - LCD: MolDX: Molecular Diagnostic Tests (MDT) (L35025) — Centers for Medicare & Medicaid Services --- # The 7 Most Common Claim Denial Reasons (and How to Fix Each) URL: https://converus.ai/knowledge-base/most-common-claim-denial-reasons/ Updated: 2026-05-06 Your EOB shows CO-50 again. Or CO-197. Or B15. If you're seeing the same denial codes week after week, the problem isn't bad luck, it's a workflow gap you haven't plugged yet. Here's what each code means and the specific fix. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## Denial 1: CO-50, Medical Necessity Not Established CO-50 is the most common denial in specialty and genetic testing billing. The payer received your claim but decided the clinical information doesn't support coverage under their policy. **The fix**: This is almost always a documentation problem, not a clinical one. The ordering physician's notes may clearly support the service, but if you didn't include the specific diagnosis codes, the NCCN category reference, or the clinical history that matches the payer's policy criteria, the reviewer can't make the connection. Pull the payer's medical policy for the test or drug. Find the coverage criteria. File your appeal with a letter of medical necessity that addresses each criterion by name. Attach the NCCN guideline pages. Don't restate the clinical situation, map the patient to the criteria. For oncology and genetic testing, request a peer-to-peer review immediately after a CO-50 denial. This is your highest-yield move. Most payers allow 5–14 business days from denial to make that request. ## Denial 2: CO-197, Prior Authorization Not Obtained CO-197 means the service was delivered but the payer says no PA was on file. You're either dealing with a retro-auth situation or a documentation failure. **The fix**: First, verify your records. If PA was obtained, provide the authorization number and approval date in your appeal. This resolves faster than almost any other denial type. If PA genuinely wasn't obtained before service, file for retro-authorization immediately. Most payers allow retro-auth for emergent or urgent clinical situations with documentation explaining why pre-service authorization wasn't feasible. For an oncology patient where biopsy results came back requiring immediate treatment decisions, that's a documented clinical urgency. For a scheduled test where someone forgot to submit, your options are narrower. Watch your contract. Some provider agreements specify timely filing windows and retro-auth eligibility. Know the payer's window before you wait a week to file. ## Denial 3: CO-16, Claim Lacks Required Information CO-16 is a catch-all for missing or invalid data fields. Payers aren't required to tell you exactly what's missing, though many will indicate it in the remark code (look for N codes on the EOB). **The fix**: Cross-reference the claim against the payer's submission requirements. Common missing elements: referring provider NPI when required, DEX Z-code for MolDX-managed tests, place of service code mismatch, missing taxonomy code, or an ICD-10 code truncated to 3 characters when 5 are required. For genetic testing specifically, if you're billing a Medicare patient and the test is managed by Palmetto GBA under MolDX, missing the DEX Z-code in the appropriate field is an instant CO-16. Get the Z-code assigned through MolDX before billing. ## Denial 4: CO-A1, Experimental or Investigational CO-A1 or similar E&I denial codes mean the payer has classified the test or treatment as not meeting their evidentiary threshold for coverage. **The fix**: This requires the most work of any denial type. You need to build an evidentiary case: - FDA clearance or approval for the specific indication (include 510(k) number or PMA number) - NCCN guideline listing with category designation (Category 1 or 2A is your best argument) - Peer-reviewed publications demonstrating clinical utility, not just technical performance - Positive coverage determinations from other payers or CMS (NCD or LCD) - Any payer-specific exception criteria for E&I services (some plans cover E&I services when standard therapy has failed) For laboratory-developed tests that haven't completed a MolDX technical assessment, getting through that process and obtaining a DEX Z-code and positive coverage determination can change the clinical evidence landscape for commercial payer appeals. ## Denial 5: CO-4, Procedure Code Inconsistent with Modifier This one is almost always a coding error. The modifier you billed (26, TC, 59, 91, etc.) doesn't logically apply to the procedure code on the claim. **The fix**: Have your coding team review the modifier combination. Modifier 59 (distinct procedural service) is commonly over-applied to molecular testing codes, it's appropriate when the same code is billed more than once on the same day for different specimens or distinct indications, but it needs documentation to support it. Modifier 91 (repeat clinical diagnostic laboratory test) is the right modifier for repeat testing of the same analyte, but payers require documentation that the repeat was clinically necessary and not a duplicate. Correct the modifier, add documentation if required, and resubmit. ## Denial 6: B15, Payment Denied Because Your Claim Was Not Filed on Time B15 or timely filing denials happen when the claim doesn't reach the payer within the contractual or regulatory filing window. Most commercial plans have 12-month timely filing windows. Medicare Part B has a 12-month window from date of service. **The fix**: There isn't much to do if you genuinely filed late, timely filing denials are the hardest to overturn. Your appeal needs documentation proving the claim was submitted on time (fax confirmation, portal submission record, EDI transaction log). If you can show submission within the window, the denial gets reversed. If you can't, you're arguing for a hardship exception, which payers rarely grant. The real fix is upstream: implement timely filing tracking in your billing system and set automated alerts at 60, 90, and 180 days from service date. ## Denial 7: OA-23, Payment Adjusted Because This Service or Item Denied When Billed as Separate Service OA-23 typically means the payer considers your service to be bundled into another code billed on the same claim or in the same episode. **The fix**: Check the NCCI edits (National Correct Coding Initiative) for the code pair. CMS publishes NCCI tables; most clearinghouses surface these as edit warnings before submission. If the bundling is incorrect, services were truly separate and non-overlapping, appeal with documentation of the distinct clinical purpose of each service. If the NCCI edit is valid, you may need to unbundle, correct the codes, or apply appropriate modifiers. For molecular testing, this comes up when billing multiple CPT codes from the same code family on the same specimen. Payers sometimes bundle these; your appeal needs to articulate why each code represents a distinct test with a distinct result. ## Sources - HCPCS Level II code set and CMS NCCI (National Correct Coding Initiative), CMS.gov - AMA CPT Code Set, current edition - 42 CFR §405.978 (Medicare redetermination process) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans) - Palmetto GBA / MolDX program, DEX Z-code requirements --- # MRD Testing and Medicare Coverage: Why 'Covered' Depends Entirely on the Cancer and the Question Being Asked URL: https://converus.ai/knowledge-base/mrd-testing-medicare-coverage/ Updated: 2026-06-19 A patient finishes adjuvant chemotherapy for stage III colon cancer. Their oncologist wants to know, before scans would ever show anything, whether there is still cancer circulating in the bloodstream. So they order a molecular residual disease test. Months later, your lab is staring at a denial, or the oncology practice is staring at a surprise bill, and the question everyone asks is the same one that opened this paragraph in reverse: wasn't this covered? The honest answer is that "covered" is the wrong unit of analysis for MRD testing. Medicare does cover it. But coverage attaches to a specific cancer, a specific stage, and a specific clinical question, and a claim that drifts even slightly off those coordinates gets denied no matter how clinically reasonable the order was. If you run, own, or manage revenue for a lab or oncology practice that touches these assays, the difference between a paid claim and a write-off usually lives in that gap. > **Disclaimer**: This article is educational and is not medical, legal, billing, or coverage advice. It is not a coverage determination for any patient or claim. Coverage policies change frequently, Medicare Administrative Contractors apply their own local policies, and the only authoritative sources are the current LCDs, articles, and manufacturer billing guidance themselves. Treat every figure and criterion here as "true as of the cited date — verify the current policy." Consult qualified clinical, billing, and compliance professionals before making coverage, treatment, or billing decisions. Use this information at your own risk. ## What MRD testing actually is, and why coverage is awkward Molecular residual disease testing — also called minimal residual disease testing — looks for tiny amounts of tumor-derived circulating tumor DNA (ctDNA) in a blood sample after a patient has been treated for cancer. The premise is that ctDNA can flag residual or recurrent disease earlier and more specifically than imaging or traditional protein markers. Several assays compete in this space — among them Natera's Signatera, Guardant Health's Guardant Reveal, and Exact Sciences' Oncodetect — and they differ in important ways, some tumor-informed (designing a personalized panel from the patient's own tumor tissue), others tumor-naive. Here is what makes coverage awkward. MRD is not one test for one purpose. The same blood draw might be used to stratify recurrence risk right after surgery, to decide whether a patient needs adjuvant chemotherapy, to monitor for recurrence over years of surveillance, or to watch whether a tumor is responding to immunotherapy. Each of those is a different clinical claim, supported by different evidence, in a different patient population. Medicare does not pay for "an MRD test." It pays for an MRD test used for a purpose it has decided is reasonable and necessary, in a patient who fits the population the evidence supports. That is why there is no single national yes-or-no for MRD. There is a stack of indication-specific decisions, and they are made mostly at the contractor level. ## How MRD gets covered: MolDX and the LCD Most molecular diagnostic coverage in Medicare flows through the MolDX program, administered by Palmetto GBA and operating across several Medicare Administrative Contractors (including Noridian and others). MolDX doesn't issue one blanket rule for ctDNA. Instead, it publishes Local Coverage Determinations — LCDs — that define, in clinical detail, when a particular class of test is covered for a particular use. The practical consequence is that MRD coverage is best understood as a portfolio of indications that grows over time, each added when MolDX is persuaded the evidence supports it, and applied test by test as individual assays qualify. A use can be covered for one cancer and not another, or for recurrence monitoring but not a different use, all under the same program. This is the single most important mental model for anyone trying to get these claims paid: you are never asking "is this test covered?" You are asking "is this test, for this cancer, at this stage, used for this purpose, covered under the current LCD?" ## The colorectal pathway: the template everything else followed Colorectal cancer is where MRD coverage was first established, and it remains the most mature pathway, so it is the template worth understanding. MolDX opened the door in 2020 with a colorectal MRD policy, now reflected in LCD L38290. The first assay to secure coverage under it was Natera's Signatera, through a final Noridian decision effective October 18, 2020 — but the more durable point is what the policy actually covered, not which test got there first. It covered two distinct uses at once: post-resection risk stratification, using ctDNA status to inform adjuvant treatment decisions, and ongoing surveillance for recurrence in patients who had no evidence of disease but remained at risk. The surveillance piece carries a detail that operators repeatedly trip over. The MolDX colorectal policy doesn't authorize unlimited monitoring. It ties allowable testing frequency to the schedule for CEA (carcinoembryonic antigen) surveillance under NCCN guidelines, within roughly a one-month timing window, according to the language in the CMS Medicare Coverage Database. In other words, Medicare anchored MRD monitoring frequency to an existing, familiar surveillance cadence rather than letting it run open-ended. If you bill serial MRD tests more often than the policy contemplates, expect those extra claims to be denied even though the patient is squarely in the covered population. The colorectal policy also illustrates why payers moved at all. These LCDs rest on clinical-utility evidence that ctDNA can flag recurrence earlier and more specifically than imaging or protein markers like CEA — exactly the kind of argument that moves a coverage determination from "promising" to "reasonable and necessary." (Treat any specific performance figures you encounter, from any assay maker, as the studies' and manufacturers' reported results rather than a guarantee for any patient.) ## Expansion: more cancers, and a different question entirely Once the colorectal template existed, the story became one of expansion — both to new tumor types and to a genuinely different clinical use. On the tumor-type side, MolDX's broader MRD-for-cancer LCD (L38779) describes covered uses well beyond colorectal, spanning breast, bladder, ovarian, and lung cancer. Individual assays qualify under that policy on their own timelines; Natera, for example, reported Signatera's coverage under L38779 in mid-2025. The pattern is exactly the indication-by-indication accretion described above: each cancer arrives as its own covered use, on its own schedule, supported by its own evidence. The more conceptually interesting expansion is immunotherapy response monitoring, which the broader LCD also addresses as a pan-cancer use — reading ctDNA dynamics during treatment as a signal of whether a patient is responding. That is a different clinical question from "is there residual disease after surgery?" It is "is this drug working?" The fact that Medicare extended coverage into response monitoring shows how the same underlying technology can earn separate coverage for separate uses, and it is a reminder that you cannot assume an assay covered for post-surgical surveillance is also covered for therapy monitoring, or vice versa. The use case is part of what is being covered. ## Coverage is assay-specific, not category-wide A trap worth naming explicitly: coverage attaches to assays, not to the category. The fact that one MRD test is covered for colorectal cancer tells you nothing definitive about whether another lab's test is covered for the same patient. The competitive landscape makes this concrete, and it is genuinely multi-vendor. Guardant Health announced Medicare coverage for Guardant Reveal — a tissue-free, methylation-based ctDNA test — for colorectal cancer surveillance after curative-intent treatment (Guardant press release, January 2025). Exact Sciences announced Medicare coverage for its Oncodetect MRD test for serial use in stage II, III, and resectable stage IV colorectal cancer, in both the adjuvant and recurrence-monitoring settings (Exact Sciences press release, July 2025). Natera's Signatera, as noted above, carries its own set of covered indications. Each of these is a separate coverage decision, with its own criteria, populations, and effective dates. For an operator, the implication is operational, not academic. If your lab runs more than one MRD assay, or if an ordering practice sends specimens to multiple labs, you cannot maintain a single mental rule for "MRD coverage." You need the current criteria for each assay you bill. Mixing them up — applying one test's covered stages to another test's claim — is a clean path to denials. ## What this means for getting paid Step back from the individual policies and the operating reality comes into focus. MRD reimbursement is a moving target with several independent axes, and a claim has to land correctly on every one of them: - **The cancer type** must be one the current LCD covers for that assay. - **The stage and clinical setting** must match the covered population — post-resection risk stratification, surveillance, neoadjuvant, response monitoring, and so on are not interchangeable. - **The clinical use** must be a covered use; an assay covered for residual-disease surveillance is not automatically covered for immunotherapy monitoring. - **The frequency** of serial testing must stay within what the policy allows, which for colorectal surveillance is pegged to the CEA schedule. - **The documentation and ordering** must establish that the patient actually meets those criteria, because coverage in principle is not a payable claim — that's true across molecular diagnostics, and it's true here. None of these axes is static. New cancers get added. New assays gain coverage. Frequency language and covered settings get revised as policies are updated and replaced. A coverage fact that was accurate when a billing protocol was written can quietly go stale, and the first sign is often a denial that nobody can immediately explain. That's the real lesson buried in the MRD story. The clinical case for these tests keeps getting stronger and coverage keeps expanding — which sounds like unambiguously good news, but it means the rules you have to track are multiplying, not consolidating. For a lab or oncology practice, sustainable MRD revenue isn't a one-time exercise of confirming "this MRD test is covered." It's the ongoing discipline of knowing, for each assay and each indication you bill, what the current policy actually says, and noticing the moment it changes. That is the category Converus works in: keeping payer coverage rules current per test and per indication, so the gap between "clinically appropriate" and "actually paid" doesn't quietly become a write-off. The MRD landscape is simply one of the clearest examples of why that gap exists in the first place. As always, treat the specifics above as accurate to their cited dates and verify the current applicable LCD, article, and the assay maker's billing guidance before you rely on any coverage statement for a real claim. ## Sources - CMS Medicare Coverage Database — LCD: MolDX: Minimal Residual Disease Testing for Colorectal Cancer (L38290): https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38290&ver=5 - CMS Medicare Coverage Database — LCD: MolDX: Minimal Residual Disease Testing for Cancer (L38779): https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38779&ver=4 - CMS Medicare Coverage Database — Response to Comments: MolDX: Signatera and Minimal Residual Disease Testing for Colorectal Cancer (A58331): https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58331&ver=3 - PR Newswire — "Natera's Signatera MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer" (effective date Oct. 18, 2020): https://www.prnewswire.com/news-releases/nateras-signatera-mrd-test-receives-a-final-coverage-decision-from-noridian-in-colorectal-cancer-301128198.html - Guardant Health — "Guardant Health Receives Medicare Coverage for Guardant Reveal on Smart Liquid Biopsy Platform for Surveillance Testing in Colorectal Cancer Patients" (January 2025): https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Receives-Medicare-Coverage-for-Guardant-Reveal-on-Smart-Liquid-Biopsy-Platform-for-Surveillance-Testing-in-Colorectal-Cancer-Patients/default.aspx - Exact Sciences — "Exact Sciences Announces Medicare Coverage for Oncodetect Molecular Residual Disease Test in Colorectal Cancer" (July 2025): https://www.exactsciences.com/news-events/press-releases/exact-sciences-announces-medicare-coverage-for-oncodetect-molecular-residual-disease-test - GenomeWeb — "Natera Signatera MRD Assay Gets Broad Medicare Coverage": https://www.genomeweb.com/cancer/natera-signatera-mrd-assay-gets-broad-medicare-coverage --- # NCD 90.2 Decoded: When Medicare Covers Next-Generation Sequencing for Cancer URL: https://converus.ai/knowledge-base/ncd-90-2-medicare-ngs-coverage-explained/ Updated: 2026-06-19 Every oncology practice and molecular lab eventually asks the same question about a cancer NGS test: will Medicare pay for it? The honest answer lives in a single National Coverage Determination, NCD 90.2, and while it is often summarized as "Medicare covers NGS for advanced cancer," that summary hides the specific conditions that actually decide whether a given claim is paid or denied. This article walks through what the rule requires, in plain language, and where claims tend to fall apart even when the test was appropriate. > **Disclaimer**: This is educational, not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. Coverage rules change, Medicare Administrative Contractors apply local policies, and the only authoritative source is the current NCD and applicable LCD language. Always verify against CMS's current policy and consult qualified clinical, billing, and compliance professionals before making coverage or treatment decisions. Use this information at your own risk. ## What NCD 90.2 is, and why it exists NCD 90.2 is Medicare's national rule for covering next-generation sequencing as a diagnostic laboratory test in patients with cancer. It was finalized in March 2018 and amended in 2020. Before it existed, coverage for cancer NGS was a patchwork of local decisions; the NCD was meant to create a consistent national floor for when these tests are reasonable and necessary. The thing to understand about the rule's design is that it does two different jobs at once. It establishes a **national coverage pathway** for certain tests, and it leaves room for **local contractor discretion** for others. Knowing which door a given test comes through is the first step to predicting whether it will be paid. ## The two doors to coverage The cleaner path is for tests with FDA standing. When an NGS test is **FDA-approved or cleared as a companion in vitro diagnostic** and is used for an indication that matches the patient's cancer, NCD 90.2 provides a defined national coverage pathway, provided the patient also meets the clinical criteria below and the results are furnished to the treating physician to guide management. This is why FDA companion-diagnostic status matters so much commercially: it is the most predictable route to Medicare coverage for an NGS assay. The second path covers everything else. For NGS tests that are not FDA-approved companion diagnostics, the NCD allows **Medicare Administrative Contractors (MACs) to determine coverage** when the same clinical criteria are met. This is where the MolDX program and its Local Coverage Determinations do much of the real work, and it is why coverage for the same test can look different depending on the contractor and jurisdiction. "Medicare covers it" is rarely a national yes-or-no; for many tests it is a contractor-level decision operating inside the national framework. ## The criteria that actually decide it Both doors share the same core clinical gate. Under NCD 90.2, NGS is covered as a diagnostic laboratory test for a patient with cancer when all of the following hold: - The test is performed in a **CLIA-certified laboratory**. - The test is **ordered by the treating physician**. - The patient has **either** recurrent, relapsed, refractory, or metastatic cancer, **or** advanced stage III or IV cancer. - The patient has **not already been tested with the same NGS test** for the same primary cancer diagnosis (the rule does not cover repeating the identical test for the same cancer). - The patient has **decided to seek further cancer treatment** (for example, therapeutic chemotherapy). Read that list as a checklist, because that is how it functions on a claim. Miss any one of the elements, or fail to document it, and a test that is "covered" in the abstract becomes a denial in practice. The criteria are also explicit that they apply to **both somatic and germline** mutations, which leads to the next point. ## Somatic, germline, and the 2020 expansion The 2018 NCD was primarily understood as a somatic-testing rule, tumor testing to guide treatment. The 2020 amendment widened it. It extended coverage to include **germline (inherited) testing for certain patients with ovarian or breast cancer** who have clinical features and a family or personal history suggestive of a hereditary cancer syndrome. This distinction is not academic, because somatic and germline testing answer different questions and carry different documentation expectations. Somatic testing asks what is driving this tumor and how to treat it; germline testing asks whether the patient carries an inherited risk that affects them and their family. A claim that blurs the two, or that applies the wrong framework to the test performed, invites a denial even when some coverage pathway existed. Matching the test, the indication, and the documentation to the right framework is part of getting paid. ## The three things that most often get a covered test denied Here is the practical layer the NCD itself does not spell out. When an NGS test that should qualify under NCD 90.2 is denied anyway, it usually traces to one of three failures. The first is **stage or status not clearly documented**. The criteria turn on the patient having recurrent, relapsed, refractory, metastatic, or advanced stage III/IV disease. If that status is not unambiguously captured in the record and reflected on the claim, the reviewer cannot confirm the gate was met, and the safe default for a payer is denial. The second is **duplicate testing**. The NCD does not cover repeating the same NGS test for the same primary cancer diagnosis. A second run that looks like a repeat, even for a defensible clinical reason, can be denied unless the distinction is made clear. The third is **ordering and documentation gaps**, the test ordered by someone other than the treating physician, or a record that does not establish the patient had decided to pursue further treatment. These are not clinical disagreements; they are evidentiary gaps that prevent the payer from confirming the criteria were satisfied. ## Why "covered" keeps producing denials If NCD 90.2 establishes coverage, you would expect denials to fall over time. The data shows the opposite, and it is worth confronting. A 2025 *JAMA Network Open* study of Medicare cancer-NGS claims found the denial rate **rose from 16.8% before the NCD to 20.3% after its 2018 implementation to 27.4% after the 2020 amendment**. Coverage broadened; denials climbed. The explanation is the throughline of this whole topic: coverage and payability are different things. Each expansion of the rule added criteria, and every added criterion is one more condition a claim must document and satisfy. Broader coverage expressed as more detailed rules generates more denials, not fewer, unless the ordering, documentation, and claim keep precise pace with the policy. Coverage tells you a test *can* be paid. Meeting every criterion, on the record and on the claim, is what gets it paid. ## The strategic takeaway NCD 90.2 is a good teacher because it makes the central lesson of molecular reimbursement concrete: the gap between "this test is covered" and "this claim will be paid" is filled entirely by specific, current, well-documented criteria. The rule is national, but its application is local, contractor-dependent, and constantly refined through LCDs and program guidance. For practices and labs, the durable response is to treat coverage criteria as living rules rather than static knowledge, mapped to each test and indication, kept current as the NCD, the LCDs, and the contractor policies evolve, and applied at the point of ordering and billing so the documentation matches what today's policy actually requires. Keeping that rule layer accurate and current across payers and tests is exactly what Converus is built to do. The criteria in NCD 90.2 will keep changing; what should not change is your ability to meet them on every claim. ## Sources - National Coverage Determination (NCD 90.2): Next Generation Sequencing — Centers for Medicare & Medicaid Services (finalized March 2018; amended 2020) - Decision Memo, Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) — Centers for Medicare & Medicaid Services - Medicare Expands Access to Genetic Diagnostic Tests for Certain Ovarian and Breast Cancers — analysis of the 2020 NCD 90.2 germline expansion - Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare — *JAMA Network Open*, April 18, 2025 (doi:10.1001/jamanetworkopen.2025.5785; PubMed 40249617) --- # Peer-to-Peer Reviews: How to Win Them URL: https://converus.ai/knowledge-base/peer-to-peer-review-tactics/ Updated: 2026-05-06 Most peer-to-peer reviews are won or lost in the first two minutes. The physician who says "I just think this test is important for my patient" will lose. The physician who opens with the specific NCCN category, the patient's staging, and the treatment decision the result informs will usually win. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## Request It Immediately, the Window Closes Fast When a prior authorization comes back denied for medical necessity, the peer-to-peer request needs to happen within 48 hours. Most commercial payers allow 5–14 business days from the denial date, but you want to move immediately for two reasons. First, you need time to prepare. A peer-to-peer that happens 3 days after denial with 24 hours of prep beats one that happens 12 days later after everyone has moved on. Second, the reviewer who made the initial denial is often still active on the case. A timely peer-to-peer catches them before the case is archived. Request peer-to-peer through the payer's portal (Availity, Cigna for HCP, UHC Provider Portal) or by calling the PA line and asking specifically. Ask for a physician-to-physician review, not a nurse review, not an administrative callback. Some payers will default to a nurse reviewer if you don't ask specifically for a physician. Nurse reviewers can gather information but can't reverse a denial. ## What the Ordering Physician Needs to Know Going In The clinical prep should be brief, specific, and structured around the payer's denial reason. Pull the payer's medical policy for the service before the call. Find the coverage criteria section. The physician should be prepared to walk through each criterion and confirm the patient meets it. If you can get the specific reviewer's name from the denial letter or from the PA department, look them up. Knowing whether they're a medical oncologist, internist, or radiologist can help you tailor the clinical argument, an oncologist reviewing a CGP panel request will respond differently to an NCCN-based argument than an internal medicine physician who may need more context on why tumor profiling changes management. The physician should have at hand during the call: - Patient DOB, member ID, and the denial reference number - Diagnosis (cancer type, stage, AJCC or clinical staging) and date of diagnosis - Prior treatment history with dates and outcomes - The specific clinical question the test will answer - The NCCN guideline section (category, indication, panel type) - Any companion diagnostic or FDA-approved therapy context ## How to Structure the Opening Statement Don't wait for the reviewer to lead. Open the call by establishing clinical credibility and clarity: "This is Dr. [Name], treating oncologist for [patient initials, DOB]. I'm calling about the denial for [test/CPT code], case number [X]. My patient has [specific cancer type, stage] diagnosed [date], with [prior treatments and outcomes]. I'm requesting this [test] because [specific clinical decision it will inform, e.g., selection of a VEGFR-targeted therapy, determination of BRCA somatic status for PARP inhibitor eligibility]. This indication is covered under [payer]'s policy and supported by NCCN Category [X] for [tumor type]." That's your whole opening. Twenty seconds. The reviewer now knows this isn't a fishing expedition. ## Handle the Common Pushbacks **"This test is investigational for this indication."** Ask them to cite the specific policy language. If the test has NCCN Category 1 or 2A designation and the indication is in the policy's covered list, push back. "NCCN Category 2A reflects uniform consensus based on lower-level evidence, that's their threshold for clinical appropriateness. Can you walk me through which specific criterion isn't met?" **"The patient should try a different test first."** Ask what alternative they have in mind and why. If they're proposing an alternative that doesn't answer the same clinical question (e.g., a single-gene BRCA test instead of a panel when multiple genes are clinically relevant), explain specifically why the alternative is clinically insufficient. **"We need additional documentation."** Ask exactly what documentation is needed and the deadline to provide it. Get the name and direct fax number of the reviewer. Don't leave the call with a vague promise of "we'll let you know", confirm in writing what you're sending and when. ## After the Call Document everything: date and time, reviewer's name and credential, payer reference number, what was discussed, and the outcome. If the denial is reversed on the call, ask when you'll receive written confirmation and the PA number. Don't bill without written confirmation. If the call doesn't reverse the denial, you now have critical information for your written appeal: the specific objection the reviewer raised and the policy language they cited. Your appeal addresses exactly that. You also now have documentation that you completed a peer-to-peer before escalating, which is required by some payers before you can access external review. For Humana and Anthem Medicare Advantage denials, peer-to-peer completion is specifically documented in the administrative record for the case and referenced at the appeal stage. Keep records. ## If the Physician Won't Participate Some ordering physicians don't want to do peer-to-peer calls. That's a real operational constraint. Your options: ask a physician on your staff (a medical director or CMO at a lab, for example) to conduct the peer-to-peer on behalf of the practice with the ordering physician's documentation. Some payers allow this; others require it to be the ordering provider. Know your payer's rule before you schedule the call. If peer-to-peer truly isn't feasible, go straight to a detailed written appeal with a physician-authored letter of medical necessity. It's lower yield than a live call, but it's not nothing. ## Sources - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans) - 42 CFR §422.578 (Medicare Advantage coverage determination and appeals) - NCCN Clinical Practice Guidelines (NCCN.org), category designations by indication - ACA §2719 (independent external review requirements) - 29 USC §1133 (ERISA full and fair review) --- # Pharmacogenomic Testing Coverage: When Medicare Pays for PGx and When It Denies URL: https://converus.ai/knowledge-base/pharmacogenomic-testing-coverage/ Updated: 2026-06-19 A patient is about to start capecitabine. Their oncologist orders a DPYD test, the lab runs it, the result comes back, and Medicare pays. A few rooms away, a different clinic runs a 25-gene pharmacogenomic panel on a new patient who is on no relevant medication yet, "to have it on file." That claim gets denied. Same category of test, same CLIA-certified lab, opposite financial outcome. If you run a lab or a practice that bills PGx, understanding why those two stories end differently is the whole game. > **Disclaimer**: This is educational content, not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. Coverage rules change, Medicare Administrative Contractors apply their own local policies, and the only authoritative sources are the current NCD, LCD, and billing-article language. Always verify against CMS's current policy and consult qualified clinical, billing, and compliance professionals before making coverage or treatment decisions. Use this information at your own risk. Nothing here guarantees coverage for any test. ## The shape of the problem Pharmacogenomics sits in an awkward spot. Clinically, the field keeps maturing: the FDA maintains a Table of Pharmacogenetic Associations, and the Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes graded, genotype-based prescribing guidance. Commercially, though, the reimbursement landscape has not kept pace with the enthusiasm. There is no broad national mandate that says "Medicare covers PGx." Instead, coverage is assembled gene by gene, drug by drug, and contractor by contractor, and most of it turns on one question: was a specific drug actually in play when the test was ordered? That single question separates the two outcomes in the opening. Targeted, single gene-drug PGx tied to a medication the patient is taking or actively considering is the version that tends to get paid. Pre-emptive, broad-panel PGx run before any drug decision is the version that tends to get denied. The rest of this article explains the rules that produce that split, and where otherwise-reasonable claims still fall apart. ## The thin national layer: warfarin and not much else When people assume there must be a national Medicare rule for PGx, they are usually thinking of one narrow determination. There is a National Coverage Determination for pharmacogenomic testing for warfarin response, commonly cited as NCD 90.1. It is worth understanding precisely because it shows how conservative the national posture has been. Under NCD 90.1, testing of CYP2C9 and/or VKORC1 alleles to predict warfarin responsiveness is covered only through **coverage with evidence development (CED)** — meaning, in practice, for beneficiaries enrolled in a qualifying clinical study — and is limited to once per lifetime per beneficiary for patients who are candidates for warfarin anticoagulation and have not been previously tested. CMS's stated rationale was blunt: the available evidence did not demonstrate that this testing improves health outcomes for Medicare beneficiaries outside the CED context. ([CMS NCD 90.1](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=333)) Read that again from a revenue perspective. The one squarely national PGx coverage rule is a coverage-with-evidence-development pathway with a once-in-a-lifetime cap. That is not a generous front door. It is a signal that the national program treats PGx as something to be paid for sparingly and only when tightly justified. Almost everything else you bill for PGx lives below the national layer, in contractor territory. ## Where the real coverage lives: MolDX and the LCDs Most PGx coverage decisions are made not nationally but by Medicare Administrative Contractors, and a large share of molecular testing runs through the **MolDX** program. MolDX maintains a family of Local Coverage Determinations on pharmacogenomics testing — you will see them under IDs such as L38294, L38335, L38337, L38394, and L38435 across the participating jurisdictions — and the participating contractors apply consistent criteria. ([MolDX: Pharmacogenomics Testing L38294](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38294&ver=16)) The core logic of these policies is what you need to internalize, and it is more specific than "is this test useful." The MolDX policies frame coverage around an **actionable** gene-drug interaction. In the policy's own framing, a use is generally actionable when the genotype result may lead to selecting a therapy, avoiding a therapy, or changing a dose — and that action must be grounded in one of a short list of authorities: the **FDA drug label**, an **FDA warning or safety concern**, or a **CPIC Level A or B** gene-drug interaction. If the gene-drug pair does not clear one of those bars, you should not expect coverage. ([MolDX: Pharmacogenomics Testing L38435](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38435&ver=10)) There is a second, equally important rule embedded in the same policies, and it is the one that catches pre-emptive testing. The medication has to be chosen first, on clinical grounds, and the PGx result then informs how to use it safely. In the policy's language, the selection of the medication must derive from clinical necessity rather than from the PGx test; once a therapeutic agent is selected, the test may be considered reasonable and necessary when the result is needed for the physician's decision about safely administering or dosing that drug. ([MolDX: Pharmacogenomics Testing L38435](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38435&ver=10)) Notice what that sequence does. It puts the drug before the test. A panel ordered "so we have results on file" inverts the order — it puts the test first and hopes a drug decision will later make it relevant — and that inversion is exactly what the policy is designed to exclude. ## Single gene versus panel: a more nuanced line than "panels are bad" It is tempting to summarize all of this as "single gene-drug tests get paid, panels get denied." That is close, but it oversells the panel ban and undersells the actual rule. The MolDX policies do not categorically forbid multigene or panel testing. A panel can be payable when more than one gene on it is reasonable and necessary for the safe use of a medication, or when multiple drugs are genuinely under consideration for the patient. The disqualifier is not the number of genes; it is the absence of a drug decision driving the order. A two-drug regimen that implicates two actionable genes can support a multigene claim. A broad panel justified by "the patient might need one of these drugs someday" cannot. ([MolDX: Pharmacogenomics Testing L38294](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38294&ver=16)) And this is the heart of why pre-emptive, population-style PGx screening — the model some vendors market as "test once, use for life" — keeps colliding with Medicare. The clinical case for pre-emptive testing can be real. The coverage case, under current MolDX policy, generally is not, because the policies treat broad pre-emptive panels as not reasonable and necessary when there is no specific medication driving the test. The contractor billing and coding articles reinforce this operationally: they expect the performing lab to retain records of the drugs in use or under consideration and to submit the relevant drug information on the claim, with limits such as one test per drug in question per date of service. A pre-emptive panel with no drug attached simply cannot satisfy those instructions. ([Billing and Coding: MolDX: Pharmacogenomics Testing A58395](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58395)) ## The oncology examples worth knowing Two PGx examples come up constantly in the oncology and specialty-lab world, and they illustrate the "drug-tied, actionable" pattern cleanly. The first is **DPYD**, relevant to fluoropyrimidine chemotherapy such as 5-fluorouracil and capecitabine. Certain DPYD variants reduce the enzyme activity that clears these drugs, raising the risk of severe toxicity, which is why testing is done before treatment and why a result can change the dose or the choice of agent. Following the wave of contractor local coverage decisions, clinically indicated DPYD testing is reimbursed by Medicare across most of the country, and clinical guidance such as the NCCN colon cancer guideline supports offering DPYD testing to patients planning fluoropyrimidine therapy. ([Ho et al., Clinical Pharmacology & Therapeutics, 2025](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3567)) The second is **UGT1A1**, relevant to **irinotecan**. Reduced-function UGT1A1 variants impair clearance of irinotecan's active metabolite and are associated with increased risk of severe neutropenia and diarrhea. As one oncology-practice review put it, a series of local coverage decisions by Medicare contractors means clinically indicated PGx testing for validated genes including both UGT1A1 and DPYD is a covered service for Medicare beneficiaries across most of the United States. Both pairs are also recognized in the FDA's Table of Pharmacogenetic Associations as associations with therapeutic management implications. ([JCO Oncology Practice, 2022](https://ascopubs.org/doi/10.1200/OP.21.00840); [FDA Table of Pharmacogenetic Associations](https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations)) The pattern is the takeaway, not just the two genes. Each is tied to a specific drug class the patient is a candidate for. Each clears the actionability bar through the FDA label and CPIC guidance. Each is ordered before treatment, when the result can actually change the plan. That is what a payable PGx claim looks like. ## Where otherwise-reasonable PGx claims still get denied Even when a test is, in principle, coverable, the claim can still fall over. A few recurring failure modes are worth naming, because they are the ones that turn a clinically sound order into a write-off. The first is the **no-drug order** — the pre-emptive panel discussed above. If the documentation does not establish a specific medication being taken or actively considered, the policy's reasonable-and-necessary gate is not met, full stop. The second is the **actionability gap**. The gene-drug pair has to clear the FDA-label, FDA-safety, or CPIC Level A/B threshold. A pair that is biologically interesting but does not meet one of those authorities is unlikely to be covered, no matter how the order is written. The third is **missing drug documentation on the claim**. The MolDX billing articles expect the relevant drug information to be retained and submitted, and they impose frequency limits. A claim that omits the drug, or that exceeds the per-date-of-service limits, invites denial even when the underlying test was appropriate. ([Billing and Coding: MolDX: Pharmacogenomics Testing A58395](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58395)) The fourth is **jurisdictional drift**. Because so much of this is contractor-level, the same test can be handled differently across MACs, and policies are revised on their own schedules. A workflow validated against last year's LCD revision in one jurisdiction is not automatically safe in another, or even in the same one after an update. ## The strategic reality: PGx coverage is a moving, gene-level rulebook Step back and the structural point is hard to miss. PGx reimbursement is not governed by one rule you can learn once. It is governed by a national determination that covers essentially one drug under evidence development, plus a set of contractor LCDs and billing articles that grant coverage only for actionable gene-drug pairs tied to a real medication decision — and those pairs are defined by external authorities (the FDA label, FDA safety communications, CPIC's evolving Level A/B list) that keep changing as the science advances. CPIC has reviewed hundreds of gene-drug pairs and published guidance on a growing subset; the FDA table is periodically updated. Every one of those updates can move the coverage line for a specific test. ([CPIC overview, Clinical Pharmacology & Therapeutics](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977533/)) So getting paid for PGx is not really a clinical problem or even a billing problem in isolation. It is a tracking problem. Whether a given test is payable depends on the gene, the drug, the indication, the patient's actual medication context, and the current language of the specific contractor's policy — all of which drift over time. A lab that wins on PGx is one that knows, per gene and per drug, what the live coverage criteria are and what the order needs to look like to satisfy them. That is the category Converus works in: keeping the per-gene, per-drug, per-payer coverage rules current so reimbursement teams can order and bill against today's policy rather than last year's. You do not have to use a tool to act on the insight, though. The insight is the point. In pharmacogenomics, coverage is narrow, it is specific to the gene-drug-indication triple, and it changes — so the operators who get paid are the ones who treat policy tracking as a standing function, not a once-a-year project. ## Sources - [CMS — NCD 90.1, Pharmacogenomic Testing for Warfarin Response](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=333) - [CMS — LCD L38294, MolDX: Pharmacogenomics Testing](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38294&ver=16) - [CMS — LCD L38435, MolDX: Pharmacogenomics Testing](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38435&ver=10) - [CMS — Billing and Coding Article A58395, MolDX: Pharmacogenomics Testing](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58395) - [FDA — Table of Pharmacogenetic Associations](https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations) - [Ho et al. — A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice, Clinical Pharmacology & Therapeutics (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3567) - [Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan — Why Not?, JCO Oncology Practice (2022)](https://ascopubs.org/doi/10.1200/OP.21.00840) - [CPIC guideline development process, Clinical Pharmacology & Therapeutics](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977533/) --- # Prior Authorization vs. Precertification vs. Predetermination: What Each Term Means and Why It Decides Whether You Get Paid URL: https://converus.ai/knowledge-base/prior-authorization-vs-precertification-vs-predetermination/ Updated: 2026-06-19 ## A Word, Spelled Three Ways, With Three Different Stakes A genetics lab submits a high-cost molecular panel. The ordering clinic swears the test was "approved." The claim comes back denied. What happened? Often, the answer lives in the gap between three terms that sound like synonyms and are routinely used as if they were: **prior authorization**, **precertification**, and **predetermination**. They are all pre-service review processes. They are not the same thing, and the differences, especially whether the process was *required* and whether the payer's answer *bound them on payment*, determine whether a clean claim gets paid or written off. For lab directors, oncology clinic owners, and revenue-cycle and market-access leaders, this is not vocabulary trivia. It is the difference between a reimbursable test and an avoidable loss. > **Educational use only.** This article is general information, not medical, legal, billing, or coding advice. Terminology, definitions, and policies vary by payer and plan and change over time, and the same word can mean different things at different payers. Nothing here guarantees coverage or payment. Always verify requirements with the specific payer and plan, and consult qualified professionals before acting. Use at your own risk. ## The One Thing to Understand First: The Terms Are Inconsistent Before any definitions, internalize this, because it is the most important and most overlooked point: **the industry does not use these words consistently.** Authoritative payer documents themselves treat the terms differently from one another. Cigna states that precertification is "also called prior authorization." ([Cigna](https://www.cigna.com/health-care-providers/coverage-and-claims/precertification)) Aetna describes precertification as the utilization review process used to decide whether a requested service meets its clinical criteria for coverage, and uses "precertification" where other payers say "prior authorization." ([Aetna](https://www.aetna.com/health-care-professionals/precertification.html)) Several Blue Cross and Blue Shield plans have gone a step further and renamed "predetermination" entirely, now calling it **recommended clinical review**. ([BCBS Oklahoma](https://www.bcbsok.com/provider/education/education-reference/news-updates/2022-archive/12-22-22-predetermination-now-recommended-clinical-review)) So treat the definitions below as the common, prevailing patterns, not universal law. The operative question is never "what does this word mean in general?" It is "what does *this payer*, on *this plan*, mean by the term it is using for *this test* today?" ## Prior Authorization and Precertification: The Required, Payment-Conditioning Reviews In most payer ecosystems, **prior authorization** and **precertification** describe the same kind of process: a payer requires the provider to obtain approval *before* a service, drug, or test is delivered, and that approval turns on a review of medical necessity against the payer's clinical criteria. ([Cigna](https://www.cigna.com/health-care-providers/coverage-and-claims/precertification), [Aetna](https://www.aetna.com/health-care-professionals/precertification.html)) Two features define this category: **It is required.** When a payer mandates prior authorization or precertification for a service and the provider does not obtain it, the payer can deny the claim. Industry billing guidance is blunt: any service requiring prior authorization that is not authorized will be denied for payment, and if a patient completes a non-emergency test before approval, the payer can deny payment even if the test was clinically warranted. ([PracticeSuite](https://practicesuite.com/resources/claims-denied-for-no-prior-authorization/)) For labs, this is the dreaded "no authorization on file" denial, which is frequently hard to reverse after the fact. **Its answer is advisory on medical necessity but not a blank check.** Here is the nuance that trips up even experienced teams: an *approved* prior authorization is still **not a guarantee of payment.** Payers say so directly. Obtaining prior authorization, like checking eligibility, does not guarantee payment; benefits are determined when the claim is received and depend on the member's eligibility on the date of service, the terms of the coverage, network status, exclusions, limitations, deductibles, copays, and coinsurance. ([BCBS Illinois](https://www.bcbsil.com/provider/claims/claims-eligibility/utilization-management/predetermination)) Approval clears the medical-necessity gate; it does not clear every other condition of payment. Coding, documentation, and post-service review can still derail a claim that carried a valid authorization number. ([Integrity Billing](https://integritybillingco.com/blog/prior-authorization-approved-so-why-the-denial/)) Note the practical asymmetry: prior authorization is close to *binding against the provider* (skip it and you usually lose), while it is only *partly binding on the payer* (they approved necessity, not everything else). ## Predetermination: The Voluntary, Advisory Preview **Predetermination** is the odd one out, and the most frequently misunderstood. In its prevailing form, predetermination, now often called recommended clinical review, is a **voluntary** written request by a provider or member to learn whether a proposed treatment or service *would be* covered under the plan before it is rendered. ([BCBS Illinois](https://www.bcbsil.com/provider/claims/claims-eligibility/utilization-management/predetermination)) Multiple Blue Cross and Blue Shield plans state that submitting the request before services are rendered is **optional**, and that its purpose is to flag, in advance, situations where a service may not be covered. ([BCBS Montana](https://www.bcbsmt.com/provider/claims-and-eligibility/claims/priorauthorization-predetermination)) Two features define this category: **It is usually optional.** Skipping a predetermination does not, by itself, trigger a no-authorization denial the way skipping a required prior authorization does. It is a planning and risk-reduction tool, not a gatekeeping requirement. **It is explicitly not a guarantee of payment.** Payers are emphatic: a predetermination or recommended clinical review decision is not a guarantee of payment, and benefits are determined only once a claim is received, based on the member's eligibility and the terms of the contract applicable on the date of service. ([BCBS Illinois](https://www.bcbsil.com/provider/claims/claims-eligibility/utilization-management/predetermination)) It can tell you coverage looks likely and confirm that medical-necessity criteria appear to be met; it cannot promise the dollars. For diagnostics and genetic-testing labs, predetermination shows up constantly. In settings where coverage varies, a preauthorization or predetermination request, sometimes referred to collectively as a prior authorization request, is often completed before genetic testing begins, packaging the CPT and ICD-10 codes, ordering-provider details, and clinical documentation for the payer's review. ([Genetics in Medicine](https://www.gimjournal.org/article/S1098-3600(21)01452-0/fulltext)) Whether that submission is *required* or *advisory* depends entirely on the payer and plan. ## The Comparison at a Glance | | Prior authorization | Precertification | Predetermination | |---|---|---|---| | **Common definition** | Required pre-service approval based on medical-necessity review against payer criteria | Often the same process; many payers say it is "also called" prior authorization | Voluntary pre-service request to preview whether a service would be covered (often rebranded "recommended clinical review") | | **When it happens** | Before the service, drug, or test is delivered | Before the service is delivered | Before the service, by choice; submission is typically optional | | **Typically required?** | Yes, when the payer mandates it for that service | Yes, when the payer mandates it | Usually no; voluntary at most payers | | **Typically binding on payment?** | No. Approval is not a guarantee of payment; other conditions still apply | No. Same caveat; precertification does not guarantee payment of all billed services | No. Explicitly not a guarantee of payment | | **What it does** | Clears the medical-necessity gate in advance; produces an authorization number | Confirms the service meets clinical/coverage criteria before delivery | Previews likely coverage and helps estimate patient responsibility | | **What it does NOT do** | Guarantee final payment; eligibility, coding, network status, and exclusions still apply | Guarantee payment of every billed service | Require you to do anything, or guarantee a dollar will be paid | | **Cost of getting it wrong** | Missing a required PA often means an outright, hard-to-reverse denial | Same as PA | Treating an advisory preview as a payment promise invites a post-service surprise | Sources for the table: [Cigna](https://www.cigna.com/health-care-providers/coverage-and-claims/precertification), [Aetna](https://www.aetna.com/health-care-professionals/precertification.html), [BCBS Illinois](https://www.bcbsil.com/provider/claims/claims-eligibility/utilization-management/predetermination), [BCBS Montana](https://www.bcbsmt.com/provider/claims-and-eligibility/claims/priorauthorization-predetermination), [PracticeSuite](https://practicesuite.com/resources/claims-denied-for-no-prior-authorization/). ## Why the Distinction Hits Lab and Oncology Revenue Hardest Two failure modes follow directly from confusing these processes. The first is treating a **required precertification as optional.** A molecular panel or a tumor biomarker assay runs, the lab assumes a predetermination-style "we'll find out when we bill" posture, and the payer issues a no-authorization denial. Because the service is already complete, retroactive authorization is often unavailable, and the lab eats the cost or chases a difficult appeal. The second is treating an **advisory predetermination as a payment guarantee.** A lab sees "criteria met" language, performs the test, bills, and is then denied on eligibility, coding, or a post-service review, all of which the payer reserved the right to apply. The preview was real; the promise never existed. Both errors share a root cause: assuming the *word* tells you the *process*. It does not. The same payer can require prior authorization for one CPT-coded test, offer only voluntary predetermination for another, and use precertification language for a third, and any of those can change when the payer updates its medical policy. For genetic testing specifically, requirements differ sharply: some plans require authorization before the specimen is even collected, while others perform no pre-service review and instead apply criteria retrospectively. ([Genetics in Medicine](https://www.gimjournal.org/article/S1098-3600(21)01452-0/fulltext)) ## What to Actually Do - **Identify the process by payer, plan, and CPT code, not by the label.** Confirm, per test, whether the payer *requires* approval or merely *offers* a voluntary review. - **For required reviews, secure approval before service** and capture the authorization number on the claim. - **For approvals of any kind, remember they are not payment guarantees.** Keep eligibility, coding, and documentation airtight, because those are the conditions an authorization does not satisfy. - **Re-verify when policies change.** A test that needed no authorization last quarter may need one now. That last point is where the real operational burden lives. Knowing which process a given payer requires for a given test, and catching when that requirement changes, is exactly the kind of payer-rules logic that **Converus** tracks, so reimbursement teams aren't deciding which of three look-alike terms applies from memory. ## Sources - Cigna Healthcare, Precertifications and Prior Authorizations: https://www.cigna.com/health-care-providers/coverage-and-claims/precertification - Aetna, Precertification (Health Care Professionals): https://www.aetna.com/health-care-professionals/precertification.html - Blue Cross and Blue Shield of Illinois, Recommended Clinical Review (Predetermination): https://www.bcbsil.com/provider/claims/claims-eligibility/utilization-management/predetermination - Blue Cross and Blue Shield of Montana, Prior Authorization and Recommended Clinical Review: https://www.bcbsmt.com/provider/claims-and-eligibility/claims/priorauthorization-predetermination - Blue Cross and Blue Shield of Oklahoma, Predetermination is now Recommended Clinical Review: https://www.bcbsok.com/provider/education/education-reference/news-updates/2022-archive/12-22-22-predetermination-now-recommended-clinical-review - PracticeSuite, Claims Denied for No Prior Authorization: https://practicesuite.com/resources/claims-denied-for-no-prior-authorization/ - Integrity Billing Company, Prior Authorization Approved... So Why the Denial?: https://integritybillingco.com/blog/prior-authorization-approved-so-why-the-denial/ - Genetics in Medicine, Outcomes of prior authorization requests for genetic testing in outpatient pediatric genetics clinics: https://www.gimjournal.org/article/S1098-3600(21)01452-0/fulltext --- # Somatic vs. Germline Testing: Two Tests, Two Medicare Coverage Frameworks URL: https://converus.ai/knowledge-base/somatic-vs-germline-testing-coverage/ Updated: 2026-06-19 A tumor-only sequencing panel comes back on a 58-year-old woman with metastatic ovarian cancer. The lab ran it to find an actionable driver, somatic alterations the oncologist could target with therapy. Buried in the report is a *BRCA1* variant. Now there is a question the test was never designed to answer cleanly: is that variant something the tumor acquired, or is it inherited, sitting in every cell of her body and, by extension, possibly in her sister's and her daughter's? The honest answer from a tumor-only assay is often "we can't tell from this alone." And that single ambiguity is where two entirely separate Medicare coverage frameworks collide. > **Disclaimer**: This article is educational and is not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. Coverage policies change, Medicare Administrative Contractors apply local policies, and the only authoritative sources are the current NCD and applicable LCD language. Always verify against CMS's current policy and consult qualified clinical, billing, and compliance professionals before making coverage, treatment, or reimbursement decisions. Use this information at your own risk. ## Two tests that answer two different questions The clinical distinction is clean, even if the reimbursement consequences are not. **Somatic testing** looks for *acquired* mutations, the genetic changes that arose within a tumor as it developed. These variants are specific to the neoplasm and are not present in the patient's normal cells. The clinical question is forward-looking and therapeutic: what is driving this cancer, and what can we do about it? Somatic profiling is how oncologists find targetable alterations, fusions such as ALK, ROS1, NTRK, or RET, mutations such as BRAF or KRAS, amplifications such as HER2, and signals such as microsatellite instability, mismatch-repair deficiency, or tumor mutational burden, that point toward a specific therapy or a clinical trial. **Germline testing** looks for *inherited* mutations. Because a germline variant is present in the fertilized egg, it appears in every cell of the body, which is why it can be detected from blood or saliva rather than tumor tissue. The clinical question is different in kind: does this patient carry a hereditary predisposition that affects their lifetime risk, their surgical and surveillance choices, their eligibility for certain therapies, and the risk borne by their blood relatives? A germline *BRCA1* finding is not just about today's tumor; it is a fact about the family. The two are not competitors. A complete picture of a cancer patient often requires both, and the design of Medicare's coverage rule explicitly anticipates that clinicians may order somatic and germline testing together. The friction is not clinical. It is that Medicare reaches the two through different doors. ## The shared roof: NCD 90.2 Both somatic and germline next-generation sequencing for cancer live under the same national rule, **National Coverage Determination 90.2**, Medicare's framework for covering NGS as a diagnostic laboratory test in patients with cancer. It was finalized in March 2018 and amended effective January 27, 2020. The NCD is explicit that its criteria apply to NGS tests of **both somatic and germline mutations**, so it would be easy to assume one set of conditions governs everything. It does not work that way. NCD 90.2 is better understood as one roof over two rooms. The baseline conditions are shared, the test must be performed in a CLIA-certified laboratory, ordered by the treating physician, with results furnished to that physician to guide management, and the patient must not be receiving a repeat of the same NGS test for the same genetic content. But the *gating clinical criterion* differs depending on whether the test is somatic or germline, and that is the part that decides which medical-necessity narrative a claim has to tell. ## Two coverage pathways inside one rule **The somatic pathway** is tied to disease burden. Under NCD 90.2, somatic NGS is covered for a patient who has **recurrent, relapsed, refractory, or metastatic cancer, or advanced stage III or IV cancer**, and who has decided to seek further cancer treatment. There is a cleaner sub-path within this: when an NGS assay is **FDA-approved or cleared as a companion in vitro diagnostic** and is used for an indication matching the patient's cancer, NCD 90.2 provides a defined national coverage route. FDA companion-diagnostic standing is the most predictable way to Medicare coverage for a somatic assay precisely because it removes ambiguity about whether the test is reasonable and necessary for that cancer. Tests without that standing can still be covered, but coverage shifts to the Medicare Administrative Contractor's discretion, which is where the MolDX program and its Local Coverage Determinations do much of the real work. **The germline pathway** was added by the 2020 amendment and is built on hereditary-risk logic rather than disease stage. Effective for services on or after January 27, 2020, CMS determined that germline NGS is covered nationally when the patient has a **clinical indication for germline testing for hereditary breast or ovarian cancer** and a **risk factor** for inherited breast or ovarian cancer, and has not previously had the same germline NGS test for the same genetic content. Note what is *absent* from that pathway: there is no requirement for stage III/IV or metastatic disease. The germline question is about heredity, not tumor burden, so the criteria track family history, personal history, and clinical risk features rather than how advanced the cancer is. For germline tests beyond the FDA-approved national list, and for cancers other than breast and ovarian, contractors may again set local coverage when the patient has a clinical indication and risk factor for inherited cancer. The practical upshot: the documentation that proves "this patient has stage IV disease and is pursuing treatment" is not the documentation that proves "this patient has a personal and family history suggestive of a hereditary syndrome." Same NCD, different stories. ## Somatic vs. germline at the coverage level | | **Somatic testing** | **Germline testing** | |---|---|---| | **What it tests** | Acquired mutations in tumor tissue; not present in normal cells | Inherited mutations present in every cell; detectable from blood or saliva | | **Clinical question** | What is driving this tumor and how should it be treated? | Does the patient carry a hereditary cancer predisposition affecting them and their relatives? | | **Medicare framework** | NCD 90.2 somatic pathway: generally tied to recurrent/relapsed/refractory/metastatic or advanced stage III/IV cancer, or an FDA-approved companion diagnostic; non-CDx tests fall to MAC/MolDX discretion | NCD 90.2 germline pathway (2020 amendment): clinical indication and risk factor for hereditary breast or ovarian cancer; not stage-dependent; contractor discretion for other cancers | | **Typical medical-necessity narrative** | Advanced/metastatic disease status; intent to pursue therapy; targetable biomarker relevant to treatment selection | Personal/family history and clinical risk features suggestive of a hereditary syndrome; result informs risk management and relatives | | **Representative CPT family** | Solid-tumor genomic sequencing panels (for example, the 5–50 gene and 51-or-greater somatic panel codes) | Hereditary cancer syndrome panel codes (for example, the breast/ovarian-related hereditary panel codes) | Reference the CPT families above by concept; the exact code that applies depends on the assay, the genes, and current code definitions, which change. The point of the table is not the code numbers. It is that the column a test belongs in determines almost everything downstream, the eligible patient profile, the necessity language, and the framework a reviewer will measure the claim against. ## Where it gets genuinely hard: one sample, two frameworks Return to the opening case. Tumor-only sequencing is, by design, run on tumor tissue without a matched normal sample. That makes it efficient for finding somatic drivers, but it also means the assay detects *any* variant present in the tumor cells, including inherited ones, and generally **cannot distinguish somatic from germline on its own**. A *BRCA1* variant on a tumor-only report may be somatic, or it may be the tip of a hereditary syndrome. The literature is direct about this: tumor-only sequencing can mistakenly attribute germline variants to the tumor, and confirming a suspected germline finding usually requires a separate, dedicated germline test on a blood or saliva sample. That confirmatory test does not inherit the somatic test's coverage. It is evaluated under the germline pathway, with its own clinical-indication-and-risk-factor narrative. So a single sequencing event can implicate **both** rooms under NCD 90.2's roof: the original tumor panel under the somatic pathway, and the reflex germline confirmation under the germline pathway. Payers have noticed this sequence too; commercial utilization-management policies now specifically address hereditary (germline) testing performed *after* tumor (somatic) testing, with their own criteria for when the follow-on germline test is warranted. The blood draw or biopsy may be one physical thing. The coverage logic is two. This is also where claims quietly fail. A germline panel billed as though stage IV disease were the qualifying criterion misses the point of the germline pathway entirely, hereditary risk, not tumor burden, is what makes it reasonable and necessary. A tumor panel whose documentation leans on family history rather than advanced-disease status and treatment intent tells the wrong story for the somatic pathway. In both directions, the test might have been coverable under *its* framework, yet gets denied because the claim was matched to the wrong one. ## The strategic takeaway The clean lesson here is that "covered by Medicare" is never a single fact about a test. It is a fact about a *test plus an indication plus a framework*. Somatic and germline assays share a national rule and can share a patient and even a sample, but they are reached through different coverage pathways with different gating criteria and different medical-necessity narratives. Matching each claim to the correct pathway, and documenting to *that* pathway's criteria, is the difference between a covered test and a paid one. That per-test, per-indication coverage logic is precisely the layer that is easy to get wrong and easy to fall out of date on, because the NCD, the FDA companion-diagnostic list, and the MolDX LCDs all keep moving. Keeping that rule layer accurate, knowing which framework governs which test for which indication across payers, is exactly what Converus is built to track. The frameworks will keep evolving; what should not change is your ability to send each claim through the right door. ## Sources - [NCD - Next Generation Sequencing (NGS) (90.2)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372) — Centers for Medicare & Medicaid Services, Medicare Coverage Database (finalized March 2018; amended effective January 27, 2020). Establishes that criteria apply to both somatic and germline mutations, the advanced-cancer somatic criteria, the FDA companion-diagnostic pathway, and the germline hereditary breast/ovarian pathway. - [NCA - Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) Decision Memo](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=296) — CMS decision memo underlying the 2020 germline amendment. - [CMS finalizes coverage of Next Generation Sequencing tests, ensuring enhanced access for cancer patients](https://www.cms.gov/newsroom/press-releases/cms-finalizes-coverage-next-generation-sequencing-tests-ensuring-enhanced-access-cancer-patients) — CMS press release describing somatic actionable-mutation coverage and companion-diagnostic application to advanced cancer. - [CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients](https://www.genomeweb.com/reimbursement-news/cms-cover-fda-approved-cleared-ngs-germline-tests-breast-ovarian-cancer-patients) — GenomeWeb coverage of the January 2020 germline expansion and its clinical-indication-and-risk-factor criteria. - [LCD - MolDX: Next-Generation Sequencing for Solid Tumors (L38158)](https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38158) and [MolDX: Repeat Germline Testing (L38351)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38351) — MolDX Local Coverage Determinations distinguishing somatic (tumor) from germline (inherited) testing and contractor-level coverage. - [A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306191/) and [Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172914/) — peer-reviewed sources on tumor-only sequencing surfacing incidental germline variants and the inability to distinguish somatic from germline without a matched normal. - [Hereditary (Germline) Testing After Tumor (Somatic) Testing](https://www.evicore.com/sites/default/files/clinical-guidelines/2024-08/MOL.CU_.246.A_Hereditary%20(Germline)%20Testing%20After%20Tumor%20(Somatic)%20Testing_V2.0.2024_eff11.01.2024_pub12.31.2024.pdf) — eviCore utilization-management guideline addressing follow-on germline testing after somatic testing. - [Billing and Coding: Genetic Testing for Oncology (A59125)](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59125&ver=26) — CMS billing/coding article referencing somatic and hereditary (germline) panel CPT families. --- # State Biomarker-Testing Coverage Laws: A 2026 Reference for Labs and Clinics URL: https://converus.ai/knowledge-base/state-biomarker-testing-coverage-laws/ Updated: 2026-06-19 A lung-cancer patient in Phoenix and a lung-cancer patient in Tulsa can have the same diagnosis, the same recommended comprehensive genomic profiling, and the same commercial insurance carrier, and still get two different answers when the lab bills for the test. One reason is that biomarker-testing coverage in the United States is no longer governed by a single rule. It is governed by a fast-growing patchwork of state laws, layered on top of federal preemption that quietly exempts a large share of patients from those very laws. For a lab director or a revenue-cycle leader, that patchwork is not trivia. It decides which appeals will win, which patients you can reassure, and which "covered by law" claims will still be denied. This article is a working reference: what these laws require, which states have them, who they bind, and the one carve-out that trips up almost everyone. > **Disclaimer:** This article is educational and is not legal, billing, or coverage advice. State biomarker laws change frequently, vary in their exact language, and are interpreted by regulators and courts; statutory text and effective dates are the only authoritative sources. Nothing here guarantees coverage of any test for any patient or plan. Verify the current statute and regulations in your state and consult qualified legal and compliance counsel before acting. Use this information at your own risk. ## What a "biomarker-testing coverage law" actually does The wave of state laws traces largely to model legislation promoted by the American Cancer Society Cancer Action Network (ACS CAN) and allied groups. The core idea is consistent across states even though the wording differs: a state-regulated health plan must cover biomarker testing used for the diagnosis, treatment, appropriate management, or ongoing monitoring of a patient's disease, **when the test is supported by medical and scientific evidence**. That evidence standard is the heart of the statute. Most states define qualifying evidence by reference to a defined list of authorities. According to a peer-reviewed analysis published in *Health Affairs Scholar* (2024), every state law except Louisiana's points to the same family of criteria: FDA approval or clearance of the test, use of a test in connection with an FDA-approved drug that requires the testing for treatment decisions or monitoring, Medicare national and local coverage determinations, and nationally recognized clinical practice guidelines. In oncology, those guidelines typically mean NCCN and ASCO, which is how a non-FDA-reviewed assay can still meet the bar. Two boundaries matter as much as the mandate itself. First, these laws generally do **not** require coverage of screening biomarker tests; the same analysis found no state mandating screening coverage, and three states (California, Kentucky, and Nevada) explicitly carve screening out. Second, many of the laws also constrain how plans may use prior authorization, with some states limiting or prohibiting prior authorization for biomarker testing in advanced disease. California's law, for example, has been described as barring prior authorization for biomarker testing in enrollees with advanced or metastatic Stage III or IV cancer. The details vary by state, so the existence of a law does not automatically mean "no prior auth." ## Comprehensive vs. narrow: not all laws are equal It is tempting to treat "my state has a law" as a binary, but the laws differ enough that the distinction is operational. Researchers analyzing the statutes split them into **comprehensive** laws, which mandate coverage of biomarker testing across all state-regulated plans, and **narrower** laws, which reach fewer plan categories, address only prior authorization, or limit the populations or disease stages covered. As of mid-May 2025, that *Health Affairs Scholar* analysis counted **16 states with comprehensive laws and 5 with narrower laws**, plus roughly 13 states with legislation introduced but not yet enacted. The comprehensive group it identified included states such as Arizona, California, Illinois, Louisiana, and Rhode Island; the narrower group included states such as Arkansas, Colorado, and Florida (Louisiana appears in both characterizations in the literature, a reminder that these labels are analytic judgments, not statutory labels). The practical takeaway: read your own state's statute rather than assuming a neighbor's scope. ## The by-state snapshot (mid-2026) The table below reflects states that authoritative trackers identify as having **enacted** biomarker-testing coverage legislation. It is a snapshot, not a guarantee, and it changes nearly every legislative session. The "scope" column reflects the comprehensive-vs-narrow characterization from the 2024 peer-reviewed analysis where available; states added afterward are marked "enacted (verify scope)" because their classification was not part of that dataset. | State | Status (as of mid-2026) | Scope characterization | |---|---|---| | Arizona | Enacted | Comprehensive | | Arkansas | Enacted | Narrower | | California | Enacted | Comprehensive | | Colorado | Enacted | Narrower | | Connecticut | Enacted | Enacted (verify scope) | | Florida | Enacted | Narrower | | Georgia | Enacted | Enacted (verify scope) | | Illinois | Enacted | Comprehensive | | Indiana | Enacted | Enacted (verify scope) | | Iowa | Enacted | Enacted (verify scope) | | Kentucky | Enacted | Enacted (verify scope) | | Louisiana | Enacted | Comprehensive / narrower (see text) | | Maryland | Enacted | Enacted (verify scope) | | Minnesota | Enacted | Enacted (verify scope) | | Mississippi | Enacted ("Jill's Law," 2026) | Enacted (verify scope) | | Nebraska | Enacted | Enacted (verify scope) | | New Jersey | Enacted | Enacted (verify scope) | | New Mexico | Enacted | Enacted (verify scope) | | New York | Enacted | Enacted (verify scope) | | Oklahoma | Enacted | Enacted (verify scope) | | Pennsylvania | Enacted | Enacted (verify scope) | | Rhode Island | Enacted | Comprehensive | | Tennessee | Enacted | Enacted (verify scope) | | Texas | Enacted (effective Jan 1, 2026) | Enacted (verify scope) | Sources: ACS CAN biomarker-testing tracker (state list current through 2026); *Health Affairs Scholar* analysis (scope characterization, data as of mid-May 2025); Texas effective date per the enacting bill. The ACS CAN tracker also reports biomarker bills **introduced** in 2026 in states including Delaware, Hawaii, Maine, Massachusetts, New Hampshire, North Carolina, Ohio, Vermont, and Washington; introduction is not enactment, so those are excluded from the table above. Confirm any state's current status and effective date against its statute before relying on it. Counted together, the enacted list above is roughly **two dozen states (about 24) as of mid-2026**, consistent with AIS Health/MMIT's reporting that "more than 20 states" now mandate coverage. Treat the exact number as a moving target. ## The carve-out that matters most: ERISA and self-funded plans Here is the single most important operational fact in this entire area, and the one that most often surprises clinicians and patients: **state biomarker laws do not reach self-funded employer health plans.** State insurance mandates apply to insurance that the state regulates. That means **fully-insured commercial plans** sold in the state must comply, and the biomarker laws frequently extend to the **state's Medicaid program** as well (with state-specific exceptions; the *Health Affairs Scholar* analysis noted that Arkansas explicitly excludes Medicaid, and that Louisiana and Rhode Island statutes do not mention it). State employee plans typically comply where the statute says so. But **self-funded** (also called self-insured) employer plans are different animals. In a self-funded plan, the employer bears the claims risk and merely hires an insurer or third-party administrator to process claims. These plans are governed by the federal **Employee Retirement Income Security Act (ERISA)**, and ERISA broadly preempts state insurance mandates. A state cannot order a self-funded ERISA plan to cover biomarker testing the way it can order a fully-insured plan. This is not a loophole specific to biomarker laws; it is the long-standing structure of U.S. insurance regulation, and it applies to most state benefit mandates. The scale is what makes this decisive rather than academic. A majority of U.S. workers with employer-sponsored coverage are in self-funded plans, commonly cited in the low-to-mid 60% range of covered workers. So even in a state with a strong, comprehensive biomarker law, a large fraction of commercially insured patients may sit **outside** the mandate's reach. The law is real; its reach is narrower than the headline suggests. The trap is that you usually cannot tell the two apart from the insurance card. A patient with a major-carrier card in a mandate state may have a fully-insured plan that must comply, or a self-funded plan administered by that same carrier that does not. Determining plan type, often by checking eligibility data, ASO indicators, or asking the plan directly, is the difference between an appeal grounded in state law and one that has to stand on medical-necessity and guideline evidence alone. ## Why coverage still varies even when a law applies Suppose you have confirmed a fully-insured plan in a comprehensive-mandate state. You still are not guaranteed payment, and labs in mandate states continue to see denials. Several reasons recur: - **The evidence standard is a gate, not a rubber stamp.** The plan must cover the test *when supported by medical and scientific evidence* as the statute defines it. A test that does not map cleanly to FDA labeling, a Medicare coverage determination, or a recognized guideline can be denied as not meeting the standard, and that denial may be lawful. - **Documentation decides borderline cases.** Stage, diagnosis, intent (treatment selection vs. screening), and the clinical rationale have to be in the record. Mandates do not cover screening, so a test that looks like screening on the claim can be denied even when the underlying intent was treatment selection. - **Prior authorization persists where the law allows it.** Where a state did not bar prior authorization (or barred it only for specific stages), plans may still require it, and a missed authorization is still a denial. - **Implementation lags the statute.** Regulators issue bulletins clarifying that the biomarker law governs and that plans may not layer on extra criteria, which only happens because plans were, in fact, layering on extra criteria. The law on the books and the medical policy in production are not always in sync on day one. None of this makes the laws toothless. In the right plan, the statute is a powerful appeal argument: it lets you assert that the plan is *required* to cover an evidence-supported test and may not impose criteria the statute forecloses. But "covered by law" and "paid on first submission" are different claims, and conflating them is how revenue leaks. ## What this means operationally The honest summary is uncomfortable: to know whether a given biomarker test is covered, you need to know the patient's **state**, the patient's **plan type** (fully-insured, self-funded/ERISA, or Medicaid), the **specific statute's scope** in that state, the **evidence basis** for the test, and the **plan's current medical policy and prior-auth rules**. Each of those can change independently, and the state count itself rises most legislative sessions. That is a lot of jurisdiction-specific, plan-specific, constantly-moving logic to maintain by hand, especially for a lab that draws specimens from many states. A spreadsheet captured last quarter is already drifting out of date. This is precisely the kind of per-state, per-plan-type coverage logic that [Converus](https://converus.ai) is built to track so revenue-cycle and market-access teams can act on the current rule rather than last year's memory of it. Whatever tooling you use, the discipline is the same: treat biomarker coverage as a function of state *and* plan type, verify against the live statute and policy, and never assume a law you read about covers the patient in front of you. ## Sources - American Cancer Society Cancer Action Network (ACS CAN), "Access to Biomarker Testing" and state biomarker-testing tracker — list of enacted states and 2026 introduced bills (current through 2026). https://www.fightcancer.org/what-we-do/access-biomarker-testing - ACS CAN, "Mississippi House Passes 'Jill's Law' for Biomarker Testing Coverage" (2026). https://www.fightcancer.org/releases/mississippi-house-passes-jills-law-biomarker-testing-coverage - "The State of State Biomarker Testing Insurance Coverage Laws," *Health Affairs Scholar* / PMC (2024; data as of mid-May 2025) — comprehensive vs. narrow counts (16 comprehensive, 5 narrow), evidence criteria, screening exclusions, Medicaid treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC11590753/ - AIS Health / MMIT, "More Than 20 States Now Mandate Coverage of Biomarker Testing." https://aishealth.mmitnetwork.com/blogs/spotlight-on-market-access/more-than-20-states-now-mandate-coverage-of-biomarker-testing - Association of Community Cancer Centers (ACCC), "State Legislation Requiring Coverage of Biomarker Testing Gains Momentum." https://www.accc-cancer.org/view/state-legislation-requiring-coverage-of-biomarker-testing-gains-momentum - Discoveries in Health Policy, "Evolving Importance of State Biomarker Laws: Guidance from AZ, GA, LA, OK" (Feb 2026) — plan-type reach and FDA/Medicare incorporation. https://www.discoveriesinhealthpolicy.com/2026/02/evolving-importance-of-state-biomarker.html - DOTmed, "State biomarker legislation is accelerating — but operational complexity remains" — fully-insured vs. self-funded/ERISA distinction and self-funded share of covered workers. https://www.dotmed.com/news/story/66340 - Newfront, "ERISA Preemption of State Insurance Mandates." https://www.newfront.com/blog/erisa-preemption-of-state-insurance-mandates-2 - Texas HB 5178 / related 89th Legislature bill text — biomarker coverage, effective for plans issued or renewed on or after January 1, 2026. https://capitol.texas.gov/tlodocs/89R/billtext/html/HB05178H.htm *This is a point-in-time snapshot. The number of states, their scope, and effective dates change frequently. Verify current status against the relevant statute and your state insurance regulator before relying on any item above.* --- # Step Therapy Override Appeals: When and How to File URL: https://converus.ai/knowledge-base/step-therapy-override-appeals/ Updated: 2026-05-06 Your oncology patient needs atezolizumab. The payer's PA comes back: patient must first try and fail a different checkpoint inhibitor that's on their preferred formulary. The ordering physician says that isn't clinically appropriate. This is a step therapy override situation. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## What Step Therapy Actually Is Step therapy, sometimes called "fail first", is a payer cost management tool that requires patients to try one or more preferred (usually less expensive) treatments before the payer will authorize the requested drug or therapy. It's common in specialty oncology, biologics, and specialty genetics (pre-implantation genetic testing in some managed Medicaid plans). The logic is straightforward from the payer's perspective: why pay for a $15,000/month drug if the patient might respond to a $3,000/month drug first? The clinical problem is that step therapy protocols are designed around populations, not individual patients. An individual patient may have a biomarker profile, comorbidity, or prior treatment history that makes the preferred-step drug clinically inappropriate or contraindicated. Step therapy requirements don't eliminate access, they create a procedural barrier that you can override with the right documentation and the right legal framing. ## When You Can File an Override Override eligibility depends on the plan type and the state you're operating in. Know this before you spend time building an override request. **Fully insured commercial plans in states with step therapy laws**: A growing number of states have enacted step therapy override statutes. Texas SB 1742 (effective 2021) is among the most specific, it requires commercial plans to grant an override when certain clinical criteria are met, with defined timelines for payer response. Louisiana and other states have similar statutes. If your patient's plan is fully insured (not self-insured) and the state has a law, you have statutory override rights with teeth. **Self-insured ERISA plans**: Here's the hard part. Self-insured employer plans are governed by ERISA (29 USC §1133) and largely preempt state step therapy laws. Your override argument in an ERISA plan relies on the plan's own internal documents, the Summary Plan Description and the coverage criteria, rather than state law. ERISA appeals are slower and harder to win, but you still have the internal and external appeal pathway. **Medicare Advantage**: MA plans are subject to CMS oversight and cannot have step therapy protocols that conflict with CMS's clinical standards. For oncology drugs in particular, CMS has guidance that MA plans should not require step therapy in clinical situations where the requested drug has a distinct indication or biomarker indication that the step drug does not. Know this and use it. **Medicare Part D**: Part D plans must have a formulary exception process. Under 42 CFR §423.578, a prescriber can request a formulary exception when the requested drug is medically necessary and the formulary alternative is contraindicated or clinically inappropriate for the patient. ## The Clinical Grounds for Override Most step therapy override statutes and plan documents recognize these override criteria: 1. **Contraindication**: The required step drug is clinically contraindicated for this patient. Document the specific contraindication, not "patient can't tolerate it" but the specific comorbidity, drug-drug interaction, or allergy that makes the step drug inappropriate. 2. **Clinical failure**: The patient already tried and failed the required step drug in the current or a previous clinical episode. Past history counts. Document the prior use, the dates, and the clinical outcome (progression, toxicity, inadequate response). 3. **Disease progression risk**: Requiring the patient to try the step drug first would cause irreversible harm or worsen outcomes. This applies in oncology when time matters, requiring a patient with rapidly progressive disease to spend weeks trialing an inappropriate therapy is a patient safety argument, not just a clinical preference. 4. **Biomarker-directed therapy**: The requested drug is indicated based on a specific biomarker that the step drug doesn't address. If the patient's tumor has a specific mutation that the requested drug targets and the step drug doesn't, the drugs aren't clinically equivalent. NCCN guidelines support this argument for biomarker-driven therapy selection. ## Building the Override Request The override request is a clinical letter, not an administrative complaint. The ordering physician signs it; your team prepares the supporting package. The letter should: state which override criterion applies and why, cite the specific clinical facts that establish it, reference the applicable payer policy language or state statute, and ask for a response within the payer's required timeframe (Texas SB 1742, for example, requires response within 3 business days for urgent situations and 10 business days for standard requests). Attach: the treating physician's full clinical notes documenting the patient's history, any prior treatment documentation (dates, drugs, outcomes), pathology and biomarker results if the argument is biomarker-directed, and the relevant NCCN guideline section showing the requested drug's indication. If you're in Texas or another state with a step therapy law, cite the statute by number in the letter. Payers respond differently to a letter that says "pursuant to Texas SB 1742, we are requesting a step therapy protocol exception" than one that just argues clinical appropriateness. The statutory citation signals you know your rights. ## If the Override Is Denied Step therapy override denials follow the same appeal pathway as any other medical necessity denial. Internal appeal, then external review for fully insured plans. Under ACA §2719 and applicable state laws, you have the right to external review by an independent organization for non-grandfathered fully insured plans. External reviewers are independent of the payer and decide based on clinical standards and coverage documents. For oncology step therapy, where NCCN guidelines and biomarker evidence are well-documented, external review can be highly effective. For ERISA plans, external review depends on the plan document. Some ERISA plans voluntarily participate in external review; others don't. The plan's SPD governs. Document everything: dates, contacts, reference numbers, clinical arguments made at each step. If you eventually escalate to a state insurance department complaint (for fully insured plans), that record is your evidence. ## Sources - Texas SB 1742 (step therapy override requirements, commercial fully insured plans) - 42 CFR §423.578 (Part D formulary exceptions process) - 29 USC §1133 (ERISA full and fair review) - ACA §2719 (independent external review, non-grandfathered fully insured plans) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans) - NCCN Clinical Practice Guidelines (NCCN.org), biomarker-directed therapy indications --- # How to Track Payer Policy Changes Without a Full-Time Analyst URL: https://converus.ai/knowledge-base/track-payer-policy-changes-without-an-analyst/ Updated: 2026-05-06 Aetna quietly updated their molecular diagnostic policy in the fourth quarter and your lab spent three months losing claims you should have won. Nobody notified you. Nobody is required to. This is the problem. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## Why Policy Changes Slip Through Payers are required to notify providers of significant benefit changes before they take effect for fully insured commercial plans, but "significant" is loosely defined and the notification often arrives as a dense policy update buried in a monthly bulletin that nobody reads. For medical policies, as opposed to benefits, there's no consistent notification requirement. Payers can revise coverage criteria, add exclusions, or reclassify tests from covered to experimental/investigational with only a change to the date on the policy document. If you're not checking, you won't know until your claims start coming back differently. Medicare is more transparent. CMS publishes proposed LCDs for comment before they finalize, and MAC contractor websites post policy updates. The problem is volume, Palmetto GBA, Noridian, CGS, and others each maintain dozens of LCDs relevant to molecular testing, and tracking them all manually is a real time commitment. ## Build a Monthly Policy Audit for Your Top 10 Payers You don't need to track every payer at the same frequency. Start with your top 10 payers by volume, ranked by paid claims, not by submitted claims. A payer that generates a lot of denials may be less important to monitor than one with high paid volume that you can't afford to lose. For each payer in your top 10, assign someone on your team to: 1. Pull the current version of each applicable medical policy once a month 2. Compare the "effective date" or "reviewed date" on the policy document to last month's version 3. If the date changed, do a line-by-line comparison of the coverage criteria section 4. Document what changed and whether it affects any active test types you bill This takes about 30 minutes per payer per month if it's systematized. Most commercial payers (UnitedHealthcare, Cigna, Aetna, BCBS affiliates, Humana, Anthem) maintain searchable policy libraries on their provider portals. Bookmark the specific policy pages, don't hunt for them each time. ## Subscribe to Payer Update Emails Most major payers offer email notification for policy and bulletin updates. Go to the provider resources section of each payer's portal and find the subscription option. These emails aren't detailed and they don't tell you what specifically changed, but they tell you *when* to go look. UHC sends policy change notifications to registered provider portal users. Cigna publishes a monthly "Medical Coverage Policy Update Bulletin." Aetna distributes policy revision summaries via their NaviMedix and provider portal notification systems. BCBS plans vary by affiliate, some are excellent about notifications, others aren't. For eviCore, sign up through their provider portal for clinical guideline update notifications. They update guidelines regularly, and since eviCore manages reviews for multiple payers, a guideline change there can affect claims across several of your payer contracts simultaneously. ## Watch CMS for Medicare and Medicare Advantage CMS tracks proposed LCDs through a public comment process published on the CMS website and on MAC contractor websites. If a Palmetto GBA LCD is being proposed or revised for molecular testing, it goes through a comment period before finalization. Subscribe to Palmetto GBA's provider email list and check their MolDX program page regularly. NCD changes go through formal rulemaking. The CMS NCD database is searchable at cms.gov. Set a calendar reminder to check it quarterly, NCD changes move slowly but their impact is significant when they happen. Medicare Advantage plans don't have to follow fee-for-service LCDs, but they often do. When CMS releases a new NCD or a MAC finalizes an LCD for molecular testing, review whether your MA plan contracts reference that LCD, many contracts incorporate it by reference. ## Detect Policy Changes Through Your Denial Data Your denial logs are a leading indicator. If your approval rate on a specific test drops by 10 points or more in a single quarter with a specific payer, something changed. It's either a policy change, a personnel change at the payer's review department, or a documentation change you made internally. Pull the denial reasons for that test/payer combination. If you're seeing a new denial reason code, or the same old CO-50 but now with different policy citations in the denial letters, that's a policy change signal. Pull the current policy and compare it to the version you were working from. This retrospective detection isn't as good as prospective monitoring, but it gives you a real-world signal that's hard to miss. ## Keep a Simple Policy Version Log You don't need software for this. A shared spreadsheet with columns for: payer name, policy name, policy number, current effective date, date last reviewed by your team, and any notes on recent changes will do the job. The value of the log isn't the data itself, it's the discipline of checking it monthly. When a new biller joins the team, the log tells them which policy to pull before submitting a PA for a given test. When you get a denial, the log tells you when you last verified the policy criteria. Some practices scan and save the actual policy PDFs by effective date. That's useful for appeals, you can show that you submitted according to the policy in effect at the time of service, even if the policy has since changed. ## Sources - CMS NCD Database, cms.gov (National Coverage Determinations) - Palmetto GBA / MolDX Program, policy updates and LCD development process - CMS-0057-F (2024 Interoperability and Prior Authorization Final Rule, transparency requirements) - 42 CFR §405.901 (Medicare administrative requirements for coverage policy) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant plans, including notice requirements) --- # UnitedHealthcare Prior Authorization Requirements: A 2026 Guide for Specialty Practices URL: https://converus.ai/knowledge-base/uhc-prior-authorization-requirements-2026/ Updated: 2026-05-06 UnitedHealthcare denies more genetic testing claims than any other major commercial payer. That's not opinion, it's the pattern you'll see if you're running a molecular lab and pulling your denial reports. The good news is that their requirements are published, their portals are functional, and their policies are consistent enough to work with once you understand them. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## UHC's Policy Structure Is Layered UnitedHealthcare uses three tiers of policy documents, and your first job is knowing which one governs the service you're requesting. **Medical Policies** are UHC's foundational coverage documents. For genetic testing, look for policies under their Genetic Testing section, there are separate policies for hereditary cancer panels, somatic tumor profiling, pharmacogenomics, and inherited cardiac conditions. These are publicly available at uhcprovider.com. They change on a rolling basis, typically with 90 days' notice, so a policy you reviewed 6 months ago may not be current. **Coverage Determination Guidelines (CDGs)** are a second layer. CDGs often apply when a medical policy doesn't specifically address a test or when the plan is a self-insured employer plan with customized benefits. If you're getting a denial and the policy language doesn't seem to match, check whether a CDG is in play. **Prior Authorization Lists** tell you whether a specific CPT or HCPCS code requires PA at all. UHC publishes these by plan type (commercial, Medicare Advantage, Medicaid). Don't assume that because a test requires PA for one employer group it requires PA for all, UHC's self-insured employer clients configure their own PA lists. Check Availity or the UHC Provider Portal before submitting. ## The Right Portal Matters For commercial UHC plans, PA requests go through Availity (availity.com) or through the UHC Provider Portal directly. Don't fax unless you've confirmed the plan requires it, fax submissions go into a queue that delays processing and makes follow-up harder. For UHC Medicare Advantage plans, PA requests for certain high-cost genetic tests may route through eviCore. UHC has outsourced clinical review for some oncology testing categories to eviCore under their specialty benefit management arrangements. If you're requesting PA for an NGS panel under a UHC MA plan and you get routed to eviCore, don't fight it, log in to eviCore's portal (evicore.com) and follow their clinical pathway, which we cover in a separate article. The UHC Provider Portal tracks PA status in real time. Use the reference number from your initial submission to follow up. If a request has been pending more than 3 business days without status update, call the UHC PA line, not your standard provider services line. The numbers differ, and provider services reps can't move PA requests. ## What UHC's Genetic Testing Policies Actually Require UHC's hereditary cancer panel policy covers multi-gene hereditary cancer panels (think BRCA1/2, Lynch syndrome, and expanded panels) when the patient meets defined personal or family history criteria. The policy lists specific risk criteria, a first-degree relative with a BRCA-positive result, prior cancer diagnosis at defined ages, Ashkenazi Jewish ancestry with qualifying family history. You need to document which criterion applies. For somatic tumor profiling (comprehensive genomic profiling, NGS), UHC generally requires: confirmed solid tumor diagnosis, ICD-10 code for a specific cancer type, documentation of metastatic or locally advanced disease, and that the test is being ordered to guide treatment selection. Don't submit without specifying the cancer type in the diagnosis code, a generic "malignant neoplasm" code will get flagged. Pharmacogenomics is a different story. UHC's coverage for PGx testing is narrow and highly code-specific. Many PGx CPT codes are excluded or covered only for specific drug-gene pairs with a limited list of indications. Before ordering, verify the specific CPT code against UHC's published coverage list. ## UHC's Timelines and Your Appeal Rights Standard PA decisions: UHC is required to respond within 15 calendar days for non-urgent requests, 3 business days for urgent/expedited, and 24 hours for life-threatening situations. These timelines apply to commercial and Medicare Advantage plans, though the regulatory basis differs. If you get a medical necessity denial, you have the right to request a peer-to-peer review. Call the UHC PA line and ask specifically for a peer-to-peer; don't accept a callback from a nurse reviewer as a substitute. You want the ordering physician speaking with a UHC medical director who has authority to reverse the decision. First-level appeals must be submitted within 180 days of the denial for most commercial plans. For Medicare Advantage, the redetermination window is typically 60 days. Missing these deadlines closes your appeal pathway, so calendar them immediately when a denial lands. ## What Your Submission Needs to Include - Member ID and plan name (confirm the plan type, commercial, MA, Medicaid) - Ordering provider NPI and tax ID - CPT or HCPCS code for the specific test or drug - ICD-10 diagnosis codes, primary diagnosis first, then supporting codes - Clinical notes that document the specific policy criteria the patient meets - For hereditary cancer panels: family history documentation in the chart, not just referenced - For somatic profiling: pathology report confirming tumor type and stage UHC's denials for genetic testing are frequently overturned when the right documentation was simply not included in the initial submission. Check their published policy checklist before submitting, not after you get the denial. ## Sources - UHC Medical Policies, uhcprovider.com (current versions; verify before each submission) - CMS-0057-F (2024 Interoperability and Prior Authorization Final Rule, PA response timelines for MA plans) - 42 CFR §422.572–422.578 (Medicare Advantage coverage determination and appeals) - 45 CFR §147.136 (internal claims and appeals, ACA-compliant commercial plans) - CMS NCD 90.2 (next-generation sequencing in cancer, applicable to UHC MA plans) - NCCN Clinical Practice Guidelines (NCCN.org), referenced in UHC oncology policies --- # What Claim Denials Actually Cost a Molecular Lab URL: https://converus.ai/knowledge-base/what-claim-denials-cost-a-molecular-lab/ Updated: 2026-06-19 A denied claim is rarely a zero. It is the cost of running the test, plus the staff hours spent figuring out why it bounced, plus the appeal that may or may not happen, plus the write-off if it does not. For a molecular or genetic lab, where a single comprehensive panel can carry a four-figure charge, denials are not a back-office annoyance. They are a direct hit to margin, and the data says the hit is getting bigger. > **Disclaimer**: This is educational, not billing, legal, financial, or medical advice. Payer policies, coverage criteria, and reimbursement rates change frequently, and your situation may differ from the examples here. Always verify current requirements against the payer's most recent published policy and consult qualified billing, compliance, or financial professionals. Use this information at your own risk. ## The size of the problem, in numbers you can trust Start with the most rigorous evidence available. A 2025 cohort study in *JAMA Network Open*, run by Georgetown University researchers and funded by the National Cancer Institute, looked at 29,919 cancer-related next-generation sequencing (NGS) claims across 24,443 Medicare beneficiaries. It found that **23.3% of those claims were denied** between 2016 and 2021. That is the headline, but the trend underneath it is the part worth sitting with. The denial rate was **16.8% before** Medicare's National Coverage Determination for NGS (NCD 90.2) took effect, **20.3% after** it was implemented in 2018, and **27.4% after** it was amended in 2020. Coverage expanded across that window. Denials climbed anyway. More on why that happens below, because it is the most important thing in this article. Outside of Medicare, the picture is at least as difficult. XiFin's 2024 Payor Denial Impact Report, drawn from more than 20 million laboratory claims, reports that roughly **35.3% of billed molecular CPT codes are denied** (this is industry data rather than peer-reviewed research, but it is directionally consistent with the Medicare findings). Now attach a dollar figure. In the *JAMA Network Open* study, the **median charge on a denied NGS claim was $3,800**, which the authors frame as the upper limit of provider or patient liability for each denial. Multiply that exposure by a denial rate in the twenties or thirties, across your annual volume, and the denial line stops looking like a rounding error and starts looking like a strategic problem. ## Denials are a margin problem wearing a billing costume It is tempting to treat denials as something the billing team handles. The economics say otherwise. Every denied claim consumes the same reagents, instrument time, and labor as a paid one. The difference is that a denied claim then *adds* cost: someone has to read the remittance, identify the reason code, decide whether to rework or appeal, assemble documentation, and resubmit. That work is incurred whether or not the dollars are ever recovered. A high denial rate is therefore a double charge against margin, the cost of the unreimbursed test plus the cost of chasing it. And here is the quietly expensive part. A 2025 *Health Affairs* study from UCSF researchers found that **46% of appealed genetic-testing denials were overturned** through independent medical review between 2019 and 2023. Yet the same study found that **fewer than 1% of denials are appealed** through that process. Read those two figures together and the implication is uncomfortable: nearly half of the genetic-testing denials that get challenged are reversed, and almost no one challenges them. The reversible revenue is sitting there. Most labs simply do not have the capacity to go get it, so they triage, pursue the cleanest cases, and write off the rest. That capacity ceiling is the real cost. It is not just the claims you lose; it is the claims you could win but never reach. ## Where you sit changes how much you bleed The denial burden is not distributed evenly, and the *JAMA Network Open* study is unusually specific about who carries the most of it. Claims for NGS testing were **more than twice as likely to be denied when performed by an independent laboratory (odds ratio 2.76)** or another non-hospital site (odds ratio 2.55) than when performed by a hospital. For independent labs specifically, the NGS denial rate reached **37.3%** in the most recent period the study examined. Panel size compounds it. The study found that claims for **50 or more genes** were more likely to be denied than smaller panels for solid tumors. So the lab profile most exposed to denials is precisely the one defining modern oncology diagnostics: an independent molecular lab running large, comprehensive panels. If that describes you, the denial rate is not a billing statistic. It is a structural feature of your business model that you have to actively manage. ## The driver almost everyone misreads Return to the trend that should bother you most: as Medicare *broadened* NGS coverage in 2018 and again in 2020, the denial rate *rose*, from 16.8% to 27.4%. If coverage expanded, why did denials go up? Because coverage and payability are not the same thing. A test can be covered in principle and still be denied in practice if the claim does not satisfy every specific condition the policy attaches to that coverage. Each expansion of NCD 90.2 came with more criteria, the right cancer stage, the right prior-testing history, the right ordering context, the right documentation. Every additional requirement is another edge a claim can fall off. Broader coverage written as more detailed rules produces more denials, not fewer, unless the lab keeps perfect pace with the rules. This is the throughline connecting every denial statistic in this article. The dominant cause of molecular denials is not payers refusing to cover good tests. It is the widening gap between what current policy requires and what the claim actually reflects. And that gap is fed by constant change. Consider just the moving pieces from the last two years: - The MolDX program made the DEX Z-Code a hard gate. Since **May 1, 2025**, MolDX claims submitted without the Z-Code in the correct claim loop deny as unprocessable (per Noridian guidance), with no clinical review at all. - UnitedHealthcare extended a DEX Z-Code requirement to its commercial molecular claims, announced for April 1, 2024 and then **delayed to June 1, 2024**, with claims denied when the Z-Code is missing, invalid, or mismatched. - The federal prior-authorization rule (CMS-0057-F) is changing payer decision timelines, requiring **72-hour** turnarounds for expedited requests and **7 calendar days** for standard ones as of January 1, 2026, with new API requirements arriving in 2027. None of those is exotic. They are the normal cadence of payer policy change, and each one quietly rewrote the conditions a clean claim has to meet. A lab that did not catch each change inherited a new denial pattern it did not choose. ## The leadership math (without the fake numbers) It would be easy to drop a tidy ROI figure here. The honest version is more useful: the economics of denials hinge on two ratios that are within your control. The first is prevention versus rework. A denial caught before submission, a missing Z-Code added, a diagnosis code positioned correctly, a test name populated on an unlisted code, costs a fraction of the same denial caught after the fact, which carries remittance review, appeal assembly, and resubmission on top. The cheapest denial is the one that never happens, and most molecular denials are operational, which means they are preventable at the rule-and-scrub stage rather than the appeal stage. The second is the 46%-versus-1% gap. Every denial you do not appeal is a coin-flip-or-better you declined to take. You will never appeal everything, and you should not try, but the distance between a 1% appeal rate and a defensible one is pure recovered margin. Both ratios improve from the same root capability: knowing, precisely and currently, what each payer requires for each test and indication, and applying that knowledge before the claim goes out the door. That is not a billing function. It is a policy-operations function, and most labs do not have one. ## The strategic takeaway The molecular denial problem is often described as a coding problem or a payer problem. It is more accurate to call it a *change-management* problem. Coverage rules move constantly, across Medicare NCDs and LCDs, MolDX requirements, and dozens of commercial medical policies, and the denial rate is essentially a measure of how far your claims have drifted from the current rules. That reframing matters because it points to a durable fix. You cannot stop payers from changing their policies, and you cannot hire your way to perfect coverage of every change with spreadsheets and tribal knowledge. What you can do is treat payer policy as living data: tracked at the source, translated into the specific rules that govern each test and indication, and kept current automatically so that the claim reflects today's requirements instead of last year's. Keeping that rule layer accurate, per payer, per test, per indication, is exactly what turns a 23% denial rate into a recoverable one, and it is the problem Converus was built to solve. ## Sources - Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare — *JAMA Network Open*, April 18, 2025 (doi:10.1001/jamanetworkopen.2025.5785; PubMed 40249617) - Use of Independent Medical Review: Almost One-Half of Coverage Denials Overturned — *Health Affairs*, December 2025 (doi:10.1377/hlthaff.2025.00716) - 2024 Payor Denial Impact Report — XiFin, Inc. (analysis of 20M+ laboratory claims) - Proper Submission of DEX Z-Code for Molecular Diagnostic Services (MolDX) Claims — Noridian Healthcare Solutions (effective May 1, 2025) - Make Sure Molecular Tests Have a Z-Code Assigned — UnitedHealthcare (commercial Z-Code requirement, 2024) - CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) — Centers for Medicare & Medicaid Services --- # What Is Prior Authorization? A Practical Guide for Genetic Labs and Oncology RCM Teams URL: https://converus.ai/knowledge-base/what-is-prior-authorization/ Updated: 2026-05-06 ## The Short Answer Prior authorization (PA), sometimes called pre-authorization, pre-certification, or pre-approval, is a process by which a health insurance payer requires a provider to obtain approval *before* a service, drug, or diagnostic test is delivered. Without that approval, the payer can legitimately deny the claim, leaving the patient or the lab holding the bill. For genetic laboratories and oncology revenue cycle teams, PA is not a peripheral concern. It sits at the center of your reimbursement model. Molecular diagnostics, hereditary cancer panels, tumor biomarker assays, and specialty oncology drugs are among the most heavily managed categories in every payer's utilization management program. ## Why Payers Use Prior Authorization Payers implement PA programs for two stated reasons: clinical appropriateness and cost management. The clinical argument is that some services are only appropriate in specific clinical contexts, a BRCA1/2 test ordered without documented family history or clinical criteria, for example, may not meet coverage requirements. The cost argument is straightforward: high-cost genetic tests and oncology therapies represent significant per-unit spend, and payers use PA as a gate. In practice, utilization management programs vary enormously. Commercial payers may require PA for nearly every molecular test over a certain CPT code range. Medicare typically follows Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs), with specific coverage requirements and documentation standards. Medicaid requirements differ by state. Understanding *why* a payer uses PA for a given service helps you build better submissions from the start. ## The Policy Landscape You're Navigating Before you can submit a successful prior authorization, you need to understand which policies govern coverage for the test or treatment in question. **Local Coverage Determinations (LCDs)** are coverage rules issued by Medicare Administrative Contractors (MACs), the regional contractors that process Medicare claims. An LCD specifies which diagnoses and clinical circumstances support coverage for a given service, and which do not. For molecular diagnostics, LCDs issued by Palmetto GBA (which administers the MolDX program) are particularly important. **National Coverage Determinations (NCDs)** are coverage rules set at the federal level by the Centers for Medicare & Medicaid Services (CMS). NCDs supersede LCDs in their coverage scope. NCDs relevant to oncology include policies on next-generation sequencing (NGS) panels and certain companion diagnostics. **MolDX** is Palmetto GBA's molecular diagnostic testing program. MolDX establishes technical assessment and coverage requirements for molecular tests billed to Medicare. Labs billing tests managed under MolDX must complete a technical assessment and obtain a DEX Z-code for billing. Many commercial payers reference MolDX criteria in their own policies. **NCCN Clinical Practice Guidelines** are not payer policies, but they carry significant weight in the PA process. The National Comprehensive Cancer Network publishes evidence-based guidelines for oncology, and payers frequently cite NCCN category designations (Category 1, 2A, 2B, 3) when determining whether a drug or test is medically necessary. Category 1 designations (based on high-level evidence with uniform NCCN consensus) are the most likely to be covered without dispute. **Medical policies** are insurer-specific documents that define coverage criteria for services beyond what LCDs and NCDs specify. Every major commercial payer publishes medical policies, and these can differ substantially from one payer to the next, even for the same test or drug. ## The Prior Authorization Workflow A standard PA workflow for genetic testing or oncology involves the following steps: 1. **Service identification**: The ordering clinician determines which test or treatment is needed and whether it requires PA under the patient's plan. 2. **Policy lookup**: The lab or provider's RCM team identifies the applicable coverage policy, LCD, NCD, medical policy, or formulary, and confirms the specific clinical criteria required. 3. **Documentation assembly**: The team gathers supporting clinical documentation: diagnosis codes (ICD-10), procedure codes (CPT/HCPCS), treating physician notes, prior treatment history (relevant to step therapy requirements), and any supporting clinical literature or guideline references. 4. **Submission**: The PA request is submitted through the payer's portal, fax, or EDI channel, depending on what that payer supports. 5. **Payer review**: The payer's medical director or designated reviewer evaluates the request against their policy criteria. Turnaround times vary; federally mandated timeframes exist for certain plan types and urgency levels. 6. **Decision**: The payer issues an approval (with or without conditions), a denial, or a request for additional information (a "pend" or "hold"). 7. **Appeals (if denied)**: If the initial request is denied, the provider has the right to appeal through defined escalation pathways. ## Common Terms to Know - **Medical necessity**: The clinical justification that a service is appropriate, reasonable, and necessary for the diagnosis or treatment of a covered condition. Most PA denials cite failure to establish medical necessity. - **CPT codes**: Current Procedural Terminology codes that identify the specific procedure or test being requested. - **ICD-10 codes**: International Classification of Diseases codes that document the patient's diagnosis and clinical context. - **HCPCS codes**: Healthcare Common Procedure Coding System codes used primarily for Medicare and Medicaid billing, including J-codes for injectable drugs. - **Formulary**: A payer's list of covered drugs; specialty oncology drugs are often tiered or require PA regardless of tier. - **Peer-to-peer review**: A direct conversation between the ordering physician and the payer's medical director, often the most effective tool when an initial request is denied. ## What Makes Genetic Testing and Oncology Different Standard PA workflows are built for high-volume, relatively simple services. Genetic testing and oncology are neither. Molecular diagnostic tests involve complex coding requirements (including DEX Z-codes for MolDX), evolving coverage policies that frequently lag behind the science, and clinical context that is difficult to capture in a standard form. Oncology drugs often require demonstration of biomarker expression (PD-L1, HER2, EGFR, MSI/MMR status), specific line-of-therapy sequencing, or companion diagnostic results, all of which must be documented precisely. A submission that would be straightforward for a standard service becomes a clinical narrative exercise for a next-generation sequencing panel or a checkpoint inhibitor. That is the gap Converus is built to close. --- # Why Molecular and Genetic Test Claims Get Denied (and How to Prevent It) URL: https://converus.ai/knowledge-base/why-molecular-and-genetic-claims-get-denied/ Updated: 2026-06-19 A molecular or genetic test can be ordered by the right physician, for the right patient, performed flawlessly in a CLIA-certified lab, and still come back denied. For diagnostics and genetic labs, denials are not an unlucky edge case. They are a structural feature of how molecular testing gets reimbursed, the rate is high, and it is rising. The encouraging part, and the reason this article exists, is that most of those denials are preventable, because most of them were never really about the medicine. > **Disclaimer**: This is educational, not billing, legal, or medical advice. Payer policies and coverage criteria change frequently and your situation may differ from the examples here. Always verify current requirements with the payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk. ## The denial numbers are worse than most teams assume Start with the most rigorous evidence available. A 2025 cohort study in *JAMA Network Open*, conducted by Georgetown University researchers and funded by the National Cancer Institute, analyzed 29,919 cancer-related next-generation sequencing (NGS) claims among 24,443 unique Medicare beneficiaries. It found that **23.3% of those claims were denied between 2016 and 2021**, and the denial rate climbed across the study period. The trend underneath that number matters more than the headline. The claim denial rate was **16.8% before** the National Coverage Determination for NGS (NCD 90.2), **20.3% after** the NCD took effect in 2018, and **27.4% after** the NCD was amended in 2020 to include certain hereditary breast and ovarian cancer mutations. Read that sequence again: coverage *expanded* twice, and denials went *up* both times. That is the central paradox of molecular reimbursement, and we will come back to why it happens, because it explains almost everything about how to prevent denials. Industry data points the same direction. XiFin's 2024 Payor Denial Impact Report, based on more than 20 million laboratory claims, reports that roughly **35.3% of billed molecular CPT codes are denied** (industry data rather than peer-reviewed research, but directionally consistent with the Medicare-specific findings above). And the exposure per denial is not trivial: in the *JAMA Network Open* study, the **median charge on a denied NGS claim was $3,800**, which the authors describe as the upper limit of provider or patient liability for each denied claim. Put a denial rate in the twenties or thirties against a four-figure median charge across your annual volume, and denials stop being a billing nuisance and start being a line on the income statement. ## Where you sit changes your odds Denials are not distributed evenly, and the *JAMA Network Open* study is unusually specific about who absorbs the most. Claims for NGS testing were **more than twice as likely to be denied when performed by an independent laboratory (odds ratio 2.76)** or another non-hospital site (odds ratio 2.55) than when performed by a hospital. For independent labs specifically, the NGS denial rate reached **37.3%** in the most recent period the study examined. Panel size compounds it. The study found that claims for **50 or more genes** were more likely to be denied than smaller panels for solid tumors. So the profile most exposed to denials, an independent molecular lab running large, comprehensive panels, is precisely the profile that defines modern oncology diagnostics. If that describes your lab, upstream prevention is not a back-office tidiness project. It is a core financial control. ## Most denials are operational, not medical necessity Here is the reframe that changes how a team responds to a denial. The instinct, after a rejection lands, is to assume the payer weighed the clinical case and disagreed. Usually they did no such thing. The claim failed a structural check *before* any reviewer ever evaluated medical necessity, and the denial code is a symptom of a clerical or coding gap, not a clinical verdict. The most common operational causes are worth understanding individually, because each has a different fix: - **A missing or invalid MolDX Z-code.** The single most preventable hard denial, and now an outright gate (more below). A claim can be perfect in every other respect and still be rejected on this alone. - **Diagnosis-code positioning.** The ICD-10 code that actually supports coverage is on the claim, but it is buried below a non-covered indication, or it is not linked to the right line item. The information is present; the structure is wrong, and the payer's system reads "not covered." - **A missing test name or descriptor on unlisted codes.** Many molecular tests bill under unlisted codes such as CPT 81479 (and 81599, 84999). Those codes describe a category, not a specific assay, so the payer needs the test name spelled out to adjudicate. Leave it off and there is nothing for the payer to approve. - **Documentation mismatch.** The encounter note, the order, and the claim disagree about the test performed, the indication, or the date of service. Each document is fine in isolation; together they tell three slightly different stories, and the payer resolves the conflict by denying. - **Prior authorization not obtained** where the payer required it, often because the requirement changed and no one caught it. - **Experimental or investigational classification**, where the payer's medical policy has not caught up to the test's evidence base, or the claim did not cite the policy's own covered indication. Every item on that list is correctable *before* the claim goes out. That is the whole argument of this article: the denial rate is high, but a large share of it is addressable at the rule-and-scrub stage, where a fix costs minutes, rather than at the appeal stage, where it costs weeks. ## The MolDX Z-code is now a hard gate The Z-code deserves its own section because its enforcement changed. For labs billing in MolDX jurisdictions, the DEX Z-Code is no longer a soft expectation. **Effective May 1, 2025, MolDX claims submitted without the Z-Code identifier in loop 2400 (SV101-7) deny as unprocessable**, per Noridian guidance. There is no clinical review and no partial adjudication; the claim is rejected on sight. Labs have to register the test, obtain the Z-Code through the DEX Diagnostics Exchange, and submit exactly one Z-Code per MolDX CPT line, correctly matched to the assay the code represents. This is the cleanest possible illustration of a denial that has nothing to do with whether the test was appropriate. A clinically flawless order with a missing or mismatched Z-Code is an automatic loss, decided by a field on a claim form rather than by a reviewer's judgment. ## Why the denial rate keeps climbing Return to the paradox from the top: as Medicare broadened NGS coverage in 2018 and again in 2020, the denial rate rose from 16.8% to 27.4%. If more was covered, why were more claims denied? Because coverage and payability are not the same thing. A test can be covered in principle and still denied in practice if the claim does not satisfy every specific condition the policy attaches to that coverage. Each expansion of NCD 90.2 arrived with more criteria, the right cancer stage, the right prior-testing history, the right ordering context, the right documentation, and every additional requirement is one more edge a claim can fall off. Broader coverage, written as more detailed rules, produces more denials unless the lab keeps perfect pace with the rules. That is the deeper reason most molecular denials are "operational." The dominant cause is not payers refusing to cover good tests. It is the gap between what current policy requires and what the claim actually reflects, and that gap widens every time a policy changes, which is constantly. A coverage fact that was accurate when a billing protocol was written quietly goes stale, and the first sign of the drift is a denial pattern no one can immediately explain. ## Appeals work far more often than teams expect If prevention is the first lever, appeals are the second, and the data here is genuinely surprising. A 2025 *Health Affairs* study from UCSF researchers found that **46% of appealed genetic-testing denials were overturned through independent medical review (IMR)** between 2019 and 2023. Seventy percent of the claims examined were cancer-related. Overturn rates varied by state (roughly 60% in California, under 30% in Washington) and by indication (54.8% for ovarian cancer testing, 44.3% for non-small-cell lung cancer). Now the other half of the finding: **fewer than 1% of denials are appealed** through IMR. Hold those two numbers next to each other. Nearly half of the genetic-testing denials that get challenged are reversed, and almost nobody challenges them. The reversible revenue is sitting on the table, and the reason it stays there is rarely that the cases are weak. It is capacity. Appeals take skilled staff time, so labs triage, chase the cleanest and largest cases, and write off the rest, which means the true cost of a high denial rate is not only the claims you lose but the winnable ones you never reach. Building even a modest, repeatable appeals process changes that math. The appeals that succeed tend to share a structure: they identify the exact denial reason rather than arguing in general terms, they quote the payer's own coverage criteria and walk through how the patient meets each one, and they attach the specific documentation, pathology, prior results, the ordering rationale, that proves it. None of that requires heroics. It requires knowing what the governing policy actually says and matching the appeal to it, which is the same capability that prevents the denial in the first place. ## The prevention checklist The data points to a short list of upstream controls that head off the most common losses: - A valid **MolDX Z-Code** on every applicable molecular claim, every time, matched to the right assay. - **Diagnosis-code positioning** that maps the claim to the payer's covered indication, in the right order. - The **test name and descriptor** populated on every unlisted molecular code. - **Documentation that agrees with itself**, order, encounter note, and claim aligned on test, indication, and date. - **Prior authorization confirmed** before the service wherever it is required, against the payer's *current* list. - A standing process to **appeal medical-necessity denials**, given the roughly 46% overturn rate. The throughline connecting every point above is this: molecular and genetic denials are decided overwhelmingly by whether the claim satisfies the payer's current, specific rules, not by whether the test was the right call clinically. The labs that get paid are the ones that treat those rules as living data, tracked, encoded, and kept current per payer, per test, per indication, and applied before the claim is ever submitted. That is what turns a 23% denial rate into a recoverable one, and it is the problem Converus was built to solve. ## Sources - Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare — *JAMA Network Open*, April 18, 2025 (doi:10.1001/jamanetworkopen.2025.5785; PubMed 40249617) - Use of Independent Medical Review: Almost One-Half of Coverage Denials Overturned — *Health Affairs*, December 2025 (doi:10.1377/hlthaff.2025.00716) - 2024 Payor Denial Impact Report — XiFin, Inc. (analysis of 20M+ laboratory claims) - Proper Submission of DEX Z-Code for Molecular Diagnostic Services (MolDX) Claims — Noridian Healthcare Solutions (effective May 1, 2025) - National Coverage Determination (NCD 90.2): Next Generation Sequencing — Centers for Medicare & Medicaid Services --- # Glossary ## ABN (Advance Beneficiary Notice) A written notice given to a Medicare beneficiary before a service is delivered, informing them that Medicare may not pay and that the patient may be responsible for the cost. An Advance Beneficiary Notice of Noncoverage (ABN) is required by CMS when a provider believes Medicare is likely to deny coverage for a service. By signing the ABN, the patient acknowledges that they may be billed if Medicare denies the claim and agrees to be financially responsible for that cost. In genetic testing, ABNs are frequently required when a test is being ordered for an indication that does not clearly meet the applicable LCD criteria, or when the patient's clinical context is borderline for coverage. Issuing an ABN correctly protects the lab's right to bill the patient if Medicare denies. Failure to issue a required ABN means the provider may not bill the patient under any circumstances after a Medicare denial. ## AOB (Assignment of Benefits) A patient authorization allowing the provider to bill the insurance company directly and receive payment on the patient's behalf, rather than the patient receiving the reimbursement and paying the provider separately. Assignment of benefits is the mechanism by which a patient authorizes their insurer to pay the healthcare provider directly. When a provider participates in a payer's network, AOB is typically part of the standard provider agreement. For out-of-network providers such as reference laboratories, AOB is critical, without it, the payer may issue payment to the patient rather than the lab. In genetic testing and oncology billing, AOB documentation is particularly important for out-of-network laboratory services. Labs that accept assignment must verify AOB is on file for each patient before billing. Some states have laws that affect an insurer's ability to withhold payment from a provider that has a valid AOB on file. ## Appeal A formal request to a payer to reconsider a prior authorization denial or claim denial, submitted through defined administrative procedures with supporting documentation. An appeal is the formal mechanism for challenging a payer's denial decision. Most payer processes include multiple levels of internal appeal (first-level, second-level), followed by an external independent review if internal appeals are exhausted. Federal and state laws define minimum appeal rights for most plan types. Appeal success rates vary significantly by denial reason, payer, and quality of the appeal package. Medical necessity denials that go to external review are overturned at materially higher rates than internal reviews alone. A well-constructed appeal directly addresses the specific denial reason, includes applicable clinical guidelines, provides a detailed letter of medical necessity from the treating physician, and cites the relevant policy criteria the service meets. Time limits for filing appeals are strict and vary by payer, missing the window forfeits the right to appeal. ## ASCO (American Society of Clinical Oncology) The leading professional organization for oncologists, whose clinical guidelines and quality frameworks are frequently cited as supporting evidence in prior authorization submissions and appeals. The American Society of Clinical Oncology publishes clinical practice guidelines, provisional clinical opinions, and technology assessments across oncology. ASCO guidelines and policy statements carry significant evidentiary weight in appeals for oncology services, particularly when the treating oncologist is citing the current standard of care. ASCO also collaborates with the College of American Pathologists (CAP) and other organizations on biomarker testing guidelines, for example, the ASCO/CAP HER2 testing guidelines for breast cancer and the ASCO guideline on next-generation sequencing in advanced cancers. These guidelines can be cited in PA submissions to establish that a requested test meets standard-of-care criteria. ## Biomarker A measurable biological characteristic, such as a gene mutation, protein expression level, or chromosomal abnormality, used to identify patients likely to respond to a specific therapy or to diagnose a disease state. In oncology, biomarkers include DNA mutations (EGFR, KRAS, BRAF), gene amplifications (HER2), expression levels (PD-L1), microsatellite instability (MSI), tumor mutational burden (TMB), and many others. Biomarker-driven oncology is now the standard of care across many cancer types, with FDA approvals and NCCN guidelines specifying biomarker thresholds as prerequisites for specific therapies. For prior authorization and claims purposes, biomarker test results are frequently required documentation for drug PA requests. Payers require that the specific biomarker referenced in the drug's FDA label or the payer's medical policy has been tested using an approved methodology, and that the patient's result meets the threshold specified in the coverage criteria. Missing or ambiguous biomarker documentation is a leading cause of avoidable oncology PA denials. ## Companion Diagnostic An FDA-approved in vitro diagnostic test that is required or recommended to select patients who are most likely to benefit from a specific therapeutic product. A companion diagnostic (CDx) is a test that is co-developed with a targeted therapy and is part of that therapy's FDA labeling. The drug label specifies that patient selection should be based on the CDx result, meaning the test is not optional for coverage purposes when prescribing the associated therapy. Examples include the PD-L1 companion diagnostics required for certain pembrolizumab (Keytruda) indications and the KRAS/NRAS/BRAF mutation tests required for colorectal cancer therapies. For PA purposes, a companion diagnostic result is typically required documentation for the drug PA submission, payers will not authorize the drug without evidence that the companion test was performed and the patient's result meets the labeled criteria. This creates a two-step PA workflow: test PA (or test result), then drug PA. ## Coverage Determination A formal decision by a payer or CMS regarding whether a specific service, drug, or technology is covered under a benefit plan or Medicare program, distinct from a case-level prior authorization decision. A coverage determination is a policy-level decision about whether a category of service is a covered benefit, as opposed to a PA decision, which is a case-level determination that a specific patient's service meets coverage criteria. Coverage determinations include LCDs, NCDs, and insurer medical policies. Providers can request coverage determinations from Medicare (through a formal LCD or NCD development process) or from commercial payers (through a coverage decision request). This is relevant when a new molecular test or therapy lacks existing coverage, or when a payer's coverage criteria are inconsistent with clinical guidelines. Participating in public comment periods for new LCDs and NCD proposals is a pathway for labs and oncology practices to influence coverage policy for emerging technologies. ## CPT (Current Procedural Terminology) The standardized code set maintained by the AMA that identifies medical procedures and services on claims and prior authorization requests. CPT codes are maintained by the American Medical Association and serve as the universal language for identifying what procedure or service is being requested or billed. Every PA request and claim for a laboratory test or medical procedure must include the applicable CPT code. In molecular diagnostics, CPT coding is complex. Multianalyte Assay with Algorithmic Analysis (MAAA) codes and genomic sequencing procedure (GSP) codes are specific to molecular tests. Some labs bill proprietary multianalyte tests using Tier 2 MAAA codes. Payers review CPT codes during PA review to confirm the requested service is covered, matches the clinical indication, and isn't duplicative of recently performed tests. ## Denial A payer's determination that a submitted prior authorization request or claim does not meet the criteria for coverage or reimbursement under the patient's benefit plan. A denial is a payer's formal refusal to authorize or pay for a requested or delivered service. Denials at the PA stage prevent service delivery; claim denials occur after service delivery and affect reimbursement. Both types include a reason code that specifies the grounds for denial. Common denial categories include medical necessity, missing documentation, non-covered service, prior authorization not obtained, and experimental/investigational classification. Each category requires a different escalation strategy, ranging from immediate peer-to-peer review (for medical necessity denials) to coverage determination challenges (for benefit exclusions). Denial tracking, by reason code, payer, and service type, is essential for identifying systemic issues and building an effective appeals program. ## EGFR (Epidermal Growth Factor Receptor) A receptor tyrosine kinase whose activating mutations in non-small cell lung cancer (NSCLC) define eligibility for EGFR-targeted tyrosine kinase inhibitors (TKIs), making EGFR testing a required companion diagnostic for those therapies. EGFR mutations, most commonly exon 19 deletions and exon 21 L858R substitutions, are found in approximately 10–15% of NSCLC patients in the United States (higher in Asian populations and in patients with no smoking history). EGFR-mutant NSCLC is treated with EGFR TKIs including erlotinib, gefitinib, afatinib, and osimertinib (Tagrisso). For PA purposes, EGFR mutation testing results are required documentation for TKI PA requests. Payers require documentation of the specific mutation identified, the testing methodology (PCR, NGS), the tissue or liquid biopsy source, and the testing date. Resistance mutations (such as EGFR T790M, which drives resistance to first- and second-generation TKIs and guides selection of osimertinib) also have specific testing and PA documentation requirements. ## EOB (Explanation of Benefits) A document from a payer summarizing what was billed, what was covered, what was denied, and how much the patient owes for a processed claim. An Explanation of Benefits (EOB) is issued by the insurance company after processing a claim. It is not a bill; it is a summary of the claim adjudication. The EOB includes the billed amount, the payer's allowed amount, adjustments, patient cost-sharing, and, if applicable, denial reason codes. In prior authorization and revenue cycle management, EOBs serve as the primary source document for denial analysis. The denial reason code and remark code on the EOB determine the appropriate appeal strategy. For coordination of benefits (COB) situations, the primary payer's EOB must be attached to the secondary payer's claim. Retaining and systematically reviewing EOBs is foundational to an effective denial management program. ## Experimental / Investigational A payer classification applied to services, drugs, or technologies that do not yet meet the evidentiary standards required for coverage, typically requiring FDA approval, sufficient peer-reviewed evidence, and clinical guideline support. Payers classify a service as experimental or investigational (E&I) when the available evidence is insufficient to establish safety and efficacy under the payer's coverage criteria. Common E&I criteria require that a service have FDA approval or clearance for the requested indication, be supported by peer-reviewed clinical literature demonstrating clinical utility, and be recognized by established clinical guidelines. In molecular diagnostics, laboratory-developed tests (LDTs) and novel genomic assays are frequently classified as E&I until sufficient evidence accumulates. Appealing an E&I denial requires building an evidentiary record: FDA documents, peer-reviewed publications demonstrating clinical utility, NCCN guideline entries, and positive coverage determinations from other payers or CMS. When standard treatments have failed and no covered alternative exists, some payers will approve under an E&I exception for clinical necessity. ## FHIR (Fast Healthcare Interoperability Resources) The HL7 standard for exchanging healthcare data electronically, increasingly used to enable EHR integrations for prior authorization workflows and clinical data extraction. FHIR (pronounced "fire") is the modern interoperability standard for healthcare data exchange, developed by HL7 International. FHIR defines a set of structured data resources, Patient, Observation, DiagnosticReport, MedicationRequest, and others, that allow disparate healthcare systems to exchange clinical information in a standardized format. In the prior authorization context, FHIR is central to several initiatives: the Da Vinci Project's Coverage Requirements Discovery (CRD) and Prior Authorization Support (PAS) implementation guides define FHIR-based workflows for automated PA submission directly from EHR systems. CMS has also required payers to support FHIR APIs for PA status notifications under recent regulatory rules. For genetic labs and oncology practices, FHIR-based integrations enable automated clinical data extraction from EHRs, pulling diagnosis codes, lab results, and treatment history needed to populate PA requests without manual chart review. ## Formulary A payer's official list of covered drugs, typically organized in tiers that determine cost-sharing levels, with higher tiers (including specialty oncology drugs) often requiring prior authorization regardless of tier. A formulary defines which drugs are covered under a health plan and at what cost-sharing level. Drugs on lower tiers typically require lower copays; specialty drugs (including most oncology drugs) are placed on high-cost tiers and almost universally require prior authorization. Non-formulary drugs, those not on the covered list, may require coverage exception requests. For oncology billing, formulary management intersects with PA in two ways: first, the drug must be on the formulary (or a formulary exception must be obtained); second, even formulary drugs typically require PA that documents the specific indication, biomarker results, and line of therapy. When a payer's formulary does not include a newly approved oncology drug, the escalation pathway is a formulary exception request, supported by clinical documentation that the non-formulary drug is medically necessary and that formulary alternatives are inappropriate for this patient. ## Gold Carding A payer program that exempts high-performing providers from prior authorization requirements for specified services based on a demonstrated track record of high approval rates and appropriate utilization. Gold carding (also called PA exemption or provider exemption) allows qualifying providers to bypass the per-request prior authorization process for covered services. To qualify, providers typically must demonstrate a PA approval rate above a defined threshold (commonly 90%+) over a lookback period, along with sufficient request volume to establish a meaningful track record. A growing number of states have enacted gold carding laws requiring commercial insurers and managed Medicaid plans to offer exemption programs to providers who meet the qualifying criteria. Gold carding reduces administrative burden on both providers and payers, but does not eliminate documentation requirements, post-payment audits can still occur, and providers must maintain the utilization patterns that earned the exemption. ## HCPCS (Healthcare Common Procedure Coding System) A two-level code set used primarily for Medicare and Medicaid billing that extends beyond CPT to cover drugs (J-codes), supplies, and other services not captured in CPT. HCPCS Level I consists of CPT codes. HCPCS Level II is a separate set of alphanumeric codes used to bill items and services not covered by CPT, most notably injectable and infusible drugs (J-codes), which are essential for oncology drug billing. For example, J9999 and specific J-codes identify individual oncology drugs for claims and PA submissions. DEX Z-codes, used within the MolDX program to identify specific molecular diagnostic tests, are also HCPCS Level II codes. When submitting a prior authorization for a MolDX-managed molecular test, the DEX Z-code must typically be included alongside the CPT code to ensure the payer can identify the specific test and apply the correct coverage criteria. ## HER2 (Human Epidermal Growth Factor Receptor 2) A protein receptor encoded by the ERBB2 gene whose overexpression or amplification defines HER2-positive cancers, which are eligible for targeted HER2-directed therapies and their associated companion diagnostic requirements. HER2 overexpression or gene amplification occurs in approximately 15–20% of breast cancers and subsets of gastric, gastroesophageal, and other cancers. HER2 status determines eligibility for HER2-directed therapies including trastuzumab (Herceptin), pertuzumab, trastuzumab deruxtecan (Enhertu), and others. HER2 testing methodology is defined by ASCO/CAP guidelines and payer medical policies. Testing is performed by immunohistochemistry (IHC) for protein expression and fluorescence in situ hybridization (FISH) for gene amplification. For PA purposes, payers require documentation of HER2 testing methodology, result score (IHC 0, 1+, 2+, 3+ or ISH ratio), and, for IHC 2+ results, reflex FISH testing results. HER2-low status (IHC 1+ or IHC 2+/ISH non-amplified) is now recognized as a distinct category that supports eligibility for trastuzumab deruxtecan in certain settings. ## ICD-10 The International Classification of Diseases, 10th revision, the standardized code set used to document diagnoses on claims and prior authorization requests. ICD-10-CM (Clinical Modification) codes are the standard system for documenting patient diagnoses in the United States healthcare system. Every prior authorization request and claim must include one or more ICD-10 codes that establish the clinical context for the requested service. In oncology and genetic testing, ICD-10 code selection is often a critical PA success factor. Payers' LCDs and medical policies define which ICD-10 codes support coverage for specific tests. An imprecise code, for example, using a generic "neoplasm of uncertain behavior" code when the patient has a confirmed malignant diagnosis, can trigger a medical necessity denial even when the clinical documentation clearly supports the request. Code specificity matters. ## LCD (Local Coverage Determination) A Medicare coverage rule issued by a regional Medicare Administrative Contractor (MAC) that defines when a specific service or test is covered for Medicare beneficiaries in that contractor's jurisdiction. Local Coverage Determinations are binding coverage policies for Medicare claims processed by the issuing MAC. Each LCD specifies covered diagnoses (ICD-10 codes), clinical criteria, and documentation requirements for a defined service. LCDs may also list non-covered indications. For molecular diagnostics, LCDs issued by Palmetto GBA (the MAC that administers the MolDX program) are especially important. A lab billing molecular tests to Medicare must confirm that the test and the patient's clinical indication align with the applicable LCD. Violating LCD criteria, even unintentionally, results in claim denial and can trigger audit liability. ## LDT (Laboratory-Developed Test) A diagnostic test designed, validated, and performed within a single laboratory, as opposed to an FDA-cleared or FDA-approved kit, subject to distinct regulatory and coverage standards. A laboratory-developed test (LDT) is a type of in vitro diagnostic that a laboratory designs and uses only within that laboratory. Historically, LDTs were regulated primarily under CLIA (Clinical Laboratory Improvement Amendments) rather than FDA oversight. The FDA finalized a rule in 2024 to phase in oversight of LDTs, significantly changing the regulatory landscape. For coverage and PA purposes, LDT status affects how payers evaluate a test's evidentiary basis. Payers that require FDA approval for coverage may classify LDTs as experimental/investigational even when the test has been validated and is in widespread clinical use. Labs should document analytical validity, clinical validity, and clinical utility data for LDTs in their PA submissions, and reference any NCCN guideline listings, published peer-reviewed studies, or MolDX coverage determinations that support the test's clinical utility. ## MAC (Medicare Administrative Contractor) A private company contracted by CMS to process Medicare claims, issue Local Coverage Determinations, and administer Medicare benefits in a defined geographic jurisdiction. Medicare Administrative Contractors are the regional entities responsible for processing Medicare Part A and Part B claims within specific jurisdictions. Each MAC may issue its own LCDs that apply to providers and labs within its jurisdiction. The MAC that a lab or provider falls under is determined by the location of the performing entity. For molecular diagnostics, Palmetto GBA is the MAC that administers the MolDX program and has jurisdiction over a large portion of the country for molecular test coverage determinations. Noridian Healthcare Solutions is another major MAC that has adopted the MolDX program for its jurisdictions. Knowing which MAC governs a specific lab's billing is essential for identifying the applicable LCDs and completing any required MolDX technical assessments. ## Converus company that solves RCM for all labs Converus is an AI that tells you in simple english what a payer's policy means and helps you apply it to claims and PAs. ## Medical Necessity The clinical justification that a requested service is appropriate, reasonable, and necessary for the diagnosis or treatment of a patient's covered condition, the standard most payers apply when reviewing prior authorization requests. Medical necessity is the cornerstone concept of prior authorization review. Most payer policies define medical necessity as services that are (1) appropriate for the patient's symptoms, diagnosis, or treatment; (2) consistent with generally accepted standards of medical practice; (3) not primarily for convenience; and (4) the most appropriate level of service considering potential clinical benefit versus risk. Medical necessity denials, where the payer determines the submitted information does not establish that a service meets these criteria, are the most common denial type in genetic testing and oncology. The most effective response is a robust upfront submission that directly addresses the payer's specific criteria, cites applicable guidelines (NCCN, ASCO), and includes the treating physician's clinical narrative explaining why the service is necessary for this patient. ## Medical Policy An insurer-specific document defining the criteria under which a particular service, drug, or technology is covered or not covered under that payer's plans. Medical policies are published by commercial insurers and supplement LCDs and NCDs by providing payer-specific coverage criteria for services that may not be fully addressed by federal coverage rules. Each major commercial payer, UnitedHealthcare, Cigna, Aetna, Anthem, Humana, publishes its own medical policy library, and policies vary significantly across payers for the same service. For genetic testing and oncology, payer medical policies define the specific ICD-10 codes, clinical criteria, testing indications, and documentation requirements that must be met for coverage. Policies are updated periodically, and a test or drug that was previously covered may become subject to new restrictions or additional PA requirements. Proactively monitoring medical policy changes for high-volume payers is a critical component of laboratory and oncology RCM. ## Modifier A two-character code appended to a CPT or HCPCS code to provide additional information about the service, such as whether it was reduced in scope, performed bilaterally, or subject to a specific policy exception. CPT and HCPCS modifiers communicate circumstances that affect how a service was performed or billed without changing the underlying code's definition. In the context of prior authorization and claims, modifiers can indicate that a service was ordered by a different provider than the performing provider, that a test was reduced in scope, or that specific coverage rules apply. In molecular diagnostics, modifiers such as -59 (distinct procedural service) are used to demonstrate that separately billed tests are clinically distinct and not duplicative. Incorrect or missing modifiers are a common source of claim denials and billing audits. Ensuring modifiers align with the PA that was obtained is a critical step in the billing workflow. ## MolDX Palmetto GBA's Molecular Diagnostic Services program, which establishes technical assessment, coverage, and billing requirements for molecular diagnostic tests billed to Medicare. MolDX (Molecular Diagnostic Services) is administered by Palmetto GBA, a Medicare Administrative Contractor. It serves as the primary coverage determination and billing framework for molecular diagnostic tests across a large portion of Medicare jurisdictions, including most of the South and Mountain West, as well as for the DME MAC jurisdiction. Labs that want to bill molecular tests to Medicare must complete MolDX's technical assessment process, which evaluates a test's analytical validity, clinical validity, and clinical utility. Upon successful assessment, the test is assigned a DEX Z-code used for billing identification. Many commercial payers reference MolDX coverage criteria and Z-codes when establishing their own policies for molecular tests. ## MSI / MMR (Microsatellite Instability / Mismatch Repair) MSI (microsatellite instability) and MMR (mismatch repair) deficiency are related biomarkers that indicate a tumor's impaired DNA repair mechanisms, a key companion diagnostic criterion for pembrolizumab and other checkpoint inhibitors. Mismatch repair (MMR) proteins correct DNA replication errors. When MMR proteins are deficient (dMMR), DNA errors accumulate, resulting in microsatellite instability-high (MSI-H) tumors. MSI-H/dMMR status is an FDA-approved biomarker for pembrolizumab (Keytruda) in solid tumors regardless of tumor type, the first tissue-agnostic oncology approval. For prior authorization purposes, MSI-H or dMMR test results are required documentation for pembrolizumab PA requests under the tumor-agnostic indication. Payers require the specific test methodology, result, and testing date. MSI can be measured by PCR or next-generation sequencing; MMR status is typically assessed by immunohistochemistry (IHC). The testing method should align with the payer's and FDA's accepted methodologies listed in the drug's label. ## NCCN (National Comprehensive Cancer Network) A nonprofit alliance of leading cancer centers that publishes evidence-based clinical practice guidelines for oncology, widely referenced by payers when making coverage and medical necessity determinations. The National Comprehensive Cancer Network publishes the NCCN Clinical Practice Guidelines in Oncology, which are the most widely referenced clinical guidelines in oncology coverage decisions. Payers frequently cite NCCN category designations when evaluating prior authorization requests for oncology drugs and diagnostics. NCCN assigns evidence categories to each recommendation: Category 1 (high-level evidence, uniform consensus), Category 2A (lower-level evidence, uniform consensus), Category 2B (lower-level evidence, consensus), and Category 3 (major disagreement). Category 1 and 2A designations carry the most weight in PA submissions and appeals, and many payers explicitly limit coverage to NCCN Category 1 or 2A indications. ## NCD (National Coverage Determination) A federal Medicare coverage rule issued by CMS that applies uniformly across all Medicare Administrative Contractors and supersedes conflicting LCDs for the covered service. National Coverage Determinations represent CMS's formal determination of whether a service, item, or technology is covered under Medicare nationally. Unlike LCDs, which vary by MAC jurisdiction, NCDs apply in every state. When an NCD exists for a service, it takes precedence over any local LCD for that service. Key NCDs relevant to oncology include the coverage determination for next-generation sequencing (NGS) diagnostic laboratory tests for cancer, which established coverage criteria for FDA-approved NGS tests used to guide treatment decisions. Understanding whether an NCD or LCD governs a specific test is a prerequisite for building a compliant PA submission. ## NGS (Next-Generation Sequencing) High-throughput DNA sequencing technology that can simultaneously analyze hundreds or thousands of genes in a single assay, enabling comprehensive tumor profiling for oncology treatment selection. Next-generation sequencing (NGS) enables broad genomic profiling of tumor tissue or liquid biopsy samples. NGS panels range from targeted gene panels (dozens to hundreds of genes) to comprehensive genomic profiling (CGP) tests that assess the entire coding exome or genome. In oncology, NGS is used to identify actionable mutations that guide therapy selection with targeted drugs. For PA purposes, NGS panels are subject to specific coverage criteria, most notably, the CMS NCD for NGS in cancer (NCD 90.2) which covers FDA-approved NGS tests for advanced cancer patients. Coverage criteria typically require a diagnosis of recurrent, relapsed, refractory, metastatic, or advanced-stage cancer; prior standard treatment; and an intent to use results to guide treatment decisions. Labs must ensure their NGS test has completed the required MolDX technical assessment and has an assigned DEX Z-code for Medicare billing. ## Off-Label Use Use of an FDA-approved drug or device for an indication, patient population, dosage, or route of administration not included in the FDA-approved label. Off-label prescribing is common and legal in oncology, the FDA approves drugs for specific indications, but clinical evidence frequently supports use in additional settings before formal label expansion occurs. NCCN guidelines regularly include Category 2A or 2B recommendations for off-label uses of approved oncology drugs. For prior authorization purposes, off-label use requires more robust clinical documentation. Payers often require evidence that the off-label use is supported by peer-reviewed literature, a recognized clinical guideline, or a compendium listing. The most defensible PA submissions for off-label oncology drugs cite a specific NCCN guideline entry, the patient's biomarker profile, and any published clinical trial data supporting the indication, along with an explanation of why on-label alternatives are inappropriate. ## Payer Any entity that reimburses healthcare providers for services, including commercial health insurers, Medicare (through CMS and MACs), Medicaid (through state agencies), and Medicare Advantage plans, each with distinct PA requirements and coverage policies. In healthcare billing, a "payer" is any organization that pays for healthcare services. The major payer categories relevant to genetic labs and oncology are: commercial health insurers (UnitedHealthcare, Cigna, Aetna, Anthem, Humana), Medicare Fee-for-Service (administered by CMS through MACs), Medicare Advantage plans (private insurers operating under CMS contracts), and Medicaid and managed Medicaid plans (administered by states and managed care organizations). PA requirements, coverage policies, billing rules, and appeal procedures differ substantially across payer types. Medicare is governed by LCDs and NCDs; commercial payers use medical policies; Medicaid varies by state. Medicare Advantage plans can impose prior authorization requirements stricter than traditional Medicare, while being subject to CMS oversight. Understanding which payer type a patient has is the prerequisite for every downstream PA and billing decision. ## PD-L1 (Programmed Death-Ligand 1) A protein expressed on tumor cells and immune cells whose expression level serves as a predictive biomarker for response to checkpoint inhibitor immunotherapies, with expression thresholds defined in companion diagnostic requirements for specific indications. PD-L1 expression is measured by immunohistochemistry and reported as a Tumor Proportion Score (TPS), the percentage of viable tumor cells with membrane staining, or a Combined Positive Score (CPS), which includes tumor cells, lymphocytes, and macrophages. Different checkpoint inhibitors use different scoring methods and different thresholds; pembrolizumab in NSCLC first-line monotherapy requires TPS ≥50%, while CPS is used in other indications. For PA purposes, PD-L1 test results are required documentation for checkpoint inhibitor PA requests where PD-L1 is a companion diagnostic criterion. Payers require the specific assay used, the scoring method (TPS or CPS), the numerical result, and the testing date. The PD-L1 assay used must be the companion diagnostic designated for the specific drug-indication combination, as different approved companion diagnostic assays may not be interchangeable for coverage purposes. ## Peer-to-Peer Review A direct conversation between the ordering physician and the payer's medical director, typically requested after a medical necessity denial, that often yields the highest overturn rates of any single appeal intervention. A peer-to-peer (P2P) review is a physician-to-physician discussion in which the ordering or treating provider speaks directly with the payer's medical director or physician reviewer to advocate for the clinical appropriateness of a denied service. Most payers permit, and some require, a P2P request to be filed within a defined window after a medical necessity denial (commonly 5–14 business days). Data consistently shows that peer-to-peer reviews overturn medical necessity denials at a materially higher rate than written appeals alone, particularly when the treating physician can articulate the specific clinical rationale, cite relevant guidelines, and explain why alternative treatments are inappropriate. For oncology PA denials involving biomarker-driven therapies or hereditary testing, initiating a P2P review immediately after denial is typically the single highest-yield action a practice can take. ## Prior Authorization A payer requirement that providers obtain advance approval before delivering a specified service, drug, or diagnostic test in order to receive reimbursement. Prior authorization (PA) is the process by which a health insurance payer reviews and approves, or denies, a requested service before it is delivered. The payer evaluates the request against its coverage criteria and medical policies, including applicable LCDs, NCDs, and formulary rules. For genetic laboratories and oncology practices, PA applies to a broad range of services including molecular diagnostic panels, hereditary cancer testing, tumor biomarker assays, and specialty oncology drugs. Failure to obtain required PA before service delivery typically results in a non-payable claim. ## RCM (Revenue Cycle Management) The end-to-end administrative and financial process that healthcare organizations use to track patient care episodes from registration through final payment. Revenue cycle management encompasses all administrative functions associated with claims processing and reimbursement: patient eligibility verification, prior authorization, charge capture, coding, claim submission, payment posting, denial management, and appeals. For genetic laboratories and oncology practices, RCM is complex due to the volume of PA-required services, the specificity of coding requirements, and the frequency of medical necessity and experimental/investigational denials. An effective oncology RCM program includes proactive PA management (submitting before service delivery), real-time policy monitoring to anticipate coverage changes, systematic denial tracking by category and payer, and a structured appeal workflow with defined timelines and escalation criteria. Technology platforms that automate PA submission, monitor payer responses, and generate appeal documentation are increasingly central to high-performing RCM operations. ## Somatic vs. Germline Testing Somatic testing detects mutations acquired in tumor cells during a patient's lifetime; germline testing detects inherited mutations present in every cell, a distinction that determines which coverage policies, codes, and documentation requirements apply. **Somatic** mutations arise in individual cells during a person's life and are not inherited. Somatic tumor profiling (e.g., next-generation sequencing of a tumor biopsy) identifies mutations driving tumor growth and guides treatment selection with targeted therapies. Somatic testing is ordered by the oncologist and is covered under oncology-specific LCDs and NCDs. **Germline** mutations are inherited, present in every cell, and can be passed to offspring. Germline testing (e.g., BRCA1/2 hereditary cancer panels) is ordered to assess hereditary cancer risk, guide surgical decisions, and inform family member testing. Germline testing is subject to separate coverage criteria under genetic testing-specific policies, often requiring documented family history, prior cancer diagnosis, or other risk criteria. The distinction matters operationally: somatic and germline tests may use different CPT codes, require different ICD-10 codes, fall under different payer policies, and require different documentation. Mixing up somatic and germline documentation in a PA submission is a common source of denials. ## Step Therapy A payer coverage requirement that a patient try one or more lower-cost or preferred treatments before the requested treatment will be authorized. Step therapy (also called "fail first") requires that a patient try and fail a specified first-line treatment before a payer will authorize a preferred second-line or specialty treatment. The payer's rationale is cost management: cheaper alternatives should be exhausted before moving to expensive specialty drugs. In oncology, step therapy requirements can be clinically inappropriate when patient-specific biomarkers or tumor characteristics make first-line agents ineffective or contraindicated. Many states have enacted step therapy override laws requiring payers to grant exceptions when a patient's clinical history, genetics, or contraindications make the step-therapy requirement inappropriate. For PA submissions involving biomarker-driven targeted therapies, documenting the specific biomarker result that supports the requested drug, and any prior treatments received, is essential to avoiding step therapy denials. ## TMB (Tumor Mutational Burden) A measure of the total number of mutations in a tumor's genome, used as a biomarker to identify patients who may respond to checkpoint inhibitor immunotherapy regardless of tumor type. Tumor mutational burden (TMB) is measured as the number of somatic mutations per megabase (mut/Mb) of genomic sequence. High TMB (TMB-H) is associated with increased neoantigen production and greater likelihood of immune recognition, making it a predictive biomarker for checkpoint inhibitor response. Pembrolizumab (Keytruda) has FDA approval for TMB-H (≥10 mut/Mb) solid tumors in adults and children who have progressed on prior treatment. For PA purposes, TMB results must be generated by an FDA-approved companion diagnostic (the FoundationOne CDx assay is the approved CDx for pembrolizumab's TMB-H indication). PA submissions must include the specific TMB score, the assay used, and the testing date. The ≥10 mut/Mb threshold must be clearly documented; borderline or ambiguously reported results commonly trigger additional information requests. ## Utilization Management The set of payer programs, including prior authorization, step therapy, quantity limits, and concurrent review, designed to ensure that healthcare services are clinically appropriate and cost-effective. Utilization management (UM) is the umbrella term for the processes payers use to review and manage healthcare service utilization. UM tools include prior authorization, step therapy requirements, quantity limits, concurrent review (ongoing authorization for continuing services), retrospective review (post-service review for appropriateness), and case management. In the context of genetic testing and oncology, utilization management is increasingly intensive. Payers' UM programs for molecular diagnostics often involve multiple layers of criteria, test-specific LCDs, companion diagnostic requirements, specific ICD-10 coding requirements, and vendor-specific review (some payers route molecular test PAs through specialty benefit managers). Understanding a payer's UM structure for specific services is the first step in designing an efficient PA workflow.